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NATURE: APHORISMS BY GOETHE
NATURE! We  are surrounded  and embraced by her: powerless to separate
ourselves  from  her,  and  powerless  to  penetrate  beyond  her.  Without  asking,  or
warning, she snatches us up into her circling dance, and whirls us on until we are
tired, and drop from her arms. She is ever shaping new forms: what is, has never yet
been; what has been, comes not again. Everything is new, and yet nought but the old.
We live in her midst and know her not. She is incessantly speaking to us, but betrays
not her secret. We constantly act upon her, and yet have no power over her. The one
thing she seems to aim at is Individuality; yet she cares nothing for individuals. She is
always building up and destroying; but her workshop is inaccessible. Her life is in her
children; but where is the mother? She is the only artist; working-up the most uniform
material into utter opposites; arriving, without a trace of effort, at perfection, at the
most exact precision, though always veiled under a certain softness. Each of her works
has an essence of its own; each of her phenomena a special characterisation: and yet
their diversity is in unity. She performs a play; we know not whether she sees it herself,
and yet she acts for us, the lookers-on. Incessant life, development, and movement are
in her, but she advances not. She changes for ever and ever, and rests not a moment.
Quietude is inconceivable to her, and she has laid her curse upon rest. She is firm. Her
steps are measured, her exceptions  rare,  her  laws  unchangeable.  She  has  always
thought and always thinks; though not as a man, but as Nature. She broods over an
all-comprehending idea, which no searching can find out. rejoices the more they win.
With many, her moves are so hidden, that the game is over before they know it. That
which is most unnatural is still Nature; the stupidest philistinism has a touch of her
genius. Whoso cannot see her everywhere, sees her nowhere rightly. She loves herself,
and her innumberable eyes and affections  are  fixed  upon  herself. She  has  divided
herself that she may be her own delight. She causes an endless succession  of  new
capacities for enjoyment to spring up, that her insatiable sympathy may be assuaged.
She rejoices in illusion. Whoso destroys it in himself and others, him she punishes with
the sternest tyranny. Whoso follows her in faith, him she takes as a child to her bosom.
Her children are numberless. To none is  she  altogether  miserly; but  she  has  her
favourites, on whom she squanders much, and for whom she makes great sacrifices.
Over greatness she spreads her shield. She tosses her creatures out of nothingness,
and tells them not whence they came, nor whither they go. It is their business to run,
she knows the road. Her mechanism has few spring, but they never wear out,  are
always active and manifold.The  spectacle  of  Nature  is  always  new,  for  she  is  always  renewing  the
spectators. Life is her most exquisite invention; and death is her expert contrivance to
get plenty of life. She wraps man in darkness, and makes him forever long for light.
She creates him dependent upon the earth, dull and heavy; and yet is always shaking
him until he attempts to soar  above it. She creates needs because she loves action.
Wondrous! That she produces all this action so easily. Every need is a benefit, swiftly
satisfied, swiftly renewed. —Every fresh want is a new source of pleasure, but she soon
reaches an equilibrium. Every instant she commences an immense journey, and every
instant she has reached her goal. She is vanity of vanities; but not to us, to whom she
has made herself of the greatest importance. She allows every child to play tricks with
her; every fool to have judgment upon her; thousands to walk stupidly over her and see
nothing; and takes her pleasure and finds her account in them all. We obey her laws
even when we rebel against them; we work with her even when we desire to  work
against her. She makes every gift a benefit by causing us to want it. She delays, that we
may desire her; she hastens, that we may not weary of her. She has neither language
nor discourse; but she creates tongues and hearts, by which she feels and speaks. Her
crown  is  love.  Through  love  alone  dare  we  come  near  her.  She  separates  all
existences, and all tend to intermingle. She has isolated all things in order that all may
approach one another. She holds a couple of draughts from the cup of love to be fair
payment for the pains of a lifetime. She is all things. She rewards herself and punishes
herself; is her own joy and her own misery.  She  is  rough  and  tender,  lovely  and
hateful, powerless and omnipotent. She is  an  eternal present.  Past  and  future are
unknown to her. The present is her eternity. She is beneficent. I praise her and all her
works. She is silent and wise. No explanation is wrung from her; no present won from
her, which she does not give freely. She is cunning, but for good ends; and it is best not
to notice her tricks. She is complete, but never finished. As she works now, so can she
always work. Everyone sees her in his own fashion. She hides under a thousand names
and phrases, and is always the same. She has brought me here and will also lead me
away. I trust her. She may scold me, but she will not hate her work. It was not I who
spoke of her. No! What is false and what is true, she has spoken it all. The fault, the
merit, is all hers.
Translated by T. H. HUXLEY (Original script is in Appendix IX)i
Molekulare  Hematologie,  Haus  23B  Labor
EI45,  Klinikum  J.W.  Goethe-Universität,
Theodor-Stern-Kai7, 60590 Frankfurt.
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Abstract
A gene trap strategy was used to identify genes induced in hematopoietic cells
undergoing  apoptosis  by  growth  factor  withdrawal.  IL-3  dependent  survival  of
hematopoietic cells relies on a delicate balance between proliferation and apoptosis that
is controlled by the availability of cytokines (Thompson,  1995;  Iijima  et al., 2002).
From  our  previous  results  of  gene trap assay,  we  postulated  that  transcriptionally
activated antagonistic genes against apoptosis might actually block or delay cell death
(Wempe  et  al.,  2001)  causing  cells  to  have  carcinogenic  behavior.  The  analysis
attempted  to  better  understand  the  outcome  of  a  death  program  following  IL-3
deprivation and to identify those survival genes whose expression is affected by time
dependent manner.
As described in the chapter 4, there would be two major conclusions  evident
from  the  three separate  experiments  (Genetrap,  Atlas  cDNA  array  and  Affymetrix
chips): Firstly 56% of trapped genes, that are up-regulated by IL-3 withdrawal (28 of
50),  are  directly  related  to  cell  death  or  survival.  Secondly,  unlike  most  array
technologies,  gene trapping  only  selects  for  the  transiently  induced  genes  that  is
independent of pre-existing steady state mRNA levels. In regarding correlations of the
genes with potential carcinogenesis, the pre-existing mRNA makes difficult to describe
the unique characteristics of deregulated tumor tissue genes.
For a joint project with Schering (Schering AG, Berlin), the genes of our GTSTs
were examined. The first screen with custom array was used to look for whether the
survival genes of our GTSTs are involved in various cancer cell lines, whilst the second
screen with Matched Tumor/Normal Array was used to characterize if the selected seven
genes (ERK3, Plekha2, KIAA1140, PI4P5Ka/g,  KIAA0740,  KIAA1036 and  PEST
domains) are transformation-related genes or not in different tumor tissues.
Twenty-six genes were identified as either induced or repressed in one or more
cell lines. Genetic information  is  expressed  in  complex  and  ever  changing patterns
throughout a life span of cells. A description of these patterns and how they relate to thevi
tissue  specific  cancer  is  crucial  for  our  understanding  of  the  network  of  genetic
interactions that underlie the processes of normal development, disease and evolution.
The development of cancer and its progression is clearly a multiplex phenotype, as a
function of  time,  involving  dozens  of  primary  genes  and  hundreds  of  secondary
modifier genes.
There would be a major conclusion evident from the three separate experiments
(Genetrap, Affymetrix mouse chip and Matched Tumor/Normal Array): ERK3 could
play a significant role in breast, stomach and uterus carcinogenesis with tissue specific
regulations. It is  clear  that ERK3  is  obvious  putative  survival  gene in  these tumor
tissues. Especially, in breast tumors, seven times up-regulation was considerable and the
activation of ERK3 could be a feature of  breast tumors.  My  results  imply  that the
unique  deregulation  of  ERK3  is  perhaps  the  major  consequence  of  possible
transformation of normal cells into malignant cancer cells, even though further analysis
remains to be determined whether an alterated activity of associated survival genes is
primarily responsible for a carcinogenesis. However unlike all the other known MAP
Kinases, no stimuli and no nuclear substrates of ERK3 is reported. Therefore, it will be
necessary first to determine the spectrum of substrates and to  identify  the  proximal
effectors for the ERK3 in breast carcinoma cells.
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CHAPTER 1
INTRODUCTION
1.1 Background
Recently, the nucleotide sequencing of the entire human genome was
completed (McPherson et al., 2001; Venter et al., 2001; Claverie, 2001). The total
genomic sequences of other organisms (such as E. coli and many other bacteria,
yeast, Arabidopsis, Caenorhabditis, Drosophila, zebrafish and mouse) are
determined. However, this achievement is just the beginning of the functional
understanding of the genome of humans and other organisms (Smaglik, 2000; Roest
Crollius et al., 2000; Sachidanandam et al., 2001). Adequate expression or functional
information is available for only ~15% of them (Stanford et al., 2001). The coding
sequences of unknown genes can be identified by computational methods such as
alignment of Expressed Sequence Tags (ESTs) with other genomes. Following
sequencing, the next step must be to assign functions to the identified genes.
Gene-trap mutagenesis is a technique that randomly generates loss-of-function
mutations and reports the expression of many mouse genes. Gene-trapping
methodology (Section 1.4) is a powerful strategy for cloning and identifying
functional genes, as it marks a gene with a tag and simultaneously generates a
corresponding genetic variation at that particular locus.
For this reason, gene trapping has become a favorable standard tool for
functional genomics, establishing a correlation between the physical and genetic
maps of the genome (Thompson et al., 1995; Russ et al., 1996b; Evans et al., 1997;
Thorey et al., 1998; Stanford et al., 2001). Gene trapping studies using interleukin-3
(IL-3) dependent cell lines have begun to shed light on the transcriptional regulation
of apoptosis. A mouse bone marrow-derived hematopoietic cell line, FDCP-1,
(Sections 1.3 and 2.1.2) was employed as our model system.INTRODUCTION
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1.2 Apoptosis
Programmed cell death (PCD) is a tightly controlled process of cellular self-
destruction at predictable time and places during development (Steller et al., 1995).
The decision to die cannot be taken lightly, and the activities of many genes influence
a cell's likelihood of activating its self-destruction program. Once the decision is
taken, proper execution of the apoptotic program requires the coordinated activation
and execution of multiple subprograms.
Here I review the basic components of the death machinery, describe how
they interact to regulate apoptosis in a coordinated manner, and discuss the main
pathways that are used to activate cell death. Apoptosis is a kind of death that is best
described as cellular suicide and it is important for normal tissue homeostasis. The
term apoptosis was coined by Kerr (Kerr et al., 1972; Table 1.1) to describe a
morphologically distinguished form of cell death compared to necrosis. In necrosis,
uncontrolled cell death leads to lysis of cells, inflammatory responses and potentially
to serious health problems. Apoptosis, by contrast, is a process in which cells play an
active role in their own death (which is why it is often referred to as cell suicide,
Figure 1.1).
Three major pathways have been elucidated so far (Gross et al., 1999; Yin,
2000) which all result in the activation of caspase-3, a cysteine proteinase that cleaves
substrates after aspartic acid residues (Figure 1.2). One is the Type I (mitochondria-
independent, Bcl-2-insensitive) pathway. The pathway involves the binding of
Fas/TNF-R1 death receptor signals to cell surface receptors, which are members of
the tumor necrosis factor receptor (TNF-R) superfamily that activate different cellular
processes depending on cell type and environmental context.
Stimulation of apoptosis via proteolytic cleavage results in a cascade of
caspase activation within the cell. The caspases comprise the key effectors of the
apoptotic pathway and are expressed in all living cells in inactive forms. Following
interactions with caspase activator proteins, they become active and cell death quicklyINTRODUCTION
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ensues. Finally, granzyme B (a cytolytic T-cell product) directly cleaves and activates
several caspases, resulting in apoptosis.
Table 1.1: Features of apoptosis vs necrosis (Kerr et al., 1972).
Apoptosis Necrosis
Chromatin condensation Nuclear swelling
Cell shrinkage Cell swelling
Preservation of organelles and cell
membranes
Disruption of organelles
Rapid engulfment by neighboring cells Rupture of cell and release of
cellular contents
DNA fragmentation Inflammatory response
Figure 1.1:  Cells dying by apoptosis. The electron micrograph shows
morphological changes of nuclear chromatin condensation,
cytoplasmic shrinking, dilated endoplasmic reticulum and membrane
blebbing in an apoptotic mammary gland cell. (Courtesy of Dr David
Ferguson)
The other is the mitochondrial pathway (mitochondria-dependent, Bcl-2-
sensitive) pathway, largely mediated through Bcl-2 family members, which results in
release of cytochrome c (cyt c), activation of apoptotic protease activating factor-1
(Apaf-1), and caspase-9 form a complex known as the apoptosome (Figure 1.2). This
results in the formation of a wheel-like structure that contains 7 molecules each of
Apaf-1, cyt c and ATP. This wheel-like structure, the apoptosome, permits the
recruitment of 7 molecules of procaspase-9 to the complex (Figure 1.5). Recently,
however, mitochondria was also suggested as an integrator in tumorigenesisINTRODUCTION
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(Augenlicht and Heerdt, 2001). The caspases can also activate other degradative
enzymes such as DNases, which begin to cleave the DNA in the nucleus.
Death receptor
(Fas/TNF-R1 )
Caspases 3, 6, 7
CAD
Type I pathway
• Death stimuli
Type II pathway
Mitochondrial
dysfunction
Cytochrome C
release
Caspase 9
Caspase 8
BCL-2
Apaf-1
dATP
Death Death Death Death
Mitochondrial
 pathway
BID
FADD
BAX
• Radiation
• Chemicals
• Growth factor
   deprivation
Figure 1.2:  Three major pathways of apoptosis. Type I (mitochondria-independent,
Bcl-2-insensitive) pathway, mitochondria-dependent (Bcl-2-sensitive)
pathway and Type II (which shares Type I and mitochondria-
dependent pathways).
The result of these biochemical changes is appearance of morphological
changes in the cell, such as nuclear chromatin condensation (Wyllie et al., 1984),
cytoplasmic shrinking, dilated endoplasmic reticulum and membrane blebbing
(Figure 1.1). Several protein families (Sections 1.2.2 and 1.2.3) have been identified
whose members are the products of constitutively expressed genes that stimulate
apoptosis (Oltvai et al., 1994; White et al., 1996). Apoptotic cell death can be
triggered by a wide variety of stimuli. One of the well documented stimuli is DNA
damage (Decker and Muller, 2002), caused by irradiation (Zhan et al., 2002) or byINTRODUCTION
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drugs used for cancer chemotherapy, which leads to apoptotic death via a p53-
dependent pathway (Zhu et al., 1994). However, in many cases, apoptosis involves
p53-independent as well as p53-dependent pathways (Pan and Griep, 1995; Blandino
et al., 1995; JacksonGrusby et al., 2001). The p53-dependent pathway may involve
activation of caspases 1, 11, and 12, whereas the p53-independent pathway may
involve activation of members of the Bcl-2 and death receptor families (Choi et al.,
2001). There are a number of mechanisms through which apoptosis can be induced in
cells (McKinstry et al., 1997). The sensitivity of cells to any of these stimuli can vary
depending on several of factors such as the expression of pro- and anti-apoptotic
proteins, the severity of the stimulus and the stage of the cell cycle. Some of the
major stimuli that can induce apoptosis are described in the following Sections.
1.2.1 Death receptors
The death receptor pathway is initiated at the cell surface through the
Fas/TNF-R1 (tumor necrosis factor receptor-1) family proteins. Fas (also CD95 or
APO-1, Ashkenazi and Dixit, 1998) induces apoptosis upon stimulation with Fas
ligand (FasL, also CD95L or APO-1L). Fas is a type I transmembrane protein that has
multiple cysteine-rich repeats in the extracellular domain and an intracellular motif
termed a death domain (DD). They play an important role in very rapid apoptosis and
can activate a caspase cascade within seconds of ligand binding (Ashkenazi and
Dixit, 1998; Dhein et al., 1994; Miyake et al., 2003).
Binding of FasL to the Fas extracellular domain induces trimerization of Fas,
resulting in the recruitment of the Fas-associated death domain (FADD), which then
recruits pro-caspase 8 (Chinnaiyan et al., 1996). FADD has a carboxy-terminal DD
and an amino-terminal death effector domain (DED). FLICE (FADD-like
interleukine-1b-converting enzyme) is a key molecule in Fas-induced apoptosis that
recruits the DED-containing apoptosis-initiating proteases caspase-8 (Muzio et al.,
1996) and caspase-10 (Kischkel et al., 2001; Wang et al., 2001) to the Fas receptor to
assemble a DISC (Kischkel et al., 1995). Activation of pro-caspase 8 through self-INTRODUCTION
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cleavage leads to a series of downstream events, including activation of pro-caspase 3
(Thornberry et al., 1997), which subsequently cleaves its substrates such as DNA
fragmentation factor 45 (DFF45, Liu et al., 1997), to execute programmed cell death.
In a similar fashion, binding of TNF to TNF-R1 results in the trimerization of
the receptor and recruitment of TRADD, which is followed by a similar reaction seen
in the activation of Fas receptors (Figure 1.3). The known difference is that TRADD
also recruits other molecules, such as TRAF2, which actually activates a protective
pathway through the transcription factors NF-kB. Thus in many types of cells, TNF
induces cell death only in the presence of transcriptional inhibitors. The best
characterised of the death receptor is TNF-R1 (Figure 1.3).
TNFa
TNFR1
TRADD
TRAF-2
plasma
membrane
Death
Domain
FADD
Pro-caspase 8
Apoptotic
pathway
Signaling
pathway
Figure 1.3:  TNF receptor signaling. Binding of TNF-a to TNF-R1 results in
receptor trimerisation and clustering of intracellular death domains.
This allows binding of an intracellular adapter molecule called
TRADD ( TNF-R-associated death domain) via interactions between
death domains. TRADD has the ability to recruit a number of different
proteins to the activated receptor. Recruitment of TRAF2 (TNF-
associated factor 2) leads to activation of NF-kB and the JNK/Apaf-1
pathway.INTRODUCTION
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1.2.2 Bcl-2 protein family
The Bcl-2 proteins are a family of proteins involved in the response to
apoptosis. Some of these proteins (such as Bcl-2, Bcl-XL and Mcl-1) are anti-
apoptotic, while others (such as Bad, Bax and Bak) are pro-apoptotic (Gross et al.,
1999, Figure 1.4).
The BH1 and BH2 domains of Bcl-2 are required to heterodimerize with Bax
and to repress cell death; conversely, the BH3 domain (Wang et al., 1996) of Bax is
required to heterodimerize with Bcl-2 and to promote cell death. The sensitivity of
cells to apoptotic stimuli can depend on the balance of pro- and anti-apoptotic Bcl-2
proteins. When there is an excess of pro-apoptotic proteins the cells are more
sensitive to apoptosis; when there is an excess of anti-apoptotic proteins the cells will
tend to be less sensitive. The pro-apoptotic Bcl-2 proteins are often found in the
cytosol where they act as sensors of cellular damage or stress. Following cellular
stress they relocate to the surface of the mitochondria where the anti-apoptotic
proteins are located.
This interaction between pro- and anti-apoptotic proteins disrupts the normal
function of the anti-apoptotic Bcl-2 proteins and can lead to the formation of pores in
the mitochondrial membrane and the release of cyt c and other pro-apoptotic
molecules from the intermembrane space (Figure 1.5).
1.2.3 Caspase protein family
Caspases are a family of proteins that contains some of the main effectors of
apoptosis (Salvesen and Dixit, 1997). They are a group of cysteine proteases that
exist within the cell as inactive pro-forms or zymogens (Donepudi and Grutter, 2002).
These zymogens can be cleaved to form active enzymes following the induction of
apoptosis. Induction of apoptosis via death receptors results in the activation of an
initiator caspase such as caspase 8 or caspase 10, which can then activate other
caspases in a cascade (Donepudi and Grutter, 2002).INTRODUCTION
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BH3-only
Pro-apoptotic
Anti-apoptotic
BCL-2
BCL-X L
BCL-W
MCL-1
A1/BFL-1
BOO/DIVA
NR-13
Mammalian BCL-2 Family
BAX
BAK
BOK/MTD
BCL-X S
BID
NIX/BNIP3
NIP3
BIM/BOD
HRK
BLK
BIK/NBK
BAD
BH1 BH2 BH3 BH4 TM
Figure 1.4:  Bcl-2 family proteins are key regulators of apoptosis (Gross et al.,
1999). According to their Structure and function, they can be classified
into 3 groups: anti-apoptotic, pro-apoptotic. The proteins with only
BH3 domain are required for enhancing cell death interaction with pro-
apoptotic proteins.
During apoptosis, cyt c is nitrosylated in mitochondria and then rapidly
released into the cytoplasm in the absence of Bcl-2 or Bcl-XL overexpression
(Schonhoff et al., 2003). Interestingly, arginine antimetabolite L-canavanine induces
apoptotic cell death in human Jurkat T cells via caspase-3 activation regulated by Bcl-
2 or Bcl-xL (Jang et al., 2002). In vitro nitrosylation of cyt c increases caspase-3
activation in cell lysates. Inhibition of intracellular cyt c nitrosylation is associated
with a decrease in apoptosis, suggesting that cyt c nitrosylation is a pro-apoptoticINTRODUCTION
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modification (Schonhoff et al., 2003). This eventually leads to the activation of the
effector caspases, such as caspase 3 and caspase 6. These are in turn responsible for
the cleavage of key cellular proteins that leads to the typical morphological changes
observed in cells undergoing apoptosis.
BAX BCL-2
Genotoxic
Damage
Cytokine
Deprivation
Cell Death Signal
Pro-apoptotic
Death
Checkpoint
Anti-apoptotic
ROS PTP D  Ym
Cyt C
Apaf-1
PAST
THE
POINT
OF NO
RETURN
Recruitment of
procaspase-9
Caspase activation
DNA fragmentation
PAST
THE
POINT
OF NO
RETURN
apoptosome
Figure 1.5: Apoptosis is initiated by growth factor deprivation or genotoxic demage.
In one case the Apaf-1, cyt c and procaspase-9 complex can act as a
stage to activate cytosolic procaspase-9 as it is recruited to the
apoptosome (a multi-protein complex consisting of cyt c, Apaf-1, pro-
caspase 9 and ATP) and the activation of the caspase cascade. DYm:
mitochondrial membrane potential, ROS: Reactive oxygen species, PTP:
Protein tyrosine phosphatase.INTRODUCTION
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Interestingly, formation of noncanonical high molecular weight caspase-3 and
-6 complexes and activation of caspase-12 during serum starvation induced apoptosis
in AKR-2B mouse fibroblasts (Kilic et al., 2002).
In some cases, the induction of cell death by cytotoxic T-lymphocytes (CTL)
or natural killer (NK) cells is one of the main ways by which higher organisms
protect themselves from infected cells with a virus or posing a risk of cancer (Shi et
al., 1997; Sutton et al., 2000; Pinkoski et al., 2001).
The granule exocytosis mechanism plays a vital role in defense against virus
infection (granzyme mediated cell death; Sutton et al., 2003). Cytolytic lymphocytes
(CL) utilize two independently initiated pathways involving either ligation of death
receptors or perforin mediated trafficking of granzyme B to the target cell cytosol to
activate a family of death proteases (caspases 3, 7, 8 and 10) in the target cell.
However, if caspases are not activated, CL can utilize a caspase-independent
pathway to ensure the death of the target cell (Sutton et al., 2000; Pinkoski et al.,
2001). Bcl-2 was found to block granzyme B mediated apoptosis and maintained the
survival of some cells, indicating that mitochondrial disruption is central to the
granzyme B apoptotic pathway (Sutton et al., 1997).
In other cases, apoptosis is initiated by intrinsic cellular stress signals. Cellular
stress may occur from exposure to radiation, chemicals or to viral infection. It might
also be a consequence of growth factor (e.g., IL-3) deprivation or genotoxic demage
(Figure 1.5). Protection of hematopoietic FDCP cells from genotoxin-induced death,
by Pim-1 kinase, was observed (Pircher et al., 2000; see Section 4.1.1.1).
These intrinsic signals initiate apoptosis via the involvement of the
mitochondria. The mitochondria are the key regulators of the caspase cascade and
apoptosis. Release of cyt c from mitochondria can lead to the activation of caspase 9,
and then of caspase 3. This effect is mediated through the formation of an
apoptosome (Figure 1.5).INTRODUCTION
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1.3 The murine myeloid cell line (FDCP-1) responsive to IL-3
During hematopoesis, differentiation of leukocytes are regulated by
hematopoietic growth factors and cytokines (Vaux et al., 1988; Rodriquez-Tarduchy
et al., 1990). In a mouse model, a leukocyte cell population was generated from the
established factor-dependent (FDCP-Mix) hemopoietic cell lines (Spooncer and
Dexter, 1997). These cells can be differentiated into monocytes or granulocytes by
the addition of specific growth factors. FDCP-1 is a cell line which was generated
from FDCP-Mix by long-term mouse marrow cultures with blocking of clonal
differentiation (Dexter et al., 1980, See Section 2.1.2). FDCP-1 cells, are non-
transformed and dependent on pleiotropic growth factors such as IL-3 or granulocyte-
macrophage colony-stimulating factor (GM-CSF) for proliferation (Miyajima et al.,
1993) and rapidly undergo programmed cell death within 1-2 days of IL-3
deprivation, are suitable for investigation of collective mRNA expression from
candidate genes that antagonize or protagonize apoptosis. The apoptotic response in
FDCP-1 cell lines are relatively well characterized (Williams et al., 1990; Antoku et
al., 1998; Cho et al., 1999; Bittorf et al., 2000a) because FDCP-1 cells are closer to
primary cells than any other such cell lines (e.g., BA/F3, Palacios et al., 1984; 32D,
Migliaccio et al., 1989; TF-1, Drexler et al., 1997). However, the precise role of IL-3
in regulating massive numbers of pro- and anti-apoptosis genes, at transcriptional
level, is still intricate (Robb et al., 1995; Nicola et al., 1996; Nishinakamura et al.,
1995; 1996). For the reason described above, FDCP-1 was used as model cell in our
laboratory to isolate genes that are transcriptionally activated during programmed cell
death by IL-3 withdrawal (Russ et al., 1996b; Rayner et al., 1994).
1.3.1  Induction of apoptosis following IL-3 withdrawal and regulation of
survival signaling
Eventually, the withdrawal of IL-3 from FDCP-1 cells leads to the activation
of caspase proteases and a commitment to cell death (Bojes et al., 1999). However in
the early course of apoptosis, IL-3 deprivation also stimulates the activation ofINTRODUCTION
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survival cellular kinases, including phophatidylinositol 3'-OH-kinase (PI-3-K) and
Akt kinase (Section 1.3.1.1).
The signal transduction pathways, activated by IL-3 and GM-CSF in FDCP-1
cells, was further correlated with various biological effects such as (i) cell
proliferation, (ii) inhibition of apoptosis (Blalock et al., 1999; Reddy et al., 2002).
Activation of each of the Jak-Stat (Section 1.3.1.2), MAPK (Section 1.3.1.3) or PI-
3K-Akt alone is not sufficient either to stimulate cell proliferation or inhibit
apoptosis, suggesting that these processes are regulated by orchestrated activation of
multiple signalling cascades (Ratajczak et al., 2001). Although cell proliferation was
related to simultaneous activation of Jak-Stat and MAPK, the effect on cell survival is
more correlated with activation of PI-3K-Akt proteins (Section 1.3.1.1).
1.3.1.1 PI-3-K and Akt survival signaling
Survival of hemopoietic progenitors (e.g., FDCP-1) is maintained by at least
two different intracellular signaling pathways, one requiring PI-3-K and one that does
not (Minshall et al., 1996). PI-3-K is a lipid kinase that catalyzes the transfer of
phosphate from ATP to the D3 position of phosphoinositide (PtdIns, Figure 1.6)
generating phosphatidylinositol-3,4,5-trisphosphate (PtdIns-3,4,5-P3, Wymann and
Pirola, 1998) and these stimulates the activation of protein kinase-dependent cell
survival signaling pathways (Pirola et al., 2001; Storz and Toker, 2002). The most
relevant survival factor among the downstream effectors of PI-3-K is Akt/PKB (see
Figure 1.7; Nolte et al., 1996, Wymann and Pirola, 1998). Akt was originally
identified as the oncogene transduced by the acute trans-forming retrovirus (Akt-8)
that was isolated from an AKR thymoma (Staal et al., 1977; Staal et al., 1987;
Bellacosa et al., 1991). The serine-threonine kinase Akt exerts its anti-apoptotic
effects through several downstream targets. Akt was recognized to phosphorylate the
pro-apoptotic Bcl-2 family member, BAD, on Ser136 (Datta et al., 1997; del Peso et
al., 1997). Expression of activated Akt inhibits apoptosis and G1 arrest induced by
growth factor withdrawal in hematopoietic cells.INTRODUCTION
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 (Zhang et al., 1997)
Figure 1.6: The multiple reactions that PIP5Ks catalyze phosphoinositide
pathways leading to production of PtdIns-3,4,5-P3. Phosphorylation of
D3-phosphate-containing phosphatidylinositols by PIP5Ks provides
routes for PtdIns-3,4-P2 and PtdIns-3,4,5-P3 production.
The biological effects of Akt were linked to the induction of c-Myc oncogene
product and Bcl-2 (Ahmed et al., 1997). When BAD is phosphorylated, it gains
affinity for the cytosolic protein 14-3-3 and forms an inactive complex with this
protein. Nonphosphorylated BAD can heterodimerize with the anti-apoptotic Bcl-2
family member Bcl-XL. Upon phosphorylation of BAD, its binding to 14-3-3 decrease
formation of the BAD/Bcl-XL heterodimer, thus permitting free Bcl-XL to protect the
cell from apoptosis (Zha et al., 1997).
The anti-apoptotic effects of both PI-3-K and Akt suggested that these two
genes might be involved in human cancer (Coffer et al., 1998). The supporting
evidence of Akt involvement in human malignancies has been well documented
(Shayesteh et al., 1999; Cantley and Neel, 1999). Frequently, overexpression of Akt
occurs in more aggressive tumors. Akt inhibits a conformational change in the pro-
apoptotic Bax protein, thus preventing the disruption of the mitochondrial inner
membrane potential, caspase-3 activation, and apoptosis in pre-B hematopoietic cells
following IL-3 withdrawal (Yamaguchi and Wang, 2001).INTRODUCTION
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1.3.1.2 Jaks and Stats signaling
Jaks (Janus kinase) and Stats (Signal Transducer and Activator of
Transcription) are essential components of cytokine receptor signaling for regulating
growth, survival, differentiation and pathogen resistance (Heim et al., 1999; Ihle,
2001). Cytokine binding induces receptor dimerization, activating the associated Jaks,
which phosphorylate the receptor itself (Figure 1.7). Receptor-bound Stats are
phosphorylated by Jaks, dissociate from the receptor, dimerize and translocate into
the nucleus. Stat dimers bind specific enhancers, regulating the transcription of target
genes (Heinrich et al., 1998; Nelms et al., 1999). Interleukin-3 signals through
multiple isoforms of Stat5 (Azam et al., 1995). In the analysis of myeloid FDCP-1
cells, that stably expressing mutant erythropoietin receptor proteins (EPOR), show
that receptors having a high potential to mediate anti-apoptotic signals also
effectively activate Stat5, whereas receptors lacking Stat5 docking sites are
diminished (Bittorf et al., 2000b). The suppressor of cytokine signaling (SOCS)
family of proteins dampen receptor signaling via homologous or heterologous
feedback regulation (Starr and Hilton, 1999; Figure 1.7).
Anti-apoptotic signaling with Stat5 has been documented (Bittorf et al.,
2000a). When Stats are activated, Jak kinases phosphorylate other signaling-adaptor
proteins, linking Jak signaling (Quelle et al., 1994) to other pathways such as the
MAP kinases. The ligand-dependent activation of the Jak/Stat pathway has been
implicated in the explanation of cytokine-specific regulation of gene expression
(Bittorf et al., 2000b).
1.3.1.3 Mitogen Activated Protein (MAP) kinase signaling
Ras mediates the activation of Raf (with other necessary factors for maximal
activation of its kinase activity; Figure 1.7). Phosphorylation of both serine/threonine
and tyrosine residues is believed to have a role in the full activation of Raf (Morrison
and Cutler, 1997). The activated Raf can phosphorylate MEK (mitogen/extracellular-
signal regulated kinase kinase), leading to its activation. KSR (kinase suppressor ofINTRODUCTION
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Ras) has been proposed as a molecular scaffold regulating the Raf/MEK/ERK kinase
cascade (Brennan et al., 2002). Suppression of c-Myc-induced apoptosis, by Ras
signalling through PI-3-K and PKB, was described by Kauffmann-Zeh (Kauffmann-
Zeh et al., 1997).
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Figure 1.7: Jak/Stat, MAPK and PI-3-K/Akt signaling pathways in IL-3 dependent
cells. Cytokine binding induces receptor dimerization that signaling
activation of Jaks and Stats. Then, dimerized Stats are translocated into
the nucleus and bind specific enhancers, regulating the transcription of
target genes. In the Raf/MEK/ERK kinase cascade pathway, Ras
mediates the activation of Raf and the activated Raf phosphorylate
MEK leading to its activation (see Section 4.3.1 for ERK). The most
relevant survival factor among the downstream effectors of PI-3-K is
Akt/PKB.INTRODUCTION
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1.3.2 Cell death by default
Apoptosis is a fundamental aspect of the maintenance of the balance between
cell growth and cell death. If the balance is tilted (e.g., by unregulated cell growth),
the result could be cancer. If tipped the other direction and the result can again be
cancer. As described in Section 1.2 and Figure 1.2, however, nature provides a way
of cell death by default (the type I pathway that ensues quick apoptosis). The concept
of cell death by default, has forced a shift in the paradigm of cancer development for
more than three decades (Parkin et al., 2001). However, the likelihood that radiation
and chemotherapy, both major modalities of cancer therapy, could not benefit from
strategies that modulate programmed cell death by default. The apoptosis process is
the result of differential expression of a number of genes, which are described in
Section 4.2.2.
1.4 Identification of transcriptionally induced genes after IL-3
withdrawal
Gene trapping has become a standard approach of functional genomics
(Stanford et al., 2001) because of its efficiency for simultaneously characterizing
gene function, sequence and expression. Current gene-trapping principle is based on
the three different types of trap vectors: the enhancer-, promoter- and gene-trap
vectors (Stanford et al., 2001). The gene trap technique combined with Cre
recombinase (Cre: causes recombination) and locus of x-ing over P1 (loxP)
recombination system (Figure 1.8) were previously developed in our laboratory (Russ
et al., 1996b). This technique was used to isolate genes from cells undergoing
apoptosis by growth factor withdrawal and to identify transcriptional mechanisms
that interfere with cell death and survival. As illustrated in the Figure 1.8, the reporter
cell line FLOXIL3 (an IL-3-dependent hematopoietic cell line) expresses a fused
reporter gene tkneo that codes for thymidine kinase and neomycin phosphotransferase
(Russ et al., 1996a). FDCP-1 cells expressing this reporter gene survive out of
selection procedure with G418 (neomycin) and IL-3. The FLOXIL3 cells were
infected again in suspension cultures of U3Cre gene trap virus with a multiplicity ofINTRODUCTION
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infection (MOI) @  0.5 . Activation of Cre (Cre-recombinase) expression from the
transduced genes delete the tkneo gene by placing the IL-3 gene just downstream of
the pgk promoter (Figure 1.8) that resulted in a permanent switching of the FLOXIL3
cells to IL-3 independence but losing neomycin resistance (Dexter et al., 1980; Sauer
and Henderson, 1988; Vaux et al., 1988; Gu et al., 1993; Russ et al., 1996b). This
rescues IL-3 dependent FDCP-1 (FLOXIL3) cells (Vaux et al., 1988; Dexter et al.,
1980) from apoptotic cell death induced by IL-3 deprivation.
loxP Tkneo pA IL-3 loxP pA pgk
tkneo-transcript
cre cre
Pol II
fusion  transcript
FLOXIL3 Infected with U3 Cre gene trap virus
Cre  recombinase
IL3 transcript
pgk loxP IL 3 pA +
loxP
Conversion  to  IL-3  independence
loxP Tkneo pA IL-3 loxP pA pgk
recombinase
pgk
IL 3 pA loxP
loxP
Figure 1.8: Site specific recombination with Cre/loxP exon trap system, applied to
transiently induced gene trapping. Activated Cre-recombinase delete
the tkneo gene by placing the IL-3 gene that resulted in a permanent
switching of the FLOXIL3 cells to IL-3 independence from apoptotic
cell death induced by IL-3 deprivation. The phenomenon allowed
selection for gene-trap integrations of activated survival genes upon
factor deprivation.INTRODUCTION
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Two PCR-based methods were applied for amplification of subtracted cDNA:
Rapid Amplification of cDNA Ends (RACE) and inverse PCR (Figure 1.9). This
approach allowed to identify several functional classes of genes (Section 3.1.1). The
gene trap sequence tags (GTSTs) library served as a reference (described in Chapter
3) for the survival genes that prevent growth factor withdrawal-mediated apoptosis in
the FDCP-1.
+IL-3
+G418
Selection
-IL-3
-G418
Conversion to IL-3 independence
• Isolation of genomic DNA and digestion with a restriction enzyme
cre cre
SspI/HincII
Provirus
genomic  DNA
exon  or intron
genomic  DNA
exon or intron 5' LTR 3' LTR
P2
SspI/HincII SspI SspI
Ligation
P1
• Inverse PCR (3'- or 5'-inverse) and RACE
• Sequencing  and  analysis through data base
Figure 1.9: Isolation and analysis of transiently induced genes. Positive selection:
FLOXIL3 expresses thymidine kinase and neomycin
phosphotransferase that endows to FDCP-1 cells survive out of
selection procedure with G418 (neomycin) and IL-3. Negative
selection: when FLOXIL3 cells were infected with U3Cre gene trap
virus, FLOXIL3 cells become independence to IL-3 but losing
neomycin resistance. The subtracted cDNAs were amplified by the
RACE and inverse PCR methods for the generation of GTSTs library.INTRODUCTION
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1.5  Aims
In hematopoietic systems, apoptosis is highly regulated as it can function to
restrict cell number, eliminate autoreactive immune cells, and control differentiation.
Followings are the well defined facts on basis of the accumulated knowledge that
published since more than a decade (Williams et al., 1990).
(a) Hematopoietic colony stimulating factors, such as IL-3, promote cell
survival by suppressing apoptosis.
(b) Withdrawal of essential cytokines has been shown to initiate the apoptotic
cascade in variety of myeloid lineages and cells.
However, our previous results and observations (unpublished data, Wempe, F.
and von Melchner, H.) strongly suggested that IL-3 does not singularly control
survival of the hematopoietic cell line FDCP-1, because some of survival genes (as
well as apoptotic genes) are transiently expressed after 2-4 h of IL-3 withdrawal
(Wempe et al., 2001). This phenomenon suggested a possibility that IL-3 might
activate some apoptosis genes in the different pathways. In this particular
hematopoietic system, our interest were the balance of mechanisms by which IL-3
equally mediates its biological effects on both survival and death.
Major aims:
I. To validate the gene trapping strategy for the recovery of transcriptionally
regulated survival genes.
II. To assess the efficiency of the gene trapping strategy in recovering apoptosis
related genes in the context of related Microarray and GeneChip analysis.
III. To identify cancer related genes among GTSTs recovered from FDCP-1
cells undergoing apoptosis.C
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CHAPTER 2
MATERIALS AND METHODS
2.1 Routine preparations
2.1.1 Chemicals, reagents, enzymes and instruments
All chemicals and reagents used in this research were analytical grade and
were obtained from commercial suppliers (see Appendix II). Routine procedures,
especially when they originate from current standard protocols described elsewhere,
are mentioned in this Chapter with or without modifications.
2.1.2 Eukaryotic cell lines and cell culture
Eukaryotic cells were grown in culture plates or flasks at 37 °C, 5% CO2 with
100% humidity. Cells were maintained in culture by refreshing the culture medium
every 2 to 3 days. After decantation of the culture medium, adherent cells were
incubated for 5 min at 37 °C with 3-5 ml of commercially available PBS buffer
containing 0.25% (w/v) trypsin. The reaction was stopped by addition of 10 ml of
culture medium. The cells were collected by centrifugation at 300 x g for 5 min,
resuspended in 10 ml of the appropriate medium and propagation was continued.
Except for the cell line FDCP-1 (factor dependent cell from Paterson Institute,
Dexter et al., 1980; Spooncer et al., 1997), all cells used for RNA purification were of
human origin and were obtained from the American Type Culture Collection
(ATCC). FDCP-1 cell lines were generously provided by the 
†German Collection of
Microorganisms and Cell Cultures (DSMZ, Braunschweig).
†German Collection of Microorganisms and Cell Cultures:
URL: http://www.dsmz.de/
E-mail: dsmzmutz@gbf-braunschweig.deMATERIALS AND METHODS
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Table 2.1: Cell lines used as source of RNA for array assays
(see Section 3.4.2 and Table 3.6).
Cell lines Cell type Medium* Accession number
FDCP-1 bone marrow culture of mice 1 ACC 368 
†
U937 histiocytic lymphoma 2 CRL-1593.2
K562 chronic myeloid leukemia 2 CCL-243
HEL erythroleukemia 2 TIB-180
HL-60 acute myeloid leukemia 3 CCL-240
Raji Burkitt’s lymphoma 2 CCL-86
* Media used for cell culture were:
1. Dulbecco’s modified Eagle’s medium (DMEM, Gibco-BRL),
supplemented with 10% (v/v) fetal calf serum (FCS), 5 ng/ml
recombinant mouse IL-3 and 100U/gentamycin
2. RPMI 1640 medium (Roswell Park Memorial Institute, Moore
et al., 1993) supplemented with 10% (v/v) FCS, 2 mM L-
glutamine and 100 U of /penicillin and streptomycin
3. IMDM (Iscove's modified Dulbecco's medium, Uittenbogaart et
al., 1983) supplemented with 20% FCS, 1.5 g/l sodium
bicarbonate, 2 mM L-glutamine and 100 U/ml penicillin and
streptomycin
2.1.3 IL-3 withdrawal from FDCP-1 cell culture medium
The FDCP-1 cells (6 x 35 ml) were propagated to a concentration of 1-2 x 10
6
cells/ml in DMEM. The cells were pooled and separated into 6 x 50 ml Falcon tubes.
Then, they were collected by centrifugation (300  x  g) at 4 °C for 4 min and
resuspended in fresh DMEM lacking IL-3. This step was repeated one more time.
Finally, five of the six pellets were resuspended in DMEM (supplemented only with
10% (v/v) FCS, 100 U/ml gentamycin) and portioned into 5 x 50 ml plates (density:
~1.2 x 10
6).MATERIALS AND METHODS
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One pellet was harvested directly and used as control. For study of the time
course of induction, the cells were cultured in the absence of IL-3 for 1, 2, 4, 6, and 8
h. The cells treated under each condition were collected by centrifugation, and then
the pellet was directly frozen in liquid nitrogen and kept at –80 °C until used for RNA
preparation.
2.1.4 Cell storage
For storage, 1 x 10
7 cell was  harvested by centrifugation  at 300 x g for
10 minutes and washed with PBS. They were then resuspended in 0.5 ml of RPMI
containing 20% (v/v) FCS, and then mixed with 0.5 ml of RPMI containing 20%
(v/v) DMSO. The cell suspensions were immediately transferred into cryovials and
placed into a freezing container (Mr. Frosty, Nalgene), then stored at –80 °C freezer
overnight, before being transferred into a liquid nitrogen storage freezer.
To recover the stored cells, cryopreserved cells were thawed rapidly in a 37
°C water bath and subsequently resuspended in culture medium. Following one
washing step with medium (Section 2.1.2) to remove residual DMSO, the cells were
placed into culture flasks.
2.1.5 Media for bacterial growth
Strains of E. coli were grown in LB medium (Luria and Burrous, 1957) at 37
°C supplemented with ampicillin (50 mg/ml). Stock ampicillin (50 mg/ml in H2O)
kept at –20 °C until use.
2.1.6 Agar plates for color screening
For blue white color screening, LB agar plates were treated (30 min prior to
plating the transformants) with 100 ml of 10 mM IPTG (isopropyl b-D-thiogalacto
pyranoside) and 100 ml of 2% X-gal (5-bromo-4-chloro-3-indolyl-beta-D-galactoside)
by spreading over the plates.MATERIALS AND METHODS
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2.1.7  Preparation of plasmid DNA
The method for small-scale plasmid DNA extraction by alkaline lysis, for
isolating plasmids from bacterial culture, was adapted from Silhavy's method
(Silhavy et al., 1984). However, for the best yield of plasmid DNA with efficiency,
the preparations were performed with commercially available kits and protocols
(Qiagen, Inc.). After purification, the plasmid DNAs were resuspended in TE buffer
(10 mM Tris.HCl pH 7.6, 1 mM EDTA) and stored at –20 °C.
2.1.8 DNA precipitation with ethanol
DNA was concentrated by precipitation with ethanol at low temperature in the
presence of moderate concentrations of sodium acetate. One-tenth volume of 3 M
sodium acetate, pH 5.2 and 2 volumes of ice cold ethanol was added to an aqueous
DNA sample. The precipitation was performed by treatment at –20 °C overnight and
by centrifugation at 12000 x g for 15 minutes at 4 °C. The DNA pellet was rinsed
with ice cold 80% (v/v) ethanol. The DNA pellet was dried and dissolved in TE
buffer (see Appendix III).
2.1.9 DNA extraction from agarose gels
QIAquick
TM Spin (Qiagen) kits were used to extract and purify DNA
fragments (in the size range between 70 bp and 3 kb) from gels in Tris/acetate/EDTA
electrophoresis buffer (TAE, Appendix III). The optimal elution efficiency was
achieved with 10 mM Tris-HCl (pH 7.0-8.5) and the eluted DNA was stored at –20
°C.
2.1.10 Determination of nucleic acid concentrations
The nucleic acid solution was concentrated or diluted to give an optimal range
of concentration for photometric measurement. A quartz cuvette (Ultraspec®,
Pharmacia Biotech) was filled with dilution buffer and the base line was recorded.
The absorbance of the sample was measured at 260 nm.MATERIALS AND METHODS
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The measured A260 was translated into the concentration of the nucleic acids by the
spectrophotometric conversions shown in Table 2.2. The ratio between the
absorbance readings at 260 and 280 nm gives an estimate of nucleic acid purity. The
A260/A280 ratio of pure DNA and RNA are 1.8 and 2.0, respectively.
Table 2.2: Spectrophotometric conversion of A260 to concentrations of nucleic acids.
1 A260 unit of double-stranded DNA equals 50 mg/ml
1 A260 unit of single-stranded DNA equals 33 mg/ml
1 A260 unit of single-stranded RNA equals 40 mg/ml
2.1.11 Restriction-endonuclease digestion of DNA
Target DNAs were digested with commercially available restriction
endonucleases in suitable buffers (Appendix II). Digestions were usually performed
at 37 °C for 0.5-2 h (if not recommended otherwise*) and terminated by addition of
0.25-0.5 volume of restriction-endonuclease stop mix (50 mM EDTA, 17% (v/v)
glycerol, 0.07% bromophenol blue, pH 8.5). For partial digestion, a small-scale
reaction was carried out first for optimization of the reaction. Restriction enzymes
were diluted serially and made in equivalent volumes of reaction mixtures containing
identical concentrations of plasmid DNA. Electrophoresis on agarose gels (with
1xTAE buffer) was routinely used to see the results of digests.
* One unit of enzyme: the minimal amount of enzyme required to digest all of 1 mg DNA in 1 hour.
2.1.12 Agarose gel electrophoresis
Agarose gels, from 0.7 to 2% (w/v) in 1 x TAE buffer (Appendix III)
containing 0.2 mg/ml ethidium bromide, were used for the electrophoretic separation
of DNA molecules for the following purposes.
(a) To check the progression of a restriction enzyme digestion (Section 2.1.11).
(b) To quickly determine the yield and purity of PCR products (Figure 3.9).
(c) To purify DNA fragments (Section 2.1.9).MATERIALS AND METHODS
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Agarose gel electrophoresis, for DNA separation, was carried out in a
horizontal configuration (Davis system; Sambrook et al., 1989).
Agarose and buffer mix was heated in a microwave oven until the agarose was
completely melted. The agarose solution was cooled to about 50 °C and
supplemented with ethidium bromide to a final concentration of 0.2 mg/ml. The warm
agarose solution was poured into a gel tray. The gel was completely submerged by
about 1 mm with the electrophoresis buffer. Samples of DNA were mixed with 1/4
volume of a loading buffer (2% bromophenol blue, 50% glycerol).
After samples were loaded onto a gel, electrophoresis was carried out at 50 V
until the DNA had entered the gel matrix. Electrophoresis was continued at 100 V
until the desired resolution of DNA fragments was achieved.
2.1.13 5´-Dephosphorylation of linear plasmid DNA
The terminal 5’ phosphates were removed using calf intestinal alkaline
phosphatase (CIP) to prevent self-ligation of linearised vector DNA (Sambrook et al.,
1989). Generally 1 mg of DNA was mixed with 1 Unit of CIP and 5 ml of 10 x CIP
buffer (500 mM Tris-HCl pH 8.5, 10 mM MgCl2, 10 mM ZnCl2) in a 50 ml volume.
The mixture was incubated at 37 °C for 20 min before a second aliquot of CIP was
added, then further incubated for 20 min. The enzyme was inactivated by heating the
sample at 65 °C for 20 min.
2.1.14 Ligation of DNA fragments
Fragments of DNA with sticky ends were ligated with T4 DNA ligase in the
ligation buffers described by Sambrook et al. (1989).
Ligations were carried out in a 10 ml reaction mixture containing linearized vector, a
threefold molar excess of the insert,  1 Unit of  T4-DNA ligase and 1  ml of 10 x
ligation buffer (250 mM Tris-HCl pH7.6, 50 mM MgCl2, 50 mM dithiothreitol, 5 mM
ATP). The mixtures were incubated overnight at 16 °C.MATERIALS AND METHODS
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2.1.15 Preparation of competent bacteria
The competent bacteria (XL1-Blue; Hanahan, 1983) were prepared using the
standard CaCl2 method (Morrison, 1979), dispensed into chilled sterile
microcentrifuge tubes and frozen immediately by immersing the tube in liquid
nitrogen. The aliquots (50 ml) were stored at -80 °C. However, when it was necessary
for increased transformation efficiency and blue-white color screening, commercially
available XL10-Gold ultracompetent cells were used (Table 2.3, Stratagene).
Table 2.3: Genotypes of the competent bacteria. The genes present on the F´
 episome represent the wild type bacterial alleles
Host strain Genotype
XL10-Gold  D(mcrA) 183 D(mcrCB-hsdSMR-mrr)173 endA1 supE44 thi-1
recA1 gyrA96 relA1 lac Hte [F´ proAB lac
qZDM15 Tn 10 (Tet
R)
Amy Cam
R]
XL1-Blue recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F' proAB
lacIqZDM15 Tn10 (Tet
R)]
2.1.16 Cloning in pGEM-T vector
Double stranded PCR products made with Taq DNA polymerase (the resulting
A-tailed fragments) were cloned using pGEM
®-T Vector Systems (Promega, Figure
2.1). The greatly improved efficiency of ligation is based on the fact that Taq DNA
polymerase preferentially adds a single 3’ A-deoxynucleotide to double-stranded
DNA fragments by a non-template-dependent extension reaction (Clark, 1988).
“Blue-white” color screening methods are based on the ability of b-
galactosidase (IPTG induced LacZ gene product) to hydrolyse 5-bromo-4-chloro-
indolyl-b-D-galactopyranoside (X-gal), resulting in the blue staining of a colony. As
shown in Figure 2.1, T7 and SP6 RNA polymerase promoters flank a multiple
cloning region within the peptide coding region for the b-galactosidase a-peptide.
Insertional inactivation of b-galactosidase allows recombinant clones to be directly
identified by color screening on indicator plates (Section 2.1.6).MATERIALS AND METHODS
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ori
f1 ori
pGEM-T
Vector
(3000bp)
lacZ
T T
Ampr
Sca I 1875
Xmn I 1994
T7
SP6
PCR product
ligation site
Figure 2.1:  Genetic map of the pGEM-T vector. (Promega)
2.1.17 Transformation of bacteria
An aliquot of competent E .coli bacteria was taken out of a -80 °C freezer, and
after 10 min resting on ice, 10-100 ng of plasmid (or ligation mix) were added.
Bacteria were left on ice for the next 30 min and then exposed to a 42 °C heat shock
for 2 min. 500 ml of LB (without antibiotic) were added, and samples were incubated
for 1 h in a shaking incubator. Afterwards, bacteria were transferred onto LB-
ampicillin (50 mg/ml, Section 2.1.5) agar plates. Following overnight incubation on
37 °C, individual single colonies were initially selected on the basis of ampicillin
resistance and “blue-white” color screening. The described orientation of insert was
then confirmed by PCR (Section 2.2) and sequencing of the gene (Section 2.1.18).
2.1.18 Sequencing of DNA
Sequencing reactions with double stranded plasmid DNA templates were
performed using ABI PRISM® Dye Terminator Cycle Sequencing Ready Reaction
Kits (Applied Biosystems). The underlying principle is the use of a set of four
different dye-labeled ddNTPs as terminators in a primer extension reaction. In this
reaction, DNA polymerase, dNTP mix and four fluorescence-labeled ddNTPs were
used to produce DNA ladders for the individual bases in one reaction tube. The
method is based on non-isotopic fluorescent detection of the labeled nucleic acids.
In a standard protocol, DNA (plasmid DNA: 3 mg, PCR fragment: 100-300
ng) was mixed with 10 pmol of a primer and 4 ml of the Terminator Ready ReactionMATERIALS AND METHODS
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Mix (0.05 Units/µl AmpliTaq® DNA polymerase, 400 µM each dNTP mix, 30 mM
Tris-HCl pH 8.05, 5 mM MgCl2, 100 mM KCl and labeled ddNTPs) in a final volume
of 20 ml. This mixture was denatured for 5 min at 94 °C and PCR was performed with
25 cycles, each consisting of 30 sec denaturation at 94 °C, 30 sec annealing at 50 °C
and 4 min elongation at 60 °C.
The DNA product was purified using Centri-Sept® (Princeton Separation,
USA). Following the purification 4 ml of DNA solution was mixed with 12 ml of
Template Suppression Reagent (Applied Biosystems) and denatured for 3 min at 94
°C. Separation and detection of fragments was carried out using an ABI PRISM 310
Genetic Analyser (Pekin Elmer Biosystems).
2.2 Polymerase chain reaction (PCR)
PCR techniques for amplifying segments of DNA (that lie between two
regions of known sequences or primers) consist of three basic steps: Repeated cycles
of (i) denaturation, (ii) annealing and (iii) DNA extension. The annealing temperature
and extension time were decided by G-C contents in primers and product
considerations. The automated thermal cycler (Robo Cycler Gradient 96, Stratagene)
was programmed according to the manufacturers' instructions. The target DNA for
amplification was denatured for 1 min at 94 °C and annealed for 1 min at 50-60 °C (if
GC content was £50%, annealed at 54 °C; if >50%, annealed at 60 °C), then extended
during 1-3 min at 72 °C (if product length was £500 nucleotides, extended 1 min; if
>500 nucleotides, extended 3 min). Usually, the program was run for 20-30 cycles.
However, in the case of cDNA amplification (with minimal amount of genomic DNA
template, Figure 2.7), 45 cycles were carried out. Specific applications of PCR are
described in the individual Sections.
2.2.1 Oligonucleotides
To identify nucleotide sequences that carrying our target DNAs, the GenBank
accession numbers (see Appendix I) were used as a query to search nucleotideMATERIALS AND METHODS
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databases. Specific PCR primers (Appendix IV, V and VI) were designed (with
MacVector and DNA Strider, Appendix II) from the acquired sequence information
(Clontech data bank or NCBI: http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi). All
oligonucleotides were provided by Interactiva Biotechnology and were purified by
HPLC. Usually, 10 pmol/ml (in TE buffer, pH 7.5; Appendix III) working solution
was used for PCR.
2.2.2 Quick analysis of recombinant plasmid by PCR
PCR is frequently used because it is the most sensitive assay for determining
the orientation and size of an insert in recombinant DNA. After blue-white screening
of transformants (Section 2.1.16) on the plates, single colonies were picked up with
sterilized toothpicks and cells were vigorously vortexed in 50 ml of TE buffer.
After they were centrifuged for 20 min at 30,000 g, 1 ml of the supernatant,
containing recombinant DNA, was used as template. Sense and antisense primers
were designed for the screening by PCR.
2.3 Reverse transcription-PCR for generation of cDNA fragments
RT-PCR was adapted to detect transcripts, and to amplify their sequences to
permit cloning and/or nucleotide sequencing.
Especially, for Northern blot and matched tumor/normal expression array
assays, part of the corresponding cDNA was amplified from the original cDNA
fragment that was generated from the total RNA of related cells by reverse
transcription (Superscript II RT; Gibco-BRL). Then, the cDNA was ligated into the
pGEM
®-T vector (Section 2.1.16). Sequencing of the double stranded cDNA was
done as described in Section 2.1.18.
Reverse transcription was used for another reason to produce a-
32P-labeled
first strand cDNA probes that were synthesized from total RNA (Custom array assay;
Section 2.6.5). In this case, I used gene specific primers (Section 2.2.1; see Appendix
VI) and SuperScript 
TM II RNaseH reverse transcriptase (Gibco-BRL).MATERIALS AND METHODS
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2.3.1 RT-PCR for generating cDNA templates for matched tumor/normal array
RT-PCR was used to produce cDNA from total RNA of cancer cells. The total
30 µl PCR reaction mixtures in diethylpyrocarbonate (DEPC) H2O, contained 2 ml of
SuperScript 
TM II RNaseH reverse transcriptase in 1 x reaction buffer (5 x reaction
buffer: 250 mM Tris-HCl, pH 8.3, 375 mM KCl, 15 mM MgCl2) and 1 x dNTP mix
(10 x dNTP: each of 5 mM dNTPs) with 1 ml of random hexamer primers (1 mg/ml), 3
ml of dithiothreitol (DTT, 100 mM) and 2.5 mg of total RNA of cancer cells. After the
initial denaturation of RNA at 65 °C for 10 min, the PCR reactions followed by
switching temperatures to 30 °C for 10 min, 42 °C for 90 min and final incubation at
65 °C for 15 min. 1 ml of this cDNA template was used for amplification of target
genes (Section 2.5.2).
2.4 cDNA array analysis
I used a commercially available cDNA microarray to examine the modulation
of mRNA expression following IL-3 withdrawal (Section 2.1.3). The Atlas™ Mouse
cDNA Expression Array (CLONTECH) includes 588 genes involved in key
processes (as shown in Figure 2.2) to facilitate differential expression profiling. Each
cDNA fragment contained 10 ng of cDNA, and was immobilized (on a nylon
membrane) in duplicate to assure the quality of hybridization. As shown in the Figure
2.2, the genes in the membrane were subdivided into six groups according to their
function. A: Oncogenes/tumor suppressors/cell cycle regulators; B: Stress
response/ion channels and transport; C: Apoptosis/DNA synthesis, repair and
recombination; D: Transcription factors/DNA-binding proteins; E: Receptors for
growth factors (interleukin, interferon), hormones and neurotransmitters; F: Cell-
cycle communication/cytoskeleton and mobility; G: 5, 6, 7, 12, 13, 14, 19, 20 and 21
are housekeeping genes that are commonly defined as genes that are ubiquitously
expressed at stable levels in different biological contexts. They have been used to
standardize quantitative expression studies. The methods that underlie use of the
Atlas™ Mouse cDNA Expression Array are described in Figure 2.3.MATERIALS AND METHODS
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* The list of genes is available at Clontech’s web site (      http://www.Clontech.com)     .
Figure 2.2: The Atlas™ Mouse cDNA Expression Array.
polyA+ was prepared  from total RNA
Expression profiling with simultaneous comparison
of the expression levels of all the cDNAs on the
array
Probes are generated from the RNA samples
by RT-PCR with a32P-dATP
polyA+
(Wild type)
polyA+
(2 h & 8 h withdrawal of IL-3)
Probe 1 Probe 2
Hybridization onto a positively charged nylon membrane
on which 588 cDNA fragments have been immobilized
Data analysis with GenBank
Total RNA was prepared  from FDCP-1 cells
Digestion of DNA contamination with DNAse I
Figure 2.3:  A scheme for mouse cDNA expression array assay.MATERIALS AND METHODS
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2.4.1 Isolation of total RNA from FDCP-1 cells
All of the solutions used in dealing with RNA were prepared with DEPC
treated H2O. DEPC (0.2 ml) was added to 100 ml of H2O and autoclaved. FDCP-1
cells were grown either in the presence (+IL-3) or the absence of IL-3 (–IL-3) for
periods between 1 and 8 h (Section 2.1.3). Total RNAs were prepared by the following
methods. The cell pellet (~1.2 x 10
8 cells) was dissolved in 2 ml of "RNAzol
TM B-
RNA" solution that contains 4 M guanidinium isothiocyanate, 25 mM sodium citrate
pH 7.0, 0.5% (w/v) sodium N-lauroyl sarcosinate, 0.1 M 2-mercaptoethanol, 0.2 M
sodium acetate (pH 4.0) and phenol (Chomczynski et al., 1987). Guanidinium
isothiocyanate (with phenol) is a strong agent that inactivates RNases. To extract RNA
(by phase separation), 0.1 volume of chloroform was added, mixed by shaking and the
phases were separated by centrifugation at 5000 x g for 10 min at room temperature.
The cellular DNA was precipitated at the interface of the two phases. The aqueous
phase containing RNA was transferred to a fresh tube and extracted with 800 ml of
chloroform to remove the residual phenol. After centrifugation at 12000 x g (10 min, 4
°C), the supernatant was transferred to a fresh tube. The RNA was precipitated by
mixing with 0.7 volume of isopropanol and by incubation for 30 min in ice. The RNA
was collected by centrifugation at 12000 x g (10 min, 4 °C). The RNA pellet was
rinsed with 70% (v/v) ethanol and centrifuged at 12000 x g for 10 min. The ethanol
was removed and the RNA was dissolved in DEPC-H2O and stored at –80 °C.
2.4.2 Isolation of polyA
+-RNA from total RNA
There is a lower limit to the sensitivity of Northern blotting, so that only
moderately abundant mRNAs can be detected. One way to increase the sensitivity of
Northern blotting is to enrich the RNA preparation for mRNA. When RNA is isolated
from cell lines or tissue sources, all RNA species (total RNAs: ribosomal and transfer
RNA as well as mRNA) are isolated. As noted in Figure 2.4, most mRNAs destined
for the cytoplasm and translation are modified by the addition of a 3’ poly(A) tract.MATERIALS AND METHODS
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Figure 2.4:  Probe synthesis from polyA
+-RNA (see Section 2.3.1).
An RNA preparation could be greatly enriched for mRNA species by removing
all RNA molecules that lack the 3’ poly(A) tail. Usually, mRNA makes up less than
10% of the total RNA content of a cell or tissue. In this work, ~500 mg of total RNA
was prepared using the methods described in Section 2.4.1, and it was used to obtain
10-20 mg of poly(A)
+-RNA. The method was followed as described in Klaus et al.
(1990). Total RNA (500 mg) was resuspended with 45 ml of lysis buffer (in a 50 ml
Falcon tube); 2.5 ml of sodium dodecyl sulfate (SDS, 20%) and 0.3 mg/ml proteinase
K were added and the mixture was incubated for 3 h at 37 °C. After addition of 2 ml of
oligo (dT)-cellulose (Pharmacia) suspension to the Falcon tube, it was incubated for 18
h at room temperature on a rolling incubator. The supernatant was discarded and
nonpoly(A)-containing RNA was washed away three times with 45 ml of 1 x binding
buffer (Appendix III). The RNA/ oligo (dT)-cellulose solution was then placed into a
Poly-Prep® chromatography column, (Bio-Rad), which was washed with 30 ml of 2 x
wash buffer (Appendix III). The poly(A)
+-RNA was eluted with 10 ml of elution
buffer (Appendix III) at room temperature. Fractions (500 ml each) were collected and
5 ml of each was loaded on a 1% ethidium bromide-stained agarose dry gel (withoutMATERIALS AND METHODS
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running the sample by electrophoresis) to quickly check which fractions contained
poly(A)
+-RNA  samples. Fractions containing RNA were visible on the gel. Then, the
fractions were pooled and precipitated by mixing with 0.7 volume of isopropanol and
by incubation for 30 min on ice. The RNA was collected by centrifugation at 12000 x
g (10 min, 4 °C). The RNA pellet was rinsed with 70% (v/v) ethanol and centrifuged
at 12000 x g for 10 min. The ethanol was removed and the RNA was dissolved in
DEPC-H2O. To avoid genomic DNA contamination, the polyA
+-RNA  samples were
treated with 0.5 Units of RNase-free DNase I for 2 h at 37 °C and purified with
CHROMA SPIN-200 column (Clontech). Then, a possible genomic DNA
contamination of the sample was checked by PCR (Section 2.2) with GAPDH primers
(Appendix IV) and analyzed on 2% agarose gel (Figure 3.3).
2.4.3 Probe synthesis from polyA
+-RNA  for Atlas Array assay
1 mg of polyA
+-RNA  was converted into a-
32P-labeled first strand cDNA. A
master mix (Table 2.4) was prepared for all labeling reactions. First, the polyA
+-RNA
(1 mg) was mixed with 2 ml of CDS Primer Mix (Clontech) in a 0.5 ml
microcentrifuge tube. Then, the tube was incubated in a preheated PCR thermal
cycler at 70 °C for 2 min. The temperature of the thermal cycler was reduced to 50 °C
and the sample was incubated for 2 min. 8 ml of the master mix (Table 2.4) was added
to each reaction tube without removing the RNA samples from the thermal cycler,
then it was incubated at 50 °C for 25 min. The reaction was stopped by adding 1 ml of
10 x termination mix (Appendix III) and column chromatography followed
(CHROMA SPIN-200, Clontech).
Table 2.4: Composition of the master mix for generating labeled cDNA probes
1 x
5 x Reaction buffer 2 ml
10 x dNTP mix (for dATP label) 1 ml
a-
32P-dATP (3,000 Ci/mmol, 10 mCi/ml) 3.5 ml
DTT (100 mM) 0.5 ml
MMLV reverse transcriptase (50 units/ml) 1 ml
Total volume 8 mlMATERIALS AND METHODS
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2.4.4 Hybridization of cDNA probes to the Atlas Array
First, the ExpressHyb™ solution (Clontech) and sheared salmon testes DNA
(Sigma) were prepared as follows. ExpressHyb (50ml) was prewarmed at 68 °C.
Sheared salmon testes DNA (500 mg) was heated at 95–100 °C for 5 min, then chilled
quickly on ice. Then, the heat-denatured sheared salmon testes DNA was mixed with
the prewarmed ExpressHyb and maintained in a hybridization oven (Hybridiser HB-
1D, Appendix II) at 68 °C until used.
Second, a hybridization container (Biometra) was filled with deionized H2O.
The Atlas Array membrane was placed into the container. All the water was poured
from the container. The hybridization solution (5ml), prepared in the first step, was
added into the bottle. This step was performed as quickly as possible to prevent the
array membrane from drying. It was then prehybridized for 30 min with continuous
agitation at 68 °C.
Third, the labeled probe (entire pool; 0.5–20 x 10
6 cpm) was mixed with 1/10
volume of 10 x denaturing solution (1 M NaOH, 10 mM EDTA; Appendix III). Then,
it was incubated at 68 °C for 20 min. Human Cot-1 DNA (5 ml ) and 1/2 volume of 2
x neutralizing solution (1 M NaH2PO4/Na2HPO4, pH 7.0; Appendix III) was added to
the denatured probe. Incubation was continued at 68 °C for 10 min. After the addition
of the probe, the membrane was hybridized overnight with continuous agitation in a
hybridization oven (Hybridiser HB-1D, Appendix II) at 68 °C. On the following day,
the wash solutions 1 and 2 (Appendix III) were prewarmed at 68 °C. After removal of
the hybridization solution, the Atlas Array membrane was washed (by the wash
solution 1; 200 ml) with continuous agitation for 30 min at 68 °C. This step was
repeated three more times. One 30 min wash with 200 ml of prewarmed wash
solution 2 was then carried out with continuous agitation at 68 °C.
Finally, it was washed in 200 ml of HPLC H2O for 15 min without agitation at
room temperature. After the washes, the membrane was sealed immediately in a
plastic wrap to prevent drying and exposed at –80 °C to Kodak BioMax MS film withMATERIALS AND METHODS
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an intensifying screen. Several exposures were tried for varying lengths of time (3–6
h, overnight, and 3 days). Alternatively, the membrane was exposed to a phosphor
imaging plate (Molecular Dynamics) for two to six days; the plate was scanned in a
phosphorimage analyzer
 (Phosphorimager
TM SI, Molecular Dynamics).
2.4.5 Stripping cDNA probes
To re-use the Atlas Array after exposure to X-ray film or phosphorimaging,
the cDNA probes were routinely removed by stripping. First, the stripping solution
(500 ml DEPC H2O with 0.5% SDS) was heated to boiling. Then, the plastic wrap
was removed from the Atlas Array and the membrane was immediately placed into
the boiling solution. Boiling was continued for 5–10 min. The solution was removed
from heat and allowed to cool down for 10 min. The Array was removed from the
solution and the damp membrane was immediately wrapped in plastic wrap. The
efficiency of stripping was checked by exposure to X-ray film overnight. When
radioactivity was detected, the stripping procedure was repeated. The Array was
sealed and stored in plastic wrap at –20 °C until needed.
2.4.6 General procedures and computer analysis
The hybridization signals were analyzed by using Atlas Image TM 1.0 software
(Clontech). The two images to be compared were normalized for the calculations by
selecting and utilizing 7 out of the 9 housekeeping genes included on the membrane.
In addition, the membrane contained three negative control DNAs in triplicate. The
negative control spots had to be free of radioactive signals. The results were visually
confirmed. Selective analyses were repeated twice to validate reliability and
reproducibility of the method.
To create gene expression profiles for FDCP-1 cells, the expression levels of
the 588 known genes (immobilized on the membrane) were analyzed first, then I
focused later on the genes of particular interest (related with apoptosis, DNA
synthesis, repair and recombination). The genes, which showed an adjusted intensityMATERIALS AND METHODS
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ratio above 1 or less than 1 in samples were considered to be differentially expressed
(see Section 3.1.2 and Table 3.3).
2.5  Northern hybridization
2.5.1 Isolation of polyA
+-RNA from FDCP-1 cells
The poly(A)
+-RNA from FDCP-1 cells was isolated (see Section 2.4.1 and
2.4.2) as described in Klaus et al. (1990). Samples (2.5 mg) from each of FDCP-1
cells that were grown in different conditions (Section 2.1.3) were used for
electrophoresis.
2.5.2 Formaldehyde gels and Northern blot membrane
The composition of a formaldehyde agarose gel differs from that of a standard
agarose gel used for electrophoresis of DNA. However, the same general principles of
gel preparation were followed. Formaldehyde denatures RNA by reacting covalently
with the amine groups of adenine, guanine, and cytosine and so prevents the
reformation of G-C and A-T base pairs. Usually, 0.5 mg of poly A
+-RNA was used
(with RNA size markers, 0.24-9.5 kb, Gibco-BRL) for the analysis of RNA quality. A
sample (2.5 mg) of poly A
+-RNA  was electrophoresed in 1% formaldehyde agarose
gels, transferred to a nylon membrane (Hybond-N, Amersham Life Science),
immobilized by UV light exposure (UV crosslinker® 1800, Stratagene). Following
are more details of the methods of preparations.
First, 1 g of agarose was completely dissolved in 80 ml of DEPC-water by
heating. The solution was allowed to cool to 60 °C and 10 ml of 10 x MOPS buffer
and 5.4 ml of 12.3 M formaldehyde were added to the solution. Then, DEPC-water
was added up to 100 ml final volume and poured into an electrophoresis chamber.
Second, RNA samples were prepared by mixing 2.5 mg of poly A
+-RNA  (in
3 ml of DEPC-water) with 1.5 ml of 10 x MOPS buffer, 3 ml of 37% formaldehyde
and 7.5 ml of deionized formamide. The RNA samples were denatured by treatment
at 65 °C for 10 min and chilled immediately on ice.MATERIALS AND METHODS
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Third, 2 ml of loading buffer was added to the sample and it was loaded on
the formaldehyde gel. The RNA was separated at 5 V/cm using 1 x MOPS buffer.
After electrophoresis, the RNA was visualized (by staining in DEPC-water with 0.5
mg/ml ethidium bromide and extensive washing to remove traces of ethidium
bromide) followed by UV transillumination (see Figure 3.2).
2.5.3 Labeling of DNA probes for Northern hybridization and Matched
Tumor/Normal expression array assay
Random-primed  labeling  was  devised  by  Feinberg  and  Vogelstein  (1983,
1984). The labeling is catalyzed by Klenow fragment, the large fragment of E. coli
polymerase  I  obtained  by  subtilisin  cleavage.  Klenow  fragment  lacks  the  5’Þ3’
exonuclease  activity  of  the  intactenzyme but  still  contains  the  5’Þ3’  polymerase
activity as well as the 3’Þ5’ proofreading exonuclease activity.
The  modified  random-primed  labeling  protocol  and  commercially  available
Rediprime
TM II
® reaction kit (Amersham Pharmacia Biotech) were  used to  obtain
uniform labeling. First, the DNA sample (PCR product, see also Appendix IV and V)
was diluted to a concentration of 5-25 ng in 45 ml of TE buffer, denatured by heating
to 95 °C for 5 min in a boiling water bath, and cooled immediately on ice. Then, the
denatured DNA was added to a Rediprime
TM II
® reaction tube containing dATP,
dGTP, dTTP, Klenow enzyme and random primers. The reaction solution was mixed
by pipetting in 5 ml of a-
32P-dCTP (3000 Ci/mol; 50 mCi) and then incubated at 37 °C
for 60 min. Unincorporated nucleotides were separated using a Sephadex S-200 micro
spin column (Pharmacia). Finally, a-
32P-dCTP labeled probe was prepared with the
specific activity of ~108 cpm/mg.
2.5.4 Hybridization
The membrane (carrying the immobilized RNA, Section 2.5.2) was wetted in
6 x SSC and placed in a hybridization bottle. Prewarmed ExpressHyb solution (20
ml) was added to it and the bottle was placed in a hybridization oven and incubated
with rotation for 30 min at 65 °C. The probe (prepared as in Section 2.5.3) wasMATERIALS AND METHODS
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denatured by heating in a hot block for 5 min at 100 °C, then transferred to ice. The
probe was added into the hybridization bottle and incubation was continued for 1.5 h.
The membrane was then washed using prewarmed washing solutions (65 °C, 2 x
SSC, 0.1% SDS) for 15 min and autoradiography was performed as described in
Section 2.8.
2.5.5 Stripping cDNA probes
The membranes were reused up to 4 times. After exposure, they were stripped
to remove the cDNA probe by boiling in 0.5% SDS solution for 10–15 min. The
efficiency of stripping was checked by exposure to Kodak BioMax MS film overnight.
2.6 Self-made array assay (custom made array)
Based on the knowledge gained from the gene trap assay (Section 3.1 and
Table 3.1), I designed and developed my own array system (Figure 2.5) containing
seventy cDNA spots on a nylon membrane (low density array, Figure 3.10) to verify
whether our target genes are biologically relevant and differentially expressed in tumor
vs. normal tissue cell lines.
The gene specific primers (Appendix VI) were designed with MacVector
software (International Biotechnologies) employing a sequence data base, and PCR
products were generated (Figure 3.9). Spotting on nylon membranes (Figure 3.10 and
Appendix VIII) was kindly performed by Drs Bernhard Korn and Matthias Schick
from Deutsche Krebsforschungszentrum (DKFZ).
2.6.1 Preparation of templates for cDNA amplification
Templates were prepared for amplification of target genes (from GTSTs
libraries, Table 3.1) for spotting on nylon membranes. A cDNA template was
generated from polyA
+-RNA or genomic DNA of FDCP-1 cells (Figure 2.6) that
were serially diluted to give an optimal concentration for PCR (Figure 2.7).MATERIALS AND METHODS
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Labelled cDNA
probe generation
Producing arraying material
Custom libraries from gene trap
cDNA clones
PCR Products
Hybridized array
Raw image file
Array database
Arraying on to nylon membrane
Target RNA
preparation
Read by X-ray film / phosphoimager
Processed images
Analysis with image processing software
Data output
Figure 2.5:  A scheme for use of self made array (custom made arrays) assay.
2.6.2 Cycling conditions and PCR optimization
Two different templates (cDNA and genomic DNA) and two different
annealing temperatures (54 or 61 °C) were compared to determine the optimal
settings of PCR (Figure 2.6). For PCR amplification, 1 x PCR buffer, each of the
dNTPs at 0.2 mM, 1.5 mM MgCl2, each of primers at 0.5 mM (Appendix V), 1 ml of
cDNA template (Section 2.3) and 5 units of Taq DNA polymerase were used (total
volume: 25  m l). After the PCR, 5 ml from each sample was loaded on to 1~2%
agarose gels. A cycling condition was considered optimized when a single clean band
of the expected size was obtained (Section 3.1.4.1, Figure 3.9).MATERIALS AND METHODS
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PCR start with cDNA template
Genomic DNA template
Annealing at 54˚C
Annealing at 61˚C
Yes
Yes
PCR
product
No
No
Figure 2.6:  Cycling conditions for PCR optimization.
For optimization of PCR with a genomic DNA template, I started with 200 ng
of mammalian genomic DNA template(1:1) and serial dilution of it (1:10
2, 1:10
3,
1:10
4, 1:10
5, 1:10
6, 1:10
7), and 55 cycles at 54 °C for amplification of a sample DNA
(26-32-3, Appendix VI) as shown in Figure 2.7A.
PCR was run again for 45 cyles with the diluted genomic DNA template (from
100 to 0.01 pg) and the target DNA primer pairs (26-32-3 in Appendix VI; Figure
2.7B). After PCR, the products were displayed on 1-2% agarose gels and examined
for yield, specific size and specificity. The number of cycles used depended on both
the efficiency of the reaction and the amount of template DNA in the reaction.
As shown in Figure 2.7B, 10% of the reaction produced a band that is readily
visible on an ethidium bromide-stained gel as a single predominant band. With more
templates, fewer cycles were sufficient. In this case, 45 cycles was optimal for our
target DNA amplification.
I confirmed seventy PCR products were effectively amplified and their sizes
were correct (Figure 3.9, see the Table in Appendix VI for the conditions of PCR). 100
pmol of each were spotted onto nylon membranes as described in Figure 3.10.MATERIALS AND METHODS
44
2072
1500
800
600
500
400
300
200
100
1000
(bp)
700
2072
1500
800
600
500
400
300
200
100
1000
(bp)
700
M 1:10
3
1:10
2
1:10
4
1:10
5
1:10
6
1:10
7
(A) (B)
1:10
1:10
3
1:10
2
1:10
4
1:1
M
200 pg template (55 cycles) 100 pg template (45 cycle)
Figure 2.7:  Optimization of PCR condition with a mouse genomic DNA template.
A: Templates (consisting of 2 000, 200, 20, 2, 0.2 and 0.02 pg) used
for 55 cycles at 54 °C for amplification of a sample DNA. B: Serial
dilutions consisting of 100 (1:1), 10, 1, 0.1 and 0.01 pg were used as
templates for 45 cycles at 54 °C.
2.6.3 Purification of RNA
The methods of purification of total RNA and polyA
+-RNA  from the cultured
cells (Table 2.1) were the same as described in Sections 2.3.1 and 2.3.2. For a second
purification, RNeasy kit (QIAGEN) was used. However, most of the total RNAs (for
cancer profiling assay) were kindly provided by AstaMedica (See Table 3.6).
2.6.4 cDNA labeling primers for self made array
Gene-specific primer cocktails were used for cDNA labeling (a-
32P-labelled
first single-strand cDNA). The Gene-specific primer cocktails were the mixtures of
reverse primers (antisense) for all sequences represented in Appendix VI. The
mixture of primers (100 pmol each) were extracted with phenol/chloroform/isoamyl
alcohol, precipitated with ethanol, and finally redissolved in 70 ml of DEPC-H2O to
give ~1 mg/ml.
2.6.5 Probe synthesis from total RNA for custom array assay
Total RNA was converted into a-
32P-labeled first strand cDNA (Figure 2.5).
First, the total RNA (5 mg) was precipitated with 1/5 volume of 3 M sodium acetateMATERIALS AND METHODS
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(in DEPC-H2O, Appendix III) and 2.5 volume of 95% ethanol. It was kept at –20 °C
for 1 h, then centrifuged for 10 min in 13,000 rpm in a microfuge. The pellet was
washed with 80% ethanol and dried for 10 min, then resuspended with 3 ml of gene
specific primer solution (Section 2.6.4) in a 0.5 ml microcentrifuge tube and
incubated in a preheated PCR thermal cycler at 70 °C for 2 min. After the
temperature of the thermal cycler was reduced to 45 °C, the reagents mixture (Table
2.5) was added to the tube that was incubated at 45 °C for 25 min.
The reaction was stopped by adding 1 ml of 10 x termination mix (Appendix
III). The a-
32P-labeled first strand cDNA was purified from the unincorporated 
32P
and small cDNA fragments (< 0.1 kb) with a CHROMA SPIN-200 column.
Table 2.5: Reagents mixture for generating labeled first strand cDNA probes
1 x
5 x Reaction Buffer 2 ml
10 x dNTP Mix (for dATP label) 1 ml
a-
32P-dATP (3,000 Ci/mmol, 10 mCi/ml) 4 ml
DTT (100 mM) 0.5 ml
Superscript II RT (Gibco-BRL) 1.5 ml
Total volume 9 ml
2.6.6 Hybridization of cDNA probes to the custom array
Following are the methods for hybridization of 300 ml of cDNA probe (entire
pool; ~9 x 10
7 cpm) to the custom array. ExpressHyb (20 ml) was prewarmed at 55
°C. Human Cot-1 DNA (8 ml, Gibco-BRL) and 200 mg of sheared salmon testes DNA
were heated at 95–100 °C for 5 min, then chilled quickly on ice. The heat-denatured
sheared salmon testes DNA (200 mg) was mixed with prewarmed ExpressHyb (20
ml) and added into the hybridization bottle. The membrane was prehybridized for 30
min with continuous agitation at 55 °C. The labeled probe was mixed together with
1/10 volume 10 x denaturing solution (1 M NaOH, 10 mM EDTA; Appendix III).
Then, it was incubated at 55 °C for 20 min. Human Cot-1 DNA (10 ml) and 1/2
volume of 2 x neutralizing solution (1 M sodium phosphate, pH 7.0; Appendix III)MATERIALS AND METHODS
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were added to the denatured probe. Incubation was continued at 55 °C for 10 min.
After the addition of the probe to the membrane and hybridization solution, it was
hybridized overnight with continuous agitation at 55 °C.
2.6.7 Washing steps and documentation
After hybridization, the membrane was quickly washed twice with 50 ml of
preheated (at 50 °C), washing solution 1 (Appendix III). Two 30 min washes were
performed in 100 ml of prewarmed wash solution 1 in a shaking water bath
(KötterMann, Labor Technik). Two additional 20 min washes were applied in 100 ml
preheated washing solution 2. Finally, a 20 min wash in HPLC H2O was done at room
temperature without agitation. The membrane was sealed in a plastic wrap and
exposed to X-ray film at –80 °C for 18 h, 36 h, and 2 days (see Section 2.8). Then,
the membrane was exposed to a phosphor imaging plate (Molecular Dynamics) for
three to five days.
2.6.8 Analysis of data
The steps required to determine the expression ratios from microarray
experiments are spot finding, spot quantification, background subtraction and
normalization. Prior to analysis of matched tumor/normal array data, ImageQuant
version 1.2 (Molecular Dynamics) was used as a visualization tool for the
phosphorimage file (see Appendix VII) or the TIFF file from scanned X-ray film
(Figure 3.11). Spots below a threshold intensity were eliminated and the expression
ratio data were median-centered, then the data were replaced with colors by Excel.
2.7 Matched tumor/normal expression arrays
A major limitation of gene expression profiling using microarrays has been
the substantial amount of RNA required for standard probe labeling techniques. The
cDNAs were generated (from 68 human tumors and corresponding normal tissues of
the same individual) with CLONTECH's PCR-based SMART technology (switch
mechanism at the 5'-end of RNA templates that allows accurate cDNA amplificationMATERIALS AND METHODS
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from nanogram quantities of total RNA; Vernon et al., 2000). This amount of RNA
ensures that SMART amplification yields a pool of cDNA, which reflects the
sample’s original complexity, and relative abundance of the original RNA sample.
The array is a nylon membrane on which cDNAs have been immobilized in
separate dots as shown in Figure 2.8. The array contains (a) six negative controls
(included on the right of the membrane in Figure 2.8) that were used to estimate
levels of nonspecific background (yeast total RNA, yeast tRNA, E. coli DNA,
Poly(A), Cot-1 DNA, human genomic DNA); and (b) a positive control (UBI: cDNA
probe for ubiquitin, on the right top and bottom corners of the membrane).
Total cDNAs from the cancer cell lines (1: HeLa, 2: Daudi, 3: K562, 4: HL60,
5: G361, 6: A549, 7: Molt4, 8: SW480 and 9: Raji) were spotted at the bottom from
left to right.
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Figure 2.8:  Matched tumor/normal expression array. N: cDNA from normal tissue.
T: cDNA from tumor tissue.
2.7.1 Target cDNA probe preparation
For the amplification of gene specific probes by PCR, templates were
prepared from 1 mg each of total RNAs of tumor cell lines from breast (BT-474),
ovary (OVCAR-4), pancreas (BXPC-3), lung (NCI-H-460) and colon (COLO-205) asMATERIALS AND METHODS
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described in Figure 2.9. The templates were mixed and 1 ml of the mixture was used
for generating the target cDNAs (Section 2.3.1). The primers for amplification of
cDNAs are described in Appendix V.
The amplified cDNA fragments were ligated into pGEM-T vector (Section
2.1.16). The competent cells (XL10-Gold) were transformed with the plasmids
(Section 2.1.15) and single colonies containing required plasmids were selected
(Section 2.1.17). The cDNAs were amplified from the plasmids, then purified and
sequenced. The cDNA fragment was then labeled with a-
32P-dCTP (Section 2.5.3)
and used as a probe (Figure 2.9). The hybridization temperatures of each probe are
described in Appendix V.
2.7.1.1. Preparation of ExpressHyb solution and sheared salmon testis DNA.
ExpressHyb solution (20 ml) was prewarmed at 50–60 °C. Sheared salmon
testis DNA (1.5 mg) was denatured at 95–100 °C for 5 min, and then put on ice.
Then, the salmon testis DNA was mixed with the ExpressHyb solution.
2.7.2 Hybridization
On the basis of confirmation of expressed target genes (Figure 2.9) by RT-
PCR, PCR and sequencing, the DNA probes (Section 2.7.1 and Appendix V) were
labeled as described in Section 2.5.3 and hybridized on the matched tumor/normal
array membrane (Figure 2.8 and Appendix V).
The methods of hybridization were similar to those described in Section 2.4.4
and 2.5.4 except for the following. The labeled cDNA probe (Section 2.7.1) was
mixed with 30 mg of Cot-1 DNA, 150 mg of sheared salmon testis DNA, and 50 ml of
20 x SSC in a total volume of 200 ml. The mixture was heated at 95–100 °C for 5 min
and kept at 68 °C for 30 min, then was added to the prehybridized matched
tumor/normal array membrane in a hybridization container (Biometra). Hybridization
was carried out overnight at 60-65 °C. After removal of the hybridization solution, the
array membrane was washed as described in Section 2.5.5.MATERIALS AND METHODS
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Figure 2.9:  A scheme describing the matched tumor/normal expression array assayMATERIALS AND METHODS
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2.7.3 Normalization of hybridization signals
Prior to an analysis of differential gene expression using the matched
tumor/normal expression array, ubiquitin (housekeeping gene, 23-kDa basic protein)
cDNAs was employed to normalize the results of hybridization. The array was re-
hybridized with a radiolabeled ubiquitin probe and hybridization signals were detected
by phosphorimaging for analysis (Figure 2.10).
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Figure 2.10:  Normalization with human ubiquitin cDNA control probe. Matched
colors designate tissue types on the array membrane. Two spots (top
and down corners from right) indicate ubiquitin cDNA. N, normal; T,
tumor; C, cancer cell line cDNAs.
2.7.4 Analysis
The hybridized array was exposed to a phosphorimage plate for 2-5 days. After
the visualized image was acquired (by scanning the plate), spot finding and spot
quantification were done with ImageQuant version 1.2 software (Figure 2.11). The
mean value of the background was generated from three randomly selected spots
(yellow colored B1, B2 and B3 in Figure 2.11). For background subtraction and
normalization, the Excel (Microsoft) program was used. Normalization eliminatedMATERIALS AND METHODS
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values below a threshold intensity. The final expression ratio data of tumor cells were
the values compared with normal cells (when the normal cell expression level is set to
1). An example of the data processing procedure of ERK3 is illustrated in Figure 3.12
and Tables 3.8 and 3.9.
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Figure 2.11: Spot finding, spot quantitation and background subtraction with
ImageQuant.
2.8 Documentation
For routine laboratory documentation, photographs were taken using a
Polaroid camera or digital camera with computer and software (Herolab, Appendix
II). However, for documentation of hybridization analysis, autoradiography and
phosphorimaging (Phosphorimager
TM SI, Molecular Dynamics) were used. After the
washing steps (Section 2.6.7), the membranes were exposed to X-ray film (Kodak
BioMax MS film with the corresponding intensifying screen) at –80 °C or exposed to
a phosphorimaging screen at room temperature. The optimal exposure time was
decided after overnight exposure. Figures presented in this Thesis were processed by
scanning photographs with a scanner (SNAPscan 600, AGFA) or phosphor images
were used. For drawing illustrations, Adobe
®Photoshop
® 4.0 and Canvas™ 3.5 were
employed.C
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CHAPTER 3
RESULTS
3.1 Gene trapping identifies transiently induced survival genes during
programmed cell death
As described in Section 1.6, gene trap mutagenesis and site specific
recombination (Cre/loxP) were employed to identify genes that are transiently
induced in FDCP-1 cells undergoing apoptosis by growth factor (IL-3) withdrawal
(Wempe et al., 2001). From a FDCP1 (FLOXIL3) gene trap integration library
corresponding to approximately 2 x 10
6 proviral insertions, we isolated 125 clones
that converted to factor independence upon IL-3 deprivation.
Cellular sequences adjacent to gene trap (U3Cre) integration sites (gene trap
sequence tags; GTSTs) were obtained from 102 clones by inverse PCR or 5'RACE
using Cre-specific primers. Eighty-six out of 102 GTSTs (>30 nt in length) were
informative of which 73 belonged to known genes and 13 corresponded to expressed
sequence tags (ESTs) within the GenBank/ENSEMBL databases (Figure 3.1).
This clearly reflects the progress of the international genome sequencing
projects, as only 2 years ago the majority of the GTSTs had no match in the public
databases (Wempe et al, 2001). The recovered genes are listed in Table 3.1.  Among
fifty genes having well defined functions, twenty one (42%) are directly or indirectly
related to cellular survival functions (Figure 3.1, Table 3.1). The results indicate that
the gene trap strategy effectively selected for this class of genes. Only five genes
(marked with green) demonstrate cell death function.RESULTS
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 Table 3.1: Trapped genes induced by IL-3 withdrawal*.
Clone Trapped gene Genbank ID Clone Trapped gene Genbank ID
26-11-1 TREP-132 NM_172622 30-32-6 KIAA0740/Rhobtb1 XM_125637
26-11-2 Muf1 BC022976 30-32-11 NADPH Cyto’ p450 reductase BC031463
26-11-3 Tif II e b NM_026584 30-32-12 a-1,2-mannosidase IC XM_285851
26-11-4 NEF-sp AK084640 30-32-14 FHOS XM_134529
26-11-5 1190005B03Rik NM_144536 30-32-16 YB-1 X57621
26-11-6 MEG3 NM_144513 30-32-18 Eferin/ mKIAA0665 AK083658
26-11-7 Annexin A6 NM_013472 30-41-4 ICAM4 NM_023892
26-12-2 AF15q14 homolog AK033132 30-42-1 cappucino AY186603
26-12-3 SBBI54 homolog BC018244 30-42-4 PSCDBP BC007144
26-12-4 Vav-1 BC020487 30-42-7 Syntaxin 3A D29797
26-21-3 Rad 50 NM_009012 30-42-10 Tel oncogene BC052163
26-21-4 KIAA0376 BC037464 AW16 VMP1 NM_029478
26-22-1 ATF1 NM_007497 AW17 Tmp21-I BC006774
26-22-4 1200014P05Rik NM_028765 AW19 STK-19 NM_019442
26-22-7 Collybistin II AK038840 AW21 same as AW16
26-22-8 AlkB XM_127049 AW22 Syntaxin 7 NM_016797
26-31-1 13E, HSP281fis AK008409 AW24 Jade-1 NM_172303
26-31-3 Same as 26-31-1 AW30 Ect2 BC023881
26-31-7 Same as 26-22-8 AW32 GNA15 NM_010304
26-32-1 Plekha2 NM_031257 AW33 ADH2 AJ245750
26-32-2 KIAA1036 XM_138099 AW34 same as AW22
26-32-4 14-3-3 zeta NM_011740 AW36 same as 30-42-7
26-32-5 Net1 AJ010045 AW37 IP3 receptor isoform 1 NM_010585
26-32-9 Vezf1 NM_016686 AW65 PI transfer protein AB077281
26-41-1 PI4P5K type I g NM_008844 AW66 Glucocorticoide-induced gene1 AF292939
26-41-2 L34 BC052086 AW69 TNFRSF19L NM_177073
26-41-3 PEST cont. nuclear prot. XM_132579 AW75 Smurf1 BC029097
26-41-6 ZnF407 XM_140518 AW602 ASC-1 subunit P50 AK007519
30-11-3 Myosin IB NM_010863 AW604 Pde4d NM_011056
30-11-4 GSA7 NM_028835 AW606 TOX NM_145711
30-11-5 ERK3 (?) NM_015806 AW607 nin283 AF378525
30-11-6 VMAT2 AJ555564 AW608 Formin related protein AF215666
30-12-1 5730501N20Rik XM_127032 AW611 PHAPI NM_009672
30-12-2 Hexokinase I NM_010438 AW613 Angiopoetin-1 NM_009640
30-12-4 PIP5K type I b BC003763 AW615 LOC226651 AK031319
30-21-2 EDEM NM_138677 AW618 MC1-R NM_008559
30-21-3 Nitrilase 1 NM_012049 AW619 NOPAR2/TRALPUSH NM_177855
30-21-4 LPG22P homolog AK088457 AW623 SatB1 NM_009122
30-22-1 Rec8    BC052155 AW625 2900052L18Rik NM_175248
30-22-2 NYD-sp12 NM_029150 NEUA Siat8d NM_009183
30-22-4 Ureb1 BC017642 NEUC Vars2 BC053703
30-31-5 PI145P-5Ptase XM_133934 NEUD ALS2 AB053307
30-31-6 4632413C14Rik NM_029857 NEUE BTEB1 NM_010638
30-32-1 SMARRC2 BC040363 Un1g KIAA1140 BC025613
30-32-2 L28 NM_009081 Un3g same as 26-32-1
30-32-3 Annexin A11 BC012875 Un11g 2610305M23Rik BC019973
* Red: genes with survival functions. Green: pro-apoptotic genes. Light blue: genes
with pro- and anti-apoptotic functions. KIAs, Riks and fis are full-length cDNAs with
unknown functions.RESULTS
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102 cellular sequences adjacent to U3Cre integration sites of GTSTs
86 informative GTSTs (>30 nt)
73 known genes (Nucleotides database)
50 well characterized genes
21 genes 5 22
number of genes
• Cell survival function
• Cell death function
• Cell survival & death function
   Regulator (2)
• No correlation with
   cell death/survival function
Figure 3.1: GTSTs recovered from the FLOXIL3 gene trap integration library
following IL-3 withdrawal.
Table 3.2: Functional classification of the recovered survival genes.
26-22-7 Collybistin II
26-22-1 ATF1
26-32-5 Net1
26-32-9 Vezf1
26-21-3 Rad 50
26-22-8 AlkB
30-32-16 YB-1
30-22-1 Rec8
30-42-10 Tel oncogene
NEUE BTEB1
30-11-5 ERK3
30-12-2 Hexokinase I
AW602 ASC-1 subunit P50
AW19 STK-19
AW623 SatB1
AW75 Smurf1
26-41-1 PI4P5K type I g
30-12-4 PIP45K type I b
30-32-11  Cyto’ p450 reductase
Cytoskeletal binding
26-11-7 Annexin A6
Metabolic enzyme
Kinases & phosphorylase
Small GTPases/Effectors
DNA repair
Transcription factors Ubiquitin system
26-32-4 14-3-3 zeta
30-11-6 VMAT2
30-21-2 EDEM
30-42-10 Tel oncogene
AW30 Ect2
AW608 Formin related protein
AW618 MC1-R
Other functionsRESULTS
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3.2  Mouse cDNA expression arrays reveal differential expression
of cell death and survival genes following IL-3 withdrawal
To further study transcriptional regulation during growth factor starvation, we
analyzed the expression patterns of a large number of previously characterized genes
using Atlas
TM mouse cDNA arrays (Clontech).
Atlas
TM arrays contain cDNA probes for 588 genes involved in development,
oncogenesis, DNA repair, tumor suppression and apoptosis. PolyA
+-RNA was
prepared from FDCP-1 cells at 0 and 2 hours after IL-3 withdrawal.
After verifying mRNA quality on 1% formaldehyde-agarose gels (Figure 3.2)
and excluding contamination with genomic DNA (Figure 3.3) the mRNA was reverse
transcribed in the presence of 
32P-dATP using array gene specific primers (see section
2.4.3 for details). Figure 3.4 shows that of the 588 genes displayed on the arrays, only
13 genes were differentially expressed after factor deprivation (Table 3.3).
 Differential expression of these genes was reproducible in independent array
experiments and was validated by Northern hybridization.  For Northern blots,
polyA
+-RNA was recovered from FDCP1 cells after 0, 2, 4, 6 and 8 hours of factor
deprivation using oligo (dT) beads (see section 2.4.2).
This procedure increases the mRNA detection sensitivity on Northern blots
and was chosen because several of the regulated genes were not very highly
expressed on the arrays. Moreover, attention was paid to mRNA quantification to
insure even gel-loading (Figure 3.5).
 RESULTS
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(kb)
9.49,  7.46
4.40
2.37
1.35 poly A+ RNA
M A B C D
Figure 3.2:  Quality assessment of FDCP-1 mRNA on a 1% formaldehyde-agarose
gel. M: RNA ladder (0.24-9.5 kb, GIBCO-BRL), A: Total RNA; B:
polyA
+-RNA from non-deprived cells; C: polyA
+-RNA from cells
deprived of IL-3 for 2 hours; D: polyA
+-RNA from cells deprived of
IL-3 for 8 hours.
0 h 2 h 8 h
A B A B A B
Figure 3.3:  Estimating genomic DNA contamination of mRNA preparations.
PolyA
+ RNAs were prepared from FDCP-1 cells at 0, 2 and 8 hours
after IL-3 withdrawal. Aliquots were treated for 2 hours at 37 °C with
0.5 U of DNase I and then subjected to PCR using intron specific
GAPDH primers. Amplification products were resolved on a 2%
agarose gel. Lanes A = after DNase treatment; Lanes B = before
DNase treatment.RESULTS
58
p27
PKB/Akt
Bcl-XL
Bcl-2
Chop-10 Pim-1
c-Kit
GRP78
IL-3b  R
c-Myc
JunD
Zyxin
UBF
FDCP1  after  IL-3  withdrawal  (2h)
GST  Mu1
Activin  type I rec.
p27
PKB/Akt
Bcl-XL
Activin  type I rec.
Bcl-2
Chop-10 Pim-1
c-Kit
GRP78
IL-3b  R
c-Myc
JunD
Zyxin
UBF
FDCP1  without  IL-3  withdrawal  (Wild  type)
GST  Mu1
Rad 50
Rad21
FLIP-L
Vav-1
YB-1
SatB1
Rad 50
Rad21
Vav-1
YB-1
SatB1
FLIP-L
Figure 3.4: Differential gene expressions in FDCP-1 cells after IL-3 withdrawal.
The Atlas arrays were hybridized to polyA
+ from control and factor
deprived (2 hours) cells The membranes were exposed for 16 hours to
Kodak BioMax Ms X-ray film at –80 °C. Red and blue rectangles
correspond to induced and repressed genes, respectively. Orange
circles: genes that are not differentially expressed on the Atlas arrays
but were recovered by the gene trap approach.RESULTS
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Table 3.3: Summary of the results obtained with the Atlas arrays.*
Gene/protein
Regulation
ratio Coordinate
c-Myc (proto-oncogene; Selten et al., 1984) 0.6 A2l
Pim-1 (proto-oncogene; Selten et al., 1986) 0.1 A4a
c-Kit (proto-oncogene; Qiu et al., 1988) 1.6 (8 h) A4c
Chop-10 (murine Gadd153; Ron et al., 1992) 0.1 C3a
GST (glutathione-S-transferase; Huang et al., 2003) 1.2 (8 h) C2b
Zyxin (a-actinin binding protein; Macalma et al., 1996) 1.6 B7n
IL-3 receptor (Itoh et al., 1990) 1.6 E3d
Akt (proto-oncogene, protein kinase B; Section 1.3.1.1) 2.4 C2k
JunD (transcription factor; Li et al., 1990) 1.7 A3g
Bcl-2 (apoptosis inhibitor; Section 1.2.2) 0.7 C1h
Bcl-XL (apoptosis regulator Bcl-X long form; Section 1.2.2) 0.1 C1j
FLIP-L (apoptosis inhibitor; Irmler et al., 1997) 0.5 C3h
Activin type I receptor (Verschuern et al., 1995) 0.1 E1a
*  Gene expression was quantified using the Atlas Image 1.01a (Clontech) software.
To obtain the regulation ratio, signal intensity value produced by each gene on the
membrane after hybridizing to mRNA from FDCP-1 cells deprived of IL-3 for 2
hours (8 hours for c-kit and GST) was divided by the value obtained for the same
gene with mRNA from control cells (0 h). Hence, regulation ratios below or above
1 reflect gene repression or induction, respectively.
polyA +
RNA
0.5 mg
0.1 mg
0.02 mg
0 2 h 4 h 6 h 8 h
Figure 3.5:  Quantification of polyA
+-RNA by dot-blot analysis. Serial dilutions of
polyA
+-RNA isolated from FDCP1-cells (0.5, 0.1 and 0.02 mg from
each of sample corresponding to 0, 2, 4, 6 and 8 h after IL-3
withdrawal were spotted onto a nylon membrane using a microsyringe.
a-
32P-labeled GAPDH cDNA probes were used for quantification.RESULTS
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Similar to the gene trapping results, several genes with survival functions
were up-regulated in the absence of IL-3. Among these were the survival kinase Akt,
the c-kit receptor tyrosine kinase, zyxin, a protein closely related to proteins
implicated tumorigenesis and steroid receptor binding, and the IL-3 receptor itself
(Figures 3.6 and 3.7).
    
Zyxin
JunD
Pim-1
FLIP-L
c-Myc
GAPDH
0 2 4 6 8 h
Cyclin G
GST
GAPDH
c-Kit
Bcl-XL
Elf-1
IL-3  b  chain
PKB/AKT
GAPDH
Aktivin-receptor
type  I
Figure 3.6: Northern blot analysis of differentially regulated genes. PolyA
+ RNAs
derived from FDCP-1 cells at various times after IL-3 withdrawal were
resolved on 1% formaldehyde-agarose gels, blotted onto nylon filters
and hybridized to 
32P-labeled gene specific probes. Hybridizing bands
were visualized by autoradiography using Kodak BioMax MS film
with the corresponding intensifying screen.RESULTS
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Moreover, survival functions seemed strengthened by the transient down-
regulation of the pro-apoptotic activin receptor (Figure 3.8). In confirmation of
previous results, however, the expression of several survival genes appeared IL-3
dependent. Thus, transcripts for anti-apoptotic Pim-1, c-Myc, Bcl-XL and potent
apoptosis inhibitor FLIP-L proteins were repressed in absence of IL-3. Finally, only
JunD with arguably pro-apoptotic functions was transiently up-regulated (Figure 3.7)
in these experiments.
IL-3 b  chain
GST
0.5
1
1.5
2
2.5
3
0 2 4 6 8
c-Kit
h
relative
expression
ratio
JunD
Zyxin
PKB/AKT
Figure 3.7: Kinetics of gene induction after IL-3 withdrawal. Relative expression
ratios were calculated by dividing the signal intensity values obtained
with mRNA from FDCP-1 cells after 2, 4, 6, and 8 days of factor
withdrawal to the value obtained with mRNA from non-deprived
FDCP-1 cells. Signal intensities of Phosphoimager scans were
quantified with the ImageQuant software.RESULTS
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0.4
0.6
0.8
1
1.2
0 2 4 6 8
c-Myc
Pim-1
Bcl-XL
h
relative
expression
ratio
Chop-10
FLIPL
Activin
receptor
type I
Figure 3.8:  Kinetics of gene repression after IL-3 withdrawal. For details see
legend to Figure 3.7.
3.3  Affymetrix Genechip arrays detect a large number of genes
induced by growth factor deprivation
Since the FDCP-1 integration library for recovering genes induced in cells
undergoing apoptosis was created at a time when neither the genome sequence nor
reliable high density microarrays were available, it was of interest to compare the
efficiency of the gene trap methodology with high throughput expression profiling at
a time when both genome sequence and high density microarrays are available. To
this end, an Affymetrix chip analysis was performed in collaboration with Schering
AG (Berlin). PolyA
+ RNAs from factor deprived FDCP-1 cells were hybridized to
Affymetrix Mouse A chips containing oligonucleotide probes for 5000 known genes.
We found that about 25% of all genes that were comparatively induced at some timeRESULTS
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point after IL-3 withdrawal. For practical reason, more than three times up or three
times down regulated genes were selected from 5000 known genes (see Table 3.4).
They are also the genes that corresponded to literature database (PubMed) for their
defined functions.
Of these 35 genes, 24 genes (69%) were related to cell death and survival. As
described in Table 3.4, the 21 genes of survival functions are named with red and the
3 genes having cell death functions named with green.
Similarly, 125 genes were obtained from an estimated screen of 100,000
genes in the gene trap approach. Of these 50 genes with defined functions, 28 genes
(56%) were related to cell death and survival (see Figure 3.1 and Table 3.1).
This high process specificity together with the significantly lower yield of
genes induced by factor deprivation suggests that the gene trap approach detects less
process-unrelated genes than the Gene chip arrays. Moreover, the gene trap strategy
selects for real gene inductions and, unlike the arrays and Northern blots, is
independent of pre-existing steady state mRNA levels subjected to post-
transcriptional regulation.
Taken together, these considerations suggest that for the functional analysis
of the mammalian genome, gene trapping effectively complements microarray based
strategies, which are unable to distinguish between transcriptional and/or post-
transcriptional changes of gene expression.
Table 3.5 shows the differential expression of several genes recovered by
gene trapping on Affymetrix chips. While over half of these genes were also induced
on the chips, a substantial number was unexpectedly repressed.
Interestingly, most of these repressed genes were recovered from antisense
gene trap insertions (Table 3.5), suggesting that IL-3 deprivation induces gene
specific inhibitory (antisense) transcripts. Such potentially inhibitory transcripts are
readily detected by gene trapping.RESULTS
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Table 3.4: Regulated genes in FDCP-1 cells by IL-3 withdrawal
from Affymetrix Mouse A chips assay*
3 3
5 8 6 7
2 5 7
-2 2 4 5
2 3 4
4 4
6 4 5 4
1 2 3 4
-1 2 3 3
-1 2 3 3
1 4 3 3
1 2 3 3
1 2 3 3
-2 -4 -4 -2
-2 -3 -4 -3
-2 -2 -4 -3
-2 -2 -3 -3
-1 -1 -2 -3
-3 -4 -3
-3 -3 -2 -3
-1 -2 -3
-1 -2 -3 -3
-1 -2 -3 -3
-1 -2 -2 -3
-1 -2 -3 -3
-3 -4 -4 -4
-2 -2 -3 -4
-2 -3 -3 -4
-1 -1 -2 -4
-2 -3 -5 -4
-1 -4 -5 -4
1 -1 -2 -5
-1 -2 -4 -5
1 -1 -2 -5
-1 -2 -3 -6
-1 -2 -4 -6
-3 -3 -3 -6
-7 -7 # -7
-1 -2 -6 -7
-1 -3 -6 -7
-3 # # -8
-1 -4 # #
Gene Name 2 h
4 h
6 h
8 h
x > 3
3 ³ x > 2
2 ³ x > 1
1 ³ x > -1
-1 ³ x > -2
-2 ³ x > -3
-3 ³ x
undetectable
Osf2 (Osf2/Cbfa1)
Bcl-6
cytokine A9 (MRP-2)
cyclin G2 (Ccng2)
MAD 4
Gna14
Rgs2
programmed cell death 4 (Pdcd4)
carnitine palmitoyltransferase I
cathepsin G (Ctsg)
ID-2
p2b4c receptor (P2X4 gene)
annexin I
GTP binding protein (GTP2) mRNA
thrombin receptor (F2r)
interleukin 4 receptor, alpha (Il4ra)
EIF-1A (EIF-4C)
Timm10
protein tyrosine phosphatase, receptor type K
REX-2
Nucleolar phosphoprotein P130
Vegf
phosphofructokinase
AKR group XII-2 phospholipase A2 mRNA
methenyltetrahydrofolate cyclohydrolase (Mthfd2)
Pim-1
transferrin receptor
Arx
thrombin receptor (Cf2r)
Pim-2
monocarboxylate transporter 1 (mMCT1)
GTP cyclohydrolase 1
 branched chain aminotransferase 1, cytosolic (Bcat1)
spermidine synthase
interleukin 2 receptor
c-Myc
ID-1
MRVI1a protein (Mrvi1)
T-cell receptor gamma, variable 4 (Tcrg-V4)
schlafen 2 (Slfn2)
 T cell receptor C-gamma-7.1
Contrapsin-like protease inhibitor 1 precursor
* The 21 genes with survival functions are named with red; the 3 genes with cell
death functions named with green. The numbers in the legends represent fold
of regulation in comparison with control (0 h). The positive and negative
values indicate up- and down-regulation, respectively. The extent of the
regulations is schematically visualized in seven different colors.RESULTS
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Table 3.5: Differentially expressed genes that recovered by gene trapping
on Affymetrix Mouse A chips*.
2h 4h 6h 8h
26-12-4 Vav1 (inv?)
26-21-3 Rad 50 (inv)
26-22-1 ATF-1
26-22-4 ACOX (inv.)
26-32-4 14-3-3 zeta
30-11-5 ERK3
30-12-2 Hexokinase I
30-21-3 Prefoldin2(inv.)
30-32-3 Annexin A11 undef
30-32-16 YB-1
30-42-7 Syntaxin 3A
NeuA Siat8d
Un1g KIAA1140 (inv)
AW17 Tmp21-I
AW30 ect2
AW32  GNA15 (inv)
AW34  Syntaxin-7 (inv)
AW607 nin283
AW608 FORMIN RELATED PROTEIN (inv)
AW611  PHAPI
Angiopoetin-1 (inv)
AW618 MC1-R (inv.)
AW623 SatB1
 1.2 >X ³ -1.1
 -1.1 > X ³ -1.2
 -1.2 > X
 1.3 > X ³ 1.2
 1.9 ³ X ³ 1.3
 3.0 ³ X > 1.9
* Blue cells mark genes with sense gene trap insertions. Yellow cells mark genes
with antisense gene trap insertions. The numbers in the legends represent fold of
regulation in comparison with control (0 h). The positive and negative values
indicate up- and down-regulation, respectively. The extent of the regulations are
schematically visualized in six colors
 3. 4 GTST custom arrays for the identification of cancer-relevant
genes
Based on the assumption that some of the cell death and survival genes
assembled in the GTST library might be relevant to cancer, the cDNAs from GTSTs
were spotted onto nylon membranes to collectively evaluate their differentialRESULTS
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expressions in various types of human cancers (Table 3.6). This was intended to
identify interesting genetic targets for anti-cancer drug development.
3.4.1 Custom array production
In a first step, we attempted to generate probes from all GTSTs. At that time,
72% of the GTSTs were still classified as "novel" (Wempe et al, 2001). Therefore the
following strategies were used: (i) RT-PCR using primers against the coding regions
of known genes, (ii) RT-PCR using primers against GTSTs belonging to unknown
genes and (iii) genomic PCR using primers against GTSTs belonging to unknown
genes for which RT-PCR failed to produce an amplification product.
To circumvent hybridization kinetics variability with different sized probes,
primers were designed to amplify fragments similar in size (although this was not
always possible).  The sizes of the majority of fragments are listed in Appendix VI.
Clean amplification products were obtained for 77 GTSTs (Figure 3.9).   
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Figure 3.9:  GTST probes obtained by PCR. Ethidium bromide stained agarose gels
(1~2%) showing the size of the amplification products.
After the amplification, products were verified by sequencing.  100 pmol of
each were spotted onto nylon membranes on collaboration with Drs Bernhard Korn
and Matthias Schick (Deutsche Krebsforschungszentrum; DKFZ Heidelberg). FigureRESULTS
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3.10 shows probes for each individual gene were spotted in duplicates to eliminate
potential non-specific single spot hybridization. Genes and their positions on the self
made array are listed in Appendix VIII.
Figure 3.10: Typical self-made array with seventy cDNA probes spotted in
duplicates around the guide dot G, 1 and 2 represent different probes.   
3.4.2 Array hybridization of probes from human tumor cells
We first used a trial and error approach to optimize the detection sensitivity of
human transcripts on mouse arrays. Random hexamer and oligo-d(T)18 based labeling
and array probe-specific primer cocktails (see Section 2.6.4 and Appendix VI for
details) were used for labeling the mRNA for array hybridization. Gene specific
primers were clearly superior to oligo-d(T)18 hexamers as they offered increased
sensitivity and produced a lower background.  
To check reproducibility, four randomly selected RNA samples from Hel
92.1.7, KM12, SW-620 and HL60 cells (see Table 3.6) were hybridized to the
membranes in 2 separate experiments . While some variability was noticed with
different RNA preparations, repeated hybridization with the same mRNA gave
similar results. Most of tumor cell RNA samples, which were used for hybridization,RESULTS
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were donated from an RNA bank assembled by AstaMedica (Table 3.6). Differential
expression of the various genes on cancer cell lines was estimated by comparing spot
intensity generated by cancer cells to that generated by normal tissue controls (Table
3.6). Results of the hybridizations are summarized in Table 3.7.
Table 3.6: List of human tumor cell lines and controls used for expression profiling.   
Sample Name Type of cancer Sample Name Type of cancer Sample Name Type of cancer
BA/F3 Blood SCC-15 Head&Neck HS766t Pancreas
EOL-1 Blood SCC-25 Head&Neck PA-TU-8902 Pancreas
BT-20 Breast HOP-62 Lung PA-TU-8988T Pancreas
BT-474 Breast NCI-H-226 Lung SU8686 Pancreas
MDA-MB-157 Breast NCI-H-460 Lung HUP-T4 Pancreas
MDA-MB-436 Breast H322M Lung YAPC Pancreas
MDA-MB-453 Breast BEN Lung BPH-1 Prostate
MX-1 Breast LcLc97M1 Lung
SK-BR-3 Breast ScLc214 Lung
SISO Cervix H82 Lung Control Source of Sample
CaCo-2 Colon VM-CuB1 Lung U937 Eukaryotic cell lines
COLO-205 Colon SK-Mel1 Melanoma K562 Eukaryotic cell lines
CX-1 Colon SK-Mel3 Melanoma Hel Eukaryotic cell lines
HCC-2998 Colon IGROV1 Ovary DOHH Eukaryotic cell lines
HCT-15 Colon OVCAR-3 Ovary Hel 92.1.7 Eukaryotic cell lines
KM12 Colon OVCAR-4Ö Ovary Laz509 Eukaryotic cell lines
LOVO Colon OVCAR-5Ö Ovary HL60 Eukaryotic cell lines
SW-480 Colon OVCAR-8 Ovary Raji Eukaryotic cell lines
SW-620 Colon SK-OV-3 Ovary Tumor Human lung tissue
CX-14 Colon SW-626 Ovary Normal Human lung tissue
Hec-1a Endometrium AS-PC-1 Pancreas Normal Human Brain tissue
JShikawa Endometrium BXPC-3 Pancreas Normal Human colon tissue
SCC-27 Head&Neck Capan-2 Pancreas Normal Human Prostate tissue
SCC-4 Head&Neck CFPAC-1 Pancreas Frank Monocyte (PMNL I)
SCC-9 Head&Neck DAN-G Pancreas Jiyeon Monocyte (PMNL II)
About 50% of the cDNAs showed hybridization signals from the various
mRNA sample. Intensities of individual spots were quantified with the ImageQuant
software after exposing the membranes to a Phosphoimager screen, or alternatively,
to a Kodak-BioMax X-ray film (Figure 3.11).RESULTS
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Lung
Normal
Lung
Cancer
H322M
ScLc214
NCI-H-460
H82
BEN
LcLc97M1
a g
YB-1
Plekha
KIAA0740
PEST
GAPDH KIAA1036
PIP kinase
KIAA0424
Colon
Normal
CX-14
KM-12
SW-620
KIAA0424 KIAA1036
a g
PIP kinase
YB-1
GAPDH
Plekha
KIAA0740
PEST
Figure 3.11:  Some examples of differential gene expressions of our selected GTSTs
in various cell lines. These arrays are chosen from others (see Appendix
VII) on the basis of intensity of hybridization signals that are in good
contrast to background. These genes (KIAA, PEST, Plekha) are mostly
unknown or not well defined in data bases. Lung normal, mRNA
prepared from normal lung tissues of 28 year old male (Invitrogen);
lung cancer, mRNA from tumor lung tissues of 66 year old female who
got moderately differentiated alveous cell carcinoma. Colon normal,
pooled mRNA prepared from normal whole colon (with mucosal lining)
tissues of two male (ages 35 and 50) who got sudden death (Clontech).RESULTS
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Of the most highly regulated genes, the following were selected for further
analysis: Plekha2, KIAA0740, KIAA1036, KIAA1140, PI4P5K type I a, PI4P5K
type I g and PEST containing nuclear protein.
Since the project was performed on collaboration with Schering AG (Berlin)
the selection containing of genes for further analysis included a potential drugability
of the targets. ERK3 was additionally selected, since our collaboration partners were
especially interested in targets that could be inhibited by kinase antagonists.
3.4.3 Matched tumor/normal expression array assay
Commercially available matched tumor arrays (containing sample pairs from
68 patients of different tumor types) were hybridized to probes derived from Plekha2,
KIAA0740, KIAA1036, KIAA1140, PI4P5K type I a, PI4P5K type I g, PEST
containing nuclear protein and ERK3. Probes were prepared by RT-PCR using an
RNA pool from 5 cancer cell lines and gene specific primers (see section 2.7.1 and
Figure 2.9). Hybridization patterns obtained on the matched tumor arrays with the
selected probes were as follows.
(I) ERK3 is downregulated in 10 out of 11 colon cancers and in most of the
kidney and rectum cancers (Table 3.9). In contrast, ERK3 is significantly up-
regulated in breast cancers and to a lesser extend in stomach and uterus cancers.
(II) PIPK b (corresponds to murine PIPK a) was slightly up-regulated in
colon cancers.
(III) KIAA0740 was slightly up-regulated in uterus cancer.
(IV) KIAA1140 was slightly up-regulated in stomach cancer, but showed no
significant change in the others.
Tumors consist of different cell populations and clones, and usually different
parts of a tumor are not separated for the analysis. The aberrations detected in a tumor
represent a “pool” of changes. This holds true for the specific expression patterns in
various carcinoma tissues. Using matched tumor/normal expression array (Figure 2.8)RESULTS
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analysis we investigated differential gene expressions of our seven target genes in
eleven specific tumor types (including patient age and gender, tumor stage, extent of
local invasion and sites of metastasis). As described in the following Table 3.16,
gains and losses of expression levels of the target genes in the specific tumor types
turned out to be genetically extremely complex.
Kidney
Breast
Prostate
Uterus
Kidney
Ovary
Cervix
Colon
Lung
Stomach
Rectium
Small intestine
Figure 3.12:  Tissue-specific differential expression patterns of ERK3
The colored name indicates tissue types on the membrane:
blue: kidney green: breast
azure: prostate dark brown: uterus
red: ovary black: cervix
 pink: colon white: lung
lime: stomach terracotta: rectum
violet: small intestine 
N: normal T: tumor.RESULTS
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Table 3.8: Generation of differential tumor gene expression ratio against normal
tissue gene (data for ERK3 from Figure 3.12)*
Kidney Nornal Kidney Tumor Expression Cervix Normal Cervix Tumor Expression
A1 0.45 B1 0.1 0.2 G14 0.25 H14 0.46 1.9
A2 0.64 B2 0.34 0.5 Colon Normal Colon Tumor Expression
A3 0.84 B3 0.44 0.5 J1 0.44 K1 0.11 0.3
A4 0.68 B4 0.13 0.2 J2 0.94 K2 1.5 1.6
A5 0.37 B5 0.19 0.5 J3 1.03 K3 0.65 0.6
A6 0.4 B6 0.12 0.3 J4 0.66 K4 0.45 0.7
A7 0.64 B7 0.1 0.2 J5 0.92 K5 0.48 0.5
A8 0.46 B8 0.28 0.6 J6 0.97 K6 0.78 0.8
A9 0.51 B9 0.16 0.3 J7 0.36 K7 0.32 0.9
A10 0.34 B10 0.15 0.4 J8 1.11 K8 0.4 0.4
A11 0.5 B11 0.15 0.3 J9 0.87 K9 0.38 0.4
A12 0.95 B12 0.73 0.8 J10 1.06 K10 0.31 0.3
A13 0.87 B13 0.5 0.6 J11 1.01 K11 0.72 0.7
A14 0.9 B14 0.21 0.2 Lung Normal Lung Turmor Expression
Breast Normal Breast Tumor J13 0.08 K13 0.08 1
D1 0.61 E1 0.48 0.8 J14 0.48 K14 0.8 1.7
D2 0.73 E2 0.12 0.2 J15 0.59 K15 0.65 1.1
D3 0.13 E3 0.44 3.2 Stomach Normal Stomach Tumor Expression
D4 0.25 E4 0.36 1.4 M1 0.58 N1 0.2 0.3
D5 0.05 E5 0.29 5.7 M2 1.17 N2 1.09 0.9
D6 0.05 E6 0.77 14.6 M3 0.79 N3 1.13 1.4
D7 0.53 E7 1.16 2.2 M4 0.63 N4 1 1.6
D8 0.04 E8 0.21 5.5 M5 0.19 N5 0.87 4.6
D9 0.42 E9 0.55 1.3 M6 0.32 N6 0.98 3
Prostate Normal Prostate Tumor Expression M7 -0.04 N7 0.21 0
D11 0.61 E11 0.82 1.3 M8 0.46 N8 0.7 1.5
D12 0.52 E12 0.46 0.9 Rectium Normal Rectium Tumor Expression
D13 0.29 E13 0.33 1.1 M10 1.02 N10 0.73 0.7
Uterus Normal Uterus Tumor Expression M11 1.2 N11 0.73 0.6
G1 -0.01 H1 0.18 0 M12 0.43 N12 0.34 0.8
G2 0.66 H2 1 1.5 M13 1.03 N13 0.63 0.6
G3 -0.05 H3 -0.05 0 M14 0.46 N14 0.55 1.2
G4 0.1 H4 0.31 3 M15 0.72 N15 0.65 0.9
G5 0.18 H5 0.27 1.5 M16 1.03 N16 0.08 0.1
G6 0.45 H6 0.63 1.4 SI Normal SI Tumor Expression
G7 0.12 H7 0.37 3.2 M18 0.81 N18 0.27 0.3
Ovary Normal Ovary Tumor Expression
G10 0.14 H10 0.1 0.7
G11 0.26 H11 0.25 1
G12 0.21 H12 0.14 0.6
Expression
* The hybridization signals were detected from the obtained phosphorimage. Values
shown in second and forth columns are those after normalization. The final value
of ERK3 expression ratio (in fifth column) was converted into a schematically
visualized table (as shown in Table 3.16).
 Table 3.9: Tissue-specific differential expression of ERK3 in eleven organs
(tumor tissue against the matching normal tissue).
Kidney Breast Prostate Uterus Ovary Cervix
Mean ± SE 0.5±0.08 7.4±2.4* 1.1±0.1 2.3±0.3 0.85±0.09 1.9
Colon Lung Stomach Rectum SI
Mean ± SE 0.95±0.2 1.35±0.2 2.45±0.8 0.65±0.2 0.3
*  In the breast, the differential expressions of ERK3 was significant, although the
standard error value (SE) was high because of relatively strong variations
among individual patients.RESULTS
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Figure 3.13:  Tissue-specific differential expression patterns of PIPK b between
normal and tumor tissues. As shown in 4E, PIPK b expression has
been shown to be not regulated in a patient who got medullary
carcinoma but with no metastasis.
Table 3.10: Tissue-specific differential expression of PIPK b in eleven organs*
(tumor tissue against the matching normal tissue)
Kidney Breast Prostate Uterus Ovary Cervix
Mean±SE 0.95±0.12 1.1±0.1 1.0 0.6±0.08 1.15±0.3 0.8
Colon Lung Stomach Rectum SI
Mean±SE 1.6±0.2 0.7±0.18 0.85±0.16 1.2±0.15 1.0
* The expressions of PIPK b were slightly down-regulated or not changed at all
from 7 out of 11 specific tumor types. Probably, differential expression of PIPK b
is not a prime feature of these cancers.RESULTS
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Figure 3.14:  Tissue-specific differential expression patterns of PIPK g between
normal and tumor tissues. The phosphorimage was obtained
following five days exposure to the imaging plate. *This array and
Figure 3.16 have partially darker background that results in variation
in gene expression analysis. Therefore, some values (Table 3.11) of
differential expressions of PIPK g couldn’t be regarded as genuine
differences.
Table 3.11: Tissue-specific differential expression of PIPK g in eleven organs (tumor
tissue against the matching normal tissue).
Kidney Breast Prostate Uterus Ovary Cervix
Mean±SE 0.7±0.1 0.8±0.07 1.05±0.15 0.9±0.12 0.5±0.06 0.8
Colon Lung Stomach Rectum SI
Mean±SE 1.5±0.4 1.3±0.1 0.55±0.16 1.3±0.4 1.0RESULTS
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Figure 3.15:  Tissue-specific differential expression patterns of KIAA0740
between normal and tumor tissues. The phosphorimage was obtained
following three days exposure.
Table 3.12: Tissue-specific differential expression of KIAA0740 in eleven organs
(tumor tissue against the matching normal tissue)
Kidney Breast Prostate Uterus Ovary Cervix
Mean±SE 0.5±0.08 0.85±0.15 0.4±0.18 3.05±1.0* 1.1 0.6
Colon Lung Stomach Rectum SI
Mean±SE 1.25±0.04 1.13±0.2 1.4±0.3 1.2±0.3 0.9
 * In the uterus, the differential expressions of KIAA0740 was significant, although
the standard error value (SE) was high because of relatively strong variations
among individual patientsRESULTS
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Figure 3.16:  Tissue-specific differential expression patterns of KIAA1036 (after
five days exposure). As explained in Figure 3.14, the partially darker
background that results in variation in gene expression analysis.
Table 3.13: Tissue-specific differential expression of KIAA1036 in eleven organs
(tumor tissue against the matching normal tissue)
Kidney Breast Prostate Uterus Ovary Cervix
Mean±SE 1.0±0.1 1.35±0.15 1.0±0.3 1.4±0.2 0.9±0.2 1.4
Colon Lung Stomach Rectum SI
Mean±SE 0.83±0.2 0.6±0.35 1.53±0.09 0.95±0.1 1.1RESULTS
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Figure 3.17: Tissue-specific differential expression patterns of KIAA1140 (five
days exposure). This array and Figure 3.18 are uniformly darker than
the other arrays and that has an effect on the apparent variation in
expression levels of the genes for a comparison analysis with the other
results .
Table 3.14: Tissue-specific differential expression of KIAA1140 in eleven organs
(tumor tissue against the matching normal tissue)
Kidney Breast Prostate Uterus Ovary Cervix
Mean±SE 0.85±0.07 1.1±0.3 1.25±0.09 0.7±0.2 0.8 0.7
Colon Lung Stomach Rectum SI
Mean±SE 0.9±0.2 0.6±0.17 2.3±0.07 1±0.08 0.7
.RESULTS
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Figure 3.18:  Tissue-specific differential expression patterns of Plekha2 .
Table 3.15: Tissue-specific differential expression of Plekha2 in eleven organs
(tumor tissue against the matching normal tissue).
Kidney Breast Prostate Uterus Ovary Cervix
Mean±SE 0.8±0.08 0.9±0.1 0.85±0.03 0.9±0.15 0.85±0.03 1.0
Colon Lung Stomach Rectum SI
Mean±SE 0.75±0.3 0.95±0.2 1.7±0.1 0.95±0.2 0.9RESULTS
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Table 3.16: Seven target genes with relevance to various human tumor tissues*
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A1 J1
A2 J2
A3 J3
A4 J4
A5 J5
A6 J6
A7 J7
A8 J8
A9 J9
A10 J10
A11 J11
A12 J13
A13 J14
A14 J15
D1 M1
D2 M2
D3 M3
D4 M4
D5 M5
D6 M6
D7 M7
D8 M8
D9 M10
D11 M11
D12 M12
D13 M13
G1 M14
G2 M15
G3 M16
G4 SI M18
G5
G6
G7
G10
G11
G12
Cervix G14
Ovary
Colon
Lung
Stomach
Rectum
Kidney
Breast
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Uterus
  X ³ 4
 4 > X ³ 2
 2 > X ³ 1.2
 1.2 > X ³ 0.8
 0.8 > X ³ 0.5
 0.5 > X ³ 0.25
 0.25 > X
P
I
P
K
b
P
I
P
K
g
* The numbers in legends indicate the fold of regulation in cancer against normal
tissues. Values greater than 1.2 are defined as up-regulation and those smaller
than 0.8 are down-regulation. The magnitude of regulation is visualized in
different color.C
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CHAPTER 4
DISCUSSION
Apoptosis is the counterpoint to proliferation in the regulation of cell growth.
The operational activities of cells are based on an awareness of their current state,
coupled to a programmed response to internal and external cues in a context-
dependent manner. The essence of the balance between life and death is the ability to
express only certain portions of the genome in particular cells at particular times
(Dunham, 2000; Levy and Darnell, 2002; Kavurma and Khachigian, 2003).
Apoptotic genes are activated or inactivated in a series of events that underlie
the multistage development of life and death. Therefore, these incidents possibly
reflect the differential and coordinate expression of specific genes (Gillen et al.,
1998) in the maintenance of the balance between cell growth and cell death
(Thompson et al., 1995).
After the removal of the survival factors, the cytokine-dependent
hematopoietic cell lines undergo apoptosis at a greatly accelerated pace (Askew et al.,
1991; Evan et al., 1992; Askew et al., 1993; Juin et al., 1999; Juin et al., 2002). Our
previous studies have shown that the stimulation of survival (anti-apoptotic)
mechanisms during the early stage of apoptosis induced by IL-3 deprivation results in
reduced apoptosis and improved survival of cells. Part of our findings is supported by
the studies of others that established the relevancies between some regulators (e.g., c-
Myc, Bcl-2, Bcl-XL and Pim-1) in anti- and pro-apoptotic pathways.
Since the constitutive up-regulation of survival genes and/or the inactivation
of pro-apoptotic genes are hallmarks of cancer, the susceptibility of tumor cells to
apoptosis induced by antitumor drugs could depend on the balance between pro-
apoptotic and survival (anti-apoptotic) gene regulation (Tsuruo et al., 2003).DISCUSSION
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The goal of this thesis was to identify genes that are differentially expressed
during genes apoptosis and tumorigenesis.
To achieve this, a gene trap strategy was employed to recover
transcriptionally regulated genes in FDCP-1 cells undergoing apoptosis after growth
factor (IL-3) withdrawal. Furthermore, the efficiency of recovering such genes by
gene trapping was compared to the efficiency of recovering similar genes on Atlas
arrays and Affymetrix chips. To identify cancer related genes, custom arrays
containing 70 gene trap sequence tags (GTSTs) isolated from FDCP1 cells
undergoing apoptosis were hybridized to mRNAs derived from a large collection of
cancer cell lines. Finally, to define potential targets for anti-cancer drug development,
several candidate genes identified on the custom arrays were used as probes on
matched tumor/normal-arrays from patients with various types of cancer. Of all
identified targets, the most promising was the ERK-3 serine/threonine kinase because
it is highly and specifically upregulated in breast and uterine cancers and susceptible
to synthetic antagonists (= drugable).
4.1 Assessment of the technologies
Gene trap technology is a powerful tool for identifying genes, whose
expression is induced by certain biological stimuli (Wempe et al., 2001). In this
effort, cells with gene trap insertions in loci transcriptionally induced by IL-3
withdrawal were selected from a random integration library in FDCP-1 cells. From 2
x 10
6 unique gene trap insertions, we recovered a total of 102 useful gene trap
sequence tags (GTSTs). A significant proportion of the trapped genes with well-
defined functions (28 out of 50 = 56%) were either directly or indirectly involved in
cell survival and/or cell death. A third of these genes (9 out of 28) were directly
related  to the IL-3 - and small Rho-GTPase survival pathways (Table 3.1).
To compare the gene trap approach with other strategies used to identify
differentially expressed genes, we first hybridized commercially available Atlas
cDNA arrays (Clontech) to mRNAs from FDCP1 cells undergoing apoptosis. Out ofDISCUSSION
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588 genes, 47 appeared differentially expressed. Out of these, only 13 could be
confirmed as genuinely induced by IL-3 withdrawal.
Similar experiments were performed using Affymetrix chips containing
oligonucleotide probes from 5000 known mouse genes. At low stringeny about 25%
of all genes seemed inducible by IL-3 withdrawal. However, at high stringency (over
3 fold up- or downregulated), only 34 genes appeared differentially expressed. Of
these, 24 genes (69%) were directly related to cell death and survival.
Although the number of relevant genes recovered by the two different
technologies (gene trapping vs. arrays) is quite similar (56% and 69%, respectively),
the type of genes is different. First, unlike most array technologies, gene trapping has
no bias for highly expressed genes and readily identifies subtle changes in gene
expression. Second, gene trapping selects for real gene inductions and, unlike arrays
or Northern blots, is independent of pre-existing steady state of mRNA levels
subjected to posttranscriptional regulation. Taken together, the results suggest that
gene trapping effectively complements microarray based strategies unable to
distinguish between transcriptional and post-ranscriptional gene regulation.
Interestingly, several genes recovered by gene trapping that were also
represented on the Affymetrix arrays were regulated in the opposite direction on the
chips. With one exception, the genes down-regulated on the chips corresponded to
GTSTs obtained from anti-sense gene trap insertions. As repression correlated with
anti-sense gene trap insertions, it is likely that the anti-sense transcripts induced by
IL-3 deprivation have an inhibitory function. Thus, unlike array technologies, gene
trapping can detect potential inhbitors of specific gene expression. The presence of
overlapping anti-sense transcripts has been demonstrated for several genes (e.g.,
cyclin E2 and p53BP1, Yelin et al., 2003) and it has been speculated that they might
have regulatory functions (Bains et al., 1997; Carmichael, 2003)DISCUSSION
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Fifty percent of all gene trap insertions recovered in these expreriments were
activated from non-coding strands. Compared to other gene trap screens performed in
our laboratory, the frequency of antisense gene trap insertions is relatively high and
may reflect the high sensitivity of the Cre-recombinase reporter gene used for
creating the FDCP1 integration library. Alternatively, as most antisense transcripts
are non-coding, lack of upstream ATGs may favor the selection of the Cre ATG as
the translation initiation codon in the fusion transcript. It is predicted that over 8% of
human genes have antisense transcripts (Yelin et al., 2003), although their
significance still remains to be established. In many cases sense-antisense overlaps
could have regulatory functions as has been shown repeatedly for short interfering
RNAs (RNAi) (Hannon 2002).
In summary, gene trapping appears to provide an effective and sensitive tool
for the functional annotation of the mammalian genome.
4.2 Expression profiling of the trapped genes
4.2.1 Genes recovered by gene trapping
A total of 28 genes involved in cell death and survival were recovered from a
U3Cre gene trap integration library in FDCP1 cells. These  genes can be classified
into 4 functional groups:
I. Apoptosis or survival-related proteins
Formin/diaphanous-related protein (FHOS), is a member of the formin
homology (FH) protein family  which is implicated especiall that interacts with Rac-
1, a small Rho-GTPase and activates transcription from the serum response element
(Westendorf, 2001). Similarly, another member of this family, the Formin-related
protein (FRL) also binds Rac-1 and when expressed as a dominant negative deletion
mutant reduces attachment which initiates apoptosis (anoikis) in cell culture
(Yayoshi-Yamamoto et al., 2000). Further examples are several guanine nucleotide
exchange factors (GEFs) such as NET1, Ect2, Vav-1 and Collibistin II (Table 3.2).DISCUSSION
86
The GEFs belong to the Rho-subfamily of GTPases, which regulate cell
growth and can transform cells in culture (Grosskreutz et al., 2001; Schmidt and Hall,
2002; Bassermann et al., 2002; Piccolella et al., 2003). This transformation is
dependent on the highly conserved DB-1 homology (DH) domain and in most cases
requires N-terminal truncation of the protein. Interestingly, a novel splice variant of
NET1, NET1A, was found to encode an N-terminally truncated protein that possesses
transforming activity (Alberts and Treisman, 1998). In addition to the DH domain,
GEFs have a pleckstrin homology domain that connects the Rho signal transduction
pathway to the phosphatidyl-3-phosphate kinase (PI3K) signal transduction pathway
(Bellanger et al., 2000; Blomquist et al., 2000). The latter is responsible for
mediating survival signals, particularly in hematopoietic cells, and is directly
activated by IL-3 (Guthridge et al., 2000). Surprisingly, two members of this
pathway, the phosphatidylinositol 4,5-phosphate kinases (PIP5K) type Ib (which
corresponds to human PIP5K type Ia) and type Ig, were induced by IL-3 withdrawal.
PIP5K converts the lipid phosphatidylinositol 4-phosphate (PI4-P) to
phosphatidylinositol 4,5-bisphosphate (PI4,5-P2), which enhances cell survival by at
least three mechanisms. First, PI4,5P2 directly inhibits apoptosis by inactivating
caspases 8, 9 and 3. Moreover, PIP5K type Ia overexpression in cultured cells
prevents apoptosis induced by caspase 9 or TNF-a (Secchiero et al., 2003). Second,
PI3K phosphorylates PI4,5-P2 to phosphatidylinositol 3,4,5-triphosphate (PIP3),
which activates the survival kinase Akt. Akt prevents cell death by phosphorylating
and inactivating the pro-apoptotic proteins BAD, caspase 9 and the forkhead family
transcription factor (FKHRL1). FKHRL1 induces the expression of Fas-ligand
(Suhara et al., 2002). Phosphorylated BAD is sequestrated and thereby inactivated by
14-3-3 z isoform (Shinoda et al., 2003). Interestingly, 14-3-3 z was also trapped in
these experiments. Third, PIP5K activates ATP-dependent potassium channels
thereby helping to maintain the polarity of the cell membrane (Shyng et al., 2000). As
has been shown previously, apoptotic signals can cause membrane depolarization that
leads to cell death by directly inhibiting potassium channels (Pei et al., 2003).DISCUSSION
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II. Transcription factors
The transcription factor YB-1 is directly involved in cell survival by
repressing Fas gene expression (Lasham et al., 2000). Moreover, YB-1 activates the
expression of the multi-drug resistance gene (MDR1) whose product, the P-
glycoprotein, is an efflux pump that eliminates a variety of toxins from the cell,
including pro-apoptotic anticancer drugs (Saji et al., 2003).
ATF1, which binds the same DNA motive like the Hypoxia induced factor-1
(HIF-1), activates a signal transduction pathway leading to increased expression of
genes known to compensate for hypoxic or oxidative stress (Zaman et al., 1999).
Vezf1/DB1 is described as an endothelial transcription factor that regulates
endothelin-1 expression, which has been shown to be a survival factor during c-Myc
induced apoptosis (Aitsebaomo et al., 2001; Louro et al., 2002).
Tel, a member of the Ets family of transcription factors, is a fusion partner of
AML1 or ABL in leukemic translocations (Hannemann et al., 1998). Overexpression
of Tel leads to reduced cell growth, even in cells transformed by activated Ras
(Sakurai et al., 2003).
BTEB1, a ZNF-containing transcription factor, promotes cell growth by
inducing several cell-cycle regulating genes (Zhang et al., 2002).
ASC-1 was originally isolated as a transcriptional coactivator of nuclear
receptors. However, it also appears to play an essential role in transactivation through
AP-1, SRF, and NF-kB (Jung et al., 2002) and could thus potentially modulate
survival responses of cells.
SatB1 is a nuclear protein that recruits chromatin remodeling proteins to AT-
rich DNA. SatB1 is cleaved by caspase 6 in thymocytes, which leads to its
detachment from the DNA (Galande et al., 2001). SatB1 seems to be involved in the
apoptotic clonal deletion during thymocyte maturation  (Yasui et al., 2002).
III. Proteins for DNA repair
The mouse homologs of the bacterial AlkB, the yeast rec8 and rad50 genes
were recovered as DNA-repair genes. While AlkB protects DNA from damage byDISCUSSION
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alkylating agents (Wei et al., 1996), rec8 and rad50 are proteins responsible for
double DNA strand break reapir (Parisi et al., 1999; Dasika et al., 1999; Luo et al.,
1999). The double strand breaks develop as a result of any apoptotic process.
IV. Proteins with diverse functions
VMAT2 (vesicular monoamine transporter 2) is a cytoprotective protein. It
moves cytoplasmic monoamine transmitters into secretory vesicles and prevents cell
death by sequestering pro-apoptotic molecules such as 1-methyl-4-phenylpyridinium
(MPP+) and histamine (Moriyama and Yamada, 1996; Grundemann et al., 1999).
NADPH-cytochrome P450 oxidoreductase transfers electrons from NADPH
to cytochrome P450. By catalyzing the one-electron reduction of many drugs and
xenobiotic compounds (Smith et al., 1994), this oxidoreductase is part of the cell's
detoxifying machinery and thus promotes survival.
Hexokinase I is a common metabolic enzyme of glycolysis. However, it has
been demonstrated that increased hexokinase activity protects renal epithelial cells
against acute oxidant-induced cell death (Bryson et al., 2002) and that mitochondrial
hexokinase association promotes both mitochondrial integrity and cell survival
following growth factor withdrawal (Gottlob et al., 2001)
ERK3 (extracellular signal-regulated kinase 3) is a recently characterized
member of the MAPK (mitogen-activated protein kinases) signal transduction protein
family. It is involved in the ubiquitin-proteasome pathway of protein degradation and
assumed to regulate cellular differentiation (Coulombe et al., 2003). Since ERK-3 is
likely an interesting genetic target for anti-cancer drug development it will be
discussed in more detail in Section 4.4.
Annexin V: There are numerous reports that overexpression of annexins
(annexin A6 and annexin A11 were trapped) leads to subsequent apoptosis (Canaider
et al., 2000; Kirsch et al., 2000; Solito et al., 2001). Previous findings show that
annexin-induced apoptosis is connected to annexin dependent Ca
2+ influx into the
cells (Hawkins et al., 2002; Wang et al., 2003).DISCUSSION
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Smurf1, an E3 ubiquitin ligase for bone morphogenetic protein-specific
Smads, is recruited by Smad-7 to the TGF-b (transforming growth factor-beta) type I
receptor, resulting in proteasome-dependent   degradation of the receptor (Ebisawa et
al., 2001). As TGF-b is known to prevent epithelial cell proliferation and to induce
apoptosis in lymphocytes, liver and prostate (Schuster and Krieglstein, 2002), Smurf1
could play an important modulatory role in these processes by regulating receptor
availability.
EDEM (endoplasmic reticulum-degradation-enhancing a-mannosidase–like
protein) is a quality control receptor responsible for sorting terminally malfolded
glycoproteins that are destined to destruction (Wang and Hebert, 2003)
MC1-R (melanocyte-stimulating hormone receptor) stimulates proliferation
and survival in melanocytes (Kadekaro et al., 2003).
UREB1 (upstream regulatory element binding protein 1) is a nuclear
phospho-protein that inhibits p53-stimulated transcription (Gu et al., 1995). Since p53
is a critical regulator of growth arrest and apoptosis, UREB1 promotes cell survival
by inhibiting p53 function.
PHAPI (putative HLA-DR-associated protein I), initially identified as an
MHC class I binding protein proteins, activates caspase 9 within the apoptosome
(Jiang et al., 2003) and thus suppresses tumor growth.
In conclusion, a large fraction of genes recovered by gene trapping encode
survival functions. Their induction after IL-3 withdrawal seems to reflect a short lived
cellular response to prevent cell death induced by an accidental exposure to an
apoptotic stimulus such as temporary factor deprivation. In line with this temporary
activation of a survival program is the phenomenon of apoptotic preconditioning
where a cell epxosed transiently to an apoptotic stimulus becomes more resistant to a
subsequent permanent apoptotic stimulus (Wempe et al., 2001).
However, several genes with proapoptotic functions were also induced by
factor deprivation, suggesting that the balance between pro- and antiapoptoticDISCUSSION
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functions is crucial for the final outcome. During growth factor withdrawal apoptosis,
this balance is tilted initially towards survival (Wempe et al., 2001).
4.2.2 Genes recovered by Atlas arrays
Twelve out of the 588 genes spotted onto the Atlas arrays (2%) were
differentially expressed in IL-3 deprived cells, as the observed regulation could be
confirmed by Northern blotting. All these twelve genes are linked to cell death and
survival functions.
4.2.2.1 Genes downregulated by IL-3 withdrawal
The c-Myc proto-oncogene (Selten et al., 1984; Pelengaris et al., 2002) is an
important positive regulator of cell growth and proliferation. However, c-Myc is also
a potent inducer of apoptosis when expressed in the absence of serum or growth
factors (Wagner et al., 1993; Evan and Littlewood, 1998; You et al., 2002). This
implies that Myc-induced apoptosis  can limit the growth of tumors which at certain
volumes experience shortage of growth factors. (Evan and Littlewood, 1993;
Koskinen and Alitalo, 1993; Pelengaris et al., 2002). This protective mechanism is
counteracted by Bcl-2 (Section 1.5.2) (Fanidi et al., 1992, Bissonnette et al., 1992,
Wagner et al., 1993). Consistent with this inhibition of c-Myc mediated apoptosis
Bcl-2 cooperates with c-Myc in malignant transformation of lymphoid cells in
transgenic mice (Strasser et al., 1990).
Pim-1 (pathogenesis of virally-induced mouse lymphoma gene). was
originally identified as a genetic locus frequently activated by proviral insertion in
murine leukemia virus induced T cell lymphomas (Cuypers et al., 1984, Selten et al.,
1985, Selten et al., 1986,). Although this serine/threonine kinase is primarily a
survival factor in FDCP-1 cells (Lilly and Kraft, 1997; Lilly et al., 1999), Pim-1
functions in concert with c-Myc in inducing apoptosis in the absence of growth
factors (Mochizuki et al., 1997). This cooperation is also in effect in oncogenesis
(Verbeek et al., 1991) suggesting that Pim-1 modulates Myc-triggered intracellular
pathways common to transformation and apoptosis. One substrate and effector forDISCUSSION
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Pim-1 kinase is Cdc25A (Mochizuki et al., 1999), a direct transcriptional target of c-
Myc indicatingthat the signals of Pim-1 and c-Myc might converge at this molecule.
Bcl-2 and Bcl-XL. Overexpression of Bcl-2 protects IL-3 dependent cells from
apoptosis induced upon IL-3 withdrawal (Lin et al., 1996; Ito et al., 1997). It has also
been shown that Bcl-XL expression is upregulated by hemopoietins in both immortal
and primary myeloid progenitors. Accordingly, Bcl-XL overexpression in
hematopoietic cells is highly protective against apoptosis induced by IL-3
withdrawal. (Boise et al., 1993). It was suggested that the survival genes Bcl-XL and
Bcl-2 inhibit c-Myc mediated apoptosis by inducing the cyclin mediated kinase
inhibitor p27 (Moser et al., 1997; Greider et al., 2002).
4.2.2.2 Genes upregulated by IL-3 withdrawal
c-Kit. Activation of the receptor tyrosine kinase c-Kit by its ligand SCF (stem
cell factor) eventually leads to phosphorylation of the antiapoptotic protein Stat1
(Deberry et al., 1997). In addition, activation of c-Kit is a likely determinant of the
unrestrained growth characteristic for malignant cells (Moses et al., 2002; Yamazaki
et al., 2003).
The IL-3 receptor bc chain. Binding of IL-3bc turns the low affinity
complex of IL-3 and the a-receptor chain into a high affinity receptor, which
stimulates cell proliferation and survival.
GST (Glutathione S-transferases) catalyzes the glutathione-dependent
detoxification of several chemotherapeutic drugs (conjugation of electrophilic
substrates with glutathione, Hayes and Pulford, 1995; Dirven et al., 1996).
Mitochondrial damage and the associated release of free radicals that are antagonized
by GST are major features of the apoptotic process (Khaled et al., 2001; Facchinetti
and Leon, 2002; Ding and Nam, 2003, Matsuyama et al., 2000; Figure 1.5). It has
recently been suggested that Glutathione S-transferase is implicated in protection
against apoptosis.(Huang et al., 2003). Thus, the activation of GST is likely reflectingDISCUSSION
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an antiapoptotic mechanism against the oxidative stress developing after IL-3
withdrawal (Dickinson et al., 2003).
4.2.2.3 Transiently up- or downregulated genes
Activin receptor type I. Two types of activin receptors (I and II) have been
characterized as transmembrane serine/threonine receptor kinases (Willis et al., 1996;
Harrison et al., 2003). Activins are dimeric growth and differentiation factors which
belong to the transforming growth factor-b (TGF-b) superfamily. They are involved
in the control of cell proliferation by initiating signaling through a heteromeric
complex of activin receptors. Binding of activin to its recptors  (Schulte et al., 2001)
triggers association of the rasGAP-binding protein (Dok-1) with Smad3 (Yamakawa
et al., 2002), which inhibits growth of certain types of cells (e.g., colonic epithelial
cells).
PKB/Akt is one of the most important cellular survival kinases, which already
serves a a target for several anticancer drugs (Tsuruo et al., 2003). It operates within
the phosphatidylinositol-3 kinase (PI-3-K) signal transduction pathway which has
been shown to stimulate survival of many cells in culture (Stein 2001). Whereas
repression of PKB/Akt leads to an irreversible commitment to apoptotic cell death, its
effective recruitment by appropriate survival signals results in suppression of p53-
dependent apoptosis (Fu et al., 2002).
FLIP-L (FLICE-like apoptosis inhibitory protein long form) is structurally
similar to procaspase 8 as it contains two death effector domains and a caspase-like
domain (Irmler et al., 1997). However, the caspase domain lacks the critical site for
catalytic activation. The protein is recruited to the CD95 DISC (death induced
signalling complex) in a stimulation-dependent fashion, where it then prevents
activation of procaspase 8 (Scaffidi et al., 1999).
Zyxin (a-actinin binding protein; Rottner et al., 2001) is a LIM domain
protein, which displays the architectural features of an intracellular signal transducer
(Beckerle, 1997). Its expression is significantly  upregulated  in melanoma cells whenDISCUSSION
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compared to melanocytes, where upregulation can be induced by mitogens,
indicating that zyxin is an important growth regulator (van der Gaag et al., 2002)
JunD (c-jun-related transcription factor, member of the jun proto-oncogene
family; Li et al., 1990, Weitzman et al., 2000) is a growth factor-inducible
transcription factor, It mediates survival signaling by the JNK signal transduction
pathway through collaboration with NF-kB to increase antiapoptotic gene expression.
(Lamb et al., 2003)
The specific regulation of several pro-and anti-apoptotic genes detected with
the arrays suggests induction of not only survival but also pro-apoptotic functions in
factor deprived FDCP1 cells, the balance of which will finally determine, whether the
cell will initiate apoptosis. Early after IL-3 deprivation the survival functions seem to
be dominant, as the cells can still be rescued by readdition of the cytokine. However,
during prolonged factor withdrawal this balance will shift towards apoptosis.
4.3 Identifying candidate genes for anti-cancer drug development
Since the up-regulation of survival genes and/or the inactivation of pro-
apoptotic genes are common in cancer, the relevance of the recovered GTSTs to
various cancers was investigated by first using GTST custom arrays and mRNAs
from established tumor cell lines. Of the 70 different cancer cell line mRNAs
hybridized to the GTST arrays, 26 were differentially expressed in tumor cells. Seven
genes were subjected to a final validation screen using matched tumor/normal arrays.
They were selected based on their enzymatic activity as protein kinases, which can
easily be targeted with small molecule inhibitors, or because they represent so far
uncharacterized proteins, which might be of interest in the future.
There are no previous reports of regulation of KIAA0740, KIAA1036 and
KIAA1140 in both carcinoma or normal cell lines. Correlations between these three
genes and their clinical behavior have not been demonstrated so far, because they are
still hypothetical proteins with unknown biological properties. KIAA0740 is aDISCUSSION
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putative new GTPase from the Rho-Family; which was moderately up-regulated only
in uterine tumors. KIAA1036, a completely unknown protein, was differentially
expressed in electronic Northern experiments performed in cooperation with Schering
AG and showed up-regulation in stomach and breast tumor tissues. KIAA1140
encodes a protein with 8 tetratricopeptide repeats (TPR), a motif which could serve as
an interface for interaction with activated Ras (Marty et al., 2003). The RNA for this
protein was upregulated in stomach tumors.
Plekha2 contains 2 PH-domains that implicate a role in signal transduction.
However, in most tumor tissues, Plekha2 expression was down-regulated or not
changed suggesting Plekha2 is possibly not a major sign of these cancers.
Conversely, in the analysis with the custom made array Plekha2 was up-regulated in
four different types of cancer cell lines. Probably, these discrepancies are due to
differences of cultured cancer cell lines and real tumor tissue.
However, before these proteins might be useful in target directed drug
development  approaches, they have to be characterized in more detail. Currently, one
of the most interesting classes of target molecules for drug discovery are protein
kinases, as such enzymes can effectively be inhibited with small molecule effectors.
PI4P5Ka and g. Although many cancer related functions, such as
proliferation (Klippel et al., 1998; Darmoul et al., 2003), cell adhesion (Thamilselvan
et al., 2003), apoptosis (Kennedy et al., 1997; Ehemann et al., 2003) and Ras
signaling (Downward, 1998; Bakin et al., 2003) have been suggested to be mediated
by the PI3K-signal transduction pathway, and PI4P5K type I b  and  g  were
upregulated in a variety of cancer cell lines, they appeared either repressed or not-
regulated on the matched tumor/normal arrays (Tables 3.10 and 3.11).
The most interesting candidate gene identified in this analysis was the
serine/threonine kinase ERK3. It is consistently upregulated in breast cancer and
provides a promising target for high throughput screening of small molecule librariesDISCUSSION
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for specific kinase-inhibitory drugs as it has different properties than the other known
proteins of this family.
4.4  ERK3 as putative target genes for drug development
ERK3 (=MAPK6) is the most recently described member of the MAPK
family of proteins and has been characterized in humans, rat and mouse (Boulton et
al., 1991, Meloche et al., 1996, Turgeon et al., 2000). The ERK3 gene subfamily of
consists of the two functional genes, MAPK6 and MAPK4 and several processed
pseudogenes (Turgeon et al., 2002).
Like the other ERK proteins, ERK3 encodes a protein serine/threonine kinase,
which is activated by phosphorylation. However, despite a 50% identity between
ERK3 and ERK1 and ERK2 in their catalytic domains key properties of ERK3 are
different from the two classic MAPKs (Robinson et al., 2002), Structurally ERK3is
unique among the MAP kinases as the highly conserved TXY sequence in the
activation loop is replaced in ERK3 by the amino acids SEG. This distinction might
explain the activation by different upstream regulators (Robinson et al., 2002).
The intracellular localization of ERK3 is still a matter of discussion, however,
there seems to be a shuttling between nucleus and cytoplasm, which is independent of
mitogenic  or stress stimuli and the activation status of the protein, but has an
influence on the effects of ERK3 on cell cycle progression (Julien et al., 2003).
It has been shown that ERK3 expression is upregulated upon proteasome
inhibition and that this upregulation is not dependent on p53, Bcl-2 and caspase 3 but
is apparently linked to the p38 signal transduction pathway. That indicates that ERK3
expression is a consequence of p38 pathway activation and most probably represents
an intracellular defense or rescue mechanism against cell stress and damage induced
by proteasome inhibition(Zimmermann et al., 2001). Recent microarray studies
revealed that ERK3 is also significantly upregulated by actived H-Ras (Teramoto et
al., 2003), suggestingthat it may participate in H-Ras mediated oncogenesis. In
contrast, other oncogenes such as RhoA, Rac1 and Cdc42 seem to have little effect onDISCUSSION
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ERK3 activation. In a study of colorectal cancers, ERK3 kinase activity was found
increased in about half the cases (Wang et al., 2000). Collectively, these studies and
our findings suggest that ERK3 may be involved in carcinogenesis as part of a yet
unidentified MAPK pathway.
Three ways to antagonize ERK3 function in the future could be envisioned:
I.  Targeting the SEG motif with small molecules derived from a substance library
after screening for specific ERK3 phosphorylation inhibitors.
II.  Targeting the ERK3 transcript by RNAi and, finally
III. Manipulating ERK3 degradation by interfering with proteasome function.
Unlike all the other MAP kinases, ERK3 is an unstable protein that is
constitutively degraded by the proteasome following ubiquitinylation in
proliferating cells, hence its half life is short (30 min) (Coulombe et al., 2003).
Unlike other protein kinases, the catalytic activity of ERK3 is not responsible
for its short half-life (Coulombe et al., 2003). Thus, by targeting the two
destabilization regions (NDR-1 and -2) in the N-terminal lobe of ERK3,
molecules may be obtained that promote increased ERK3 degradation whithout
affecting the other MAPKs.C
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CHAPTER 5
SUMMARY AND CONCLUSIONS
The cellular homeostasis of a multicellular organism depends on a fine
balance between proliferation and apoptosis. Disturbances of this balance can lead to
degenerative or hyperproliferative diseases. Therefore, the knowledge about the
mechanisms involved in the regulation of proliferation and apoptosis is of prime
interest for the definition of molecules, which can be targeted by pharmacological
intervention to treat diseases like cancer.
Proliferation and differentiation within the hematopoeitic system is controlled
by a large number of growth factors and cytokines and the lack of such factors often
leads to apoptosis. One model system to study the processes involved in apoptosis
induction is the murine cell line FDCP-1, a myeloic precursor of the monocyte-
granulocyte lineage. This cell line is dependent on interleukin-3 (IL-3) and
withdrawal of the cytokine leads to induction of apoptosis.
Besides the well characterized posttranslational processes involved in the
initiation and execution of apoptosis, transcriptional regulation also seems to one of
the early events. In an attempt to characterize genes upregulated upon apoptosis
induction a gene trap approach, which allows the tagging of transiently induced
genes, was used to identify loci upregulated by IL-3 withdrawal in FDCP-1 cells.
From an integration library of 2 x 10
6 gene trap insertions, we recovered a
total of 102 useful gene trap sequence tags (GTSTs). More than half of the trapped
genes with defined functions, were either directly or indirectly involved in cell
survival and/or cell death and about one third of these are directly related to the IL-3
and small Rho-GTPase pathways.SUMMARY AND CONCLUSIONS
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A comparison of the gene trap approach with other strategies used to identify
differentially expressed genes showed that the number of relevant genes recovered by
the different technologies is quite similar, although the types of genes are different.
Whereas array based searches look at steady state levels of RNA, the gene trap used
selects for true transcriptional induction and can also detect genes expressed at
extremely low levels. However genes induced from an already basic expression level
will be missed due to the selection strategy employed. Taken together, the results
suggest that gene trapping effectively complements microarray-based strategies
unable to distinguish between transcriptional and post-transcriptional gene regulation.
The analysis of the genes recovered by the different approaches revealed that
not only pro-apoptotic genes, but also a large number of survival genes are
transcriptionally induced upon IL-3 withdrawal. This suggests that the primary
response of the cells is the prevention of apoptosis. However, the upregulation of pro-
apoptotic genes indicates that it is the balance between the two responses that
determines the fate of the cell.
To identify potential target molecules for targeted drug discovery several
candidate genes were analyzed for their relevance in human tumors by using custom
arrays and matched tumor/normal arrays. This screen revealed that ERK3 might be a
suitable candidate for further evaluation due its consistent upregulation in breast
tumors and its unique properties setting it apart from other proteins of this family.REFERENCES
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APPENDIX I
Target genes and their accession numbers
Protein name: FLIP-L; apoptosis inhibitor; FLICE-like inhibitory protein long
form
GenBank Accession: U97076
Protein ID: AAC53281.1
Data base reference: GI: 2253683
Date base source: locus U97076, accession U97076.1
Protein name: Bcl-XL apoptosis regulator (bcl-x long); Bcl-2 family member
GenBank Accession: L35049
Protein ID: AAA51039.1
Data base reference: GI: 561741
Date base source: locus MUSBCLX, accession L35049.1
Protein name: Jun-D; c-jun-related transcription factor
GenBank Accession: J05205
Protein ID: AAA39345.1
Data base reference: GI: 293681
Date base source: locus MUSJUNDR, accession J05205.1
Protein name: c-Kit proto-oncogene (mast/stem cell growth factor receptor
tyrosine kinase)
GenBank Accession: Y00864
Protein ID: CAA68772.1
Data base reference: GI: 50424, SWISS-PROT: P05532
Date base source: locus 50423
Protein name: Zyxin; LIM domain protein; alpha-actinin binding protein
GenBank Accession: X99063
Protein ID: CAA67510.1
Data base reference: GI: 1430883, SWISS-PROT:Q62523
Date base source: locus MMZYX
Protein name: Chop10; murine homologue of Gadd153 (growth arrest and
DNA-damage-inducible protein)
GenBank Accession: X67083
Protein ID: CAA47465.1
Data base reference: GI: 50407, SWISS-PROT: P35639
Date base source: embl locus MMCHOP10, accession X67083.1
Protein name: Pim-1 protein kinase
GenBank Accession: M13945
Protein ID: AAA39930.1
Data base reference: GI: 387510
Date base source: locus MUSPIM1, accession M13945.2APPENDIX
120
Protein name: Cyclin G (G2/M-specific)
GenBank Accession: Z37110
Protein ID: CAA85474.1
Data base reference: GI: 558381, SWISS-PROT: P51945
Date base source: embl locus MMCYCLGMR, accession Z37110.1
Protein name: Activin type I receptor
GenBank Accession: Z31663
Protein ID: CAA83483.1
Data base reference: GI: 840813, SPTREMBL: Q61271
Date base source: embl locus MMACT1B, accession Z31663.1
Protein name: Elf-1 Ets family transcription factor
GenBank Accession: U19617
Protein ID: AAB17097.1
Data base reference: GI: 972940
Date base source: locus MMU19617, accession U19617.1
Protein name: Mouse interleukin-3 receptor
GenBank Accession: M29855
Protein ID: AAA39295.1
Data base reference: GI: 309406
Date base source: locus MUSIL3R
Protein name: Mouse glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
GenBank Accession: M32599
Protein ID: AAA37659.1
Data base reference: GI: 309243
Date base source: locus MUSGAPDH, accession M32599.1
Protein name: c-myc protein
GenBank Accession: X01023
Protein ID: CAA25508.1
Data base reference: GI: 50468, SWISS-PROT: P01108
Date base source: locus CAA25508
Protein name: interleukin-3 [Mus musculus]
GenBank Accession: BAA09848
Protein ID: g4433276
Data base reference: GI: 4433276
Date base source: locus D63766.1APPENDIX
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APPENDIX II (Commercial Suppliers)
Chemicals Suppliers
Acetic acid Merck, Darmstadt
Acetone Riedl-de Heaen, Seelze
Agarose (for cell culture) Gibco-BRL (Life Technologies)
Agarose (for gel analysis) Roth GmbH, Karlsruhe
Alcohol (methyl-, ethyl-) J.T Baker, Holland
Alcohol (propyl-, butyl-) Sigma, Steinheim
Alkaline phosphatase and buffer Boehringer-Mannheim
Ammonium sulfate Gibco-BRL (Life Technologies)
Ampicillin Boehringer-Mannheim
Bradford reagent Bio-Rad
Bromophenolblue Sigma, Deisenhofen
BSA  Sigma, Steinheim
Calcium chloride BDH
Chloroform Merck, Darmstadt
Coomassie brilliant blue Aldrich
DEPC ICN Biomedical, Ohio, USA
DMEM, RPMI 1640 (cell culture) Gibco-BRL (Life Technologies)
DMSO Merck, Darmstadt
DNA ladder (1 kb, 100 bp) Gibco-BRL (Life Technologies)
DNA purification kit (Mini,Midi,Maxi &PCR) QIAGEN
dNTPs (dGTP/dATP/dCTP/dTTP) Gibco-BRL (Life Technologies)
DTT Gibco-BRL (Life Technologies)
EDTA Appli Chem., Darmstadt
Enhancer PCR kit Gibco-BRL (Life Technologies)
Ethidium bromide Roth GmbH, Karlsruhe
ExpressHyb™ Clontech
Fetal bovine serum (FCS, cell culture) Gibco-BRL (Life Technologies)
Ficoll Sigma, Deisenhofen
Formamide Fluka, Seelze
Formaldehyde 37% Riedl-de Heaen, Seelze
Glucose Sigma, Deisenhofen
(L) Glutamine Gibco-BRL (Life Technologies)
Glycerol Appli Chem., Darmstadt
Glycogen Boehringer, Mannheim
HEPES Sigma, Steinheim
HPLC-H2O J.T Baker, Holland
Human Cot-1 DNA® Gibco-BRL (Life Technologies)
Hydrochloride, 25% Roth GmbH, Karlsruhe
IPTG Sigma, Steinheim
Kanamycin Sigma, Steinheim
Magnesium chroride-Hexahydrate  Merck, Darmstadt
Manganese chloride tetrahydrate Sigma, Steinheim
b-Mercaptoethanol Merck, Darmstadt
Murine interleukin-3 (IL-3, cell culture) TEBUAPPENDIX
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Oligo (dT) cellulose Pharmacia
Oligonucleotids Interactiva
32P-dATP & 
32P-dCTP Amersham Pharmacia
Penicillin/Streptomycin Gibco-BRL (Life Technologies)
pGEM
®-T & pGEM
®-T EASY vector Promega (Madison, USA)
Phenol Appli Chem., Darmstadt
Potassium chloride Merck, Darmstadt
RNA ladder (0.24-9.5 kb) Gibco-BRL (Life Technologies)
RNasin® Ribonuclease inhibitor Promega
RNAzol™ B (for RNA purification)  Cinna Scientific, Inc.
Salmon testes DNA Sigma
SDS Appli Chem., Darmstadt
Sephadex G-25 Pharmacia
Sodium acetate trihydrate Gibco-BRL (Life Technologies)
Sodium chloride Sigma, Steinheim
Sodium hydroxide Roth GmbH, Karlsruhe
Tris-Base Sigma, Steinheim
Trypan-blue Gibco-BRL (Life Technologies)
XL10-Gold ultracompetent cells Stratagene
Enzymes  Suppliers
Alkaline phosphatase New England Biolabs,Taunus
DNase I (RNase-free) Boehringer, Mannheim
Klenow enzyme Boehringer, Mannheim
Lysozyme Sigma
Proteinase K Sigma, Deisenhofen
T4 DNA ligase New England Biolabs, Taunus
Taq-DNA-Plolymerase (Platinium & HiFi) Gibco-BRL (Life Technologies)
Rediprime™ II (for random prime labelling) Amersham Pharmacia
Restriction endonuclease New England Biolabs, Taunus
Reverse transcriptase (Superscript II RT) Gibco-BRL (Life Technologies)
RNase A Boehringer, Mannheim
RNase H Gibco-BRL (Life Technologies)
RNeasy (for 2
nd RNA purification) QIAGEN
Sequencing Kit Amersham, Braunschweig
Instruments  Suppliers
ABI PRISM
TM 310 Genetic Analyser Perkin Elmer, Norwalk USA
ABI PRISM Sequencing Kits Applied Biosystems
Atlas Image 1.01a (Analysis program) Clontech
Cell culture flasks Nunk, Roskilde, Denmark
Cell culture plates Nunk, Roskilde, Denmark
Centricon (micro filter) Amicon
Centrifuge (Sorvall RC5B) Heraeus (Dupont), Hanau
Centrifuge (Eppendorf) Hamburg
Chroma spin -200 column Clontech
Cuvettes (quartz), Ultraspec® Pharmacia Biotech, Freiburg
Cuvettes (plastic, 1 ml) Sarstedt
DMEM, RPMI 1640 Gibco-BRL (Life Technologies)
Eppendorf tube Sarstedt, NümbrechtAPPENDIX
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Eppendorf tube (Screw cap) Sorenson
Film BioMax  Kodak, Rochester, USA
Gel electrophoresis (XCell II™) NOVEX
Glass bottle for hybridization Biometra
Hybond-N (and N
+) Amersham
Hybridiser HB-1D Techne
Latex gloves Ansell
Laboratory scales Sartorious
MEGAscript™ T7 Ambion
Micro Centrifuge 5415D  Eppendorf, Hamburg
NuPAGE™ 10% Bis-Tris Gel Invitrogen
Parafilm™ American National Can Co.
PCR machine, DNA Themal Cycler 480 Perkin Elmer, Weiterstade
PCR machine, Robo Cycler Gradient 96 Stratagene
PCR tubes (200 ml) Molecular Bioproducts
Peristaltic pump (Minipuls II) Gilson
Petri dish (plastic) Biolab Scientific Pty
PH-meter CG825 Scott
Phosphorimager
TM SI Molecular dynamics
Pipettes (10, 20, 200, 1000 ml) Gilson
Polaroid camera (Model: E.A.S.Y RH) Herolab
Power supplies Consort, Belgium
Rotors (Sorvall GS3, SE12, SS34) Heraeus (Dupont), Hanau
Scanner (SNAPSCAN600) Agfa
Scintillation Analyzer, TRI-CARB 1500 Packard
Spectrohotometer (Gene Quant II) Pharmacia  Biotech, Freiburg
UV crosslinker® 1800 Stratagene, Hamburg
UV Spectrophotometer , computer & softwere Herolab (Easy Image Plus)
Vortex (REAX 2000) Heidolph
Water purification (milliQ system) Millipore
(shaking) water bath KötterMann, Labor Technik
Sequence analysis softwares  Suppliers
DNA Strider Christian Marck
Service de Biochimie-Bat 142
Centre d’Etudes Nuclaires de
Saclay
91191 Gif-sur-Yvette Cedex
France
MacVector International Biotechnologies
P.O. Box 9558
New Haven, CT 06535
Plasmid Artist Clontech Laboratory
4030 Fabian Way
Palo Alto, CA 94303
MicroArray analysis software  Suppliers
Atlas Image 1.01a (Analysis program) Clontech
ImageQuant version 1.2  Molecular DynamicsAPPENDIX
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APPENDIX III (commonly used stock solutions)
Followings are commonly used buffers and stock solutions in the manipulation of
nucleic acids and proteins. Always deionized, distilled water and reagents of the
highest grade available were used for preparing stock solutions. Sterilization was
done by filtration through a 0.22-0.45 µm filters or by standard autoclaving.
Ammonium acetate, 10 M
Dissolve 385.4 g ammonium acetate in 150 ml H2O
Add H2O to 500 ml
CaCl2, 1 M
147 g CaCl2×2H2O
H2O to 1 liter
Dithiothreitol (DTT), 1 M
Dissolve 15.45 g DTT in 100 ml H2O
Store at -20°C
EDTA (ethylenediamine tetraacetic acid), 0.5 M (pH 8.0)
Dissolve 186.1 g Na2EDTA×2H2O in 700 ml H2O
Adjust pH to 8.0 with 10 M NaOH (~50 ml)
Add H2O to 1 liter
Ethidium bromide, 10 mg/ml
Dissolve 0.2 g ethidium bromide in 20 ml H2O
Mix well and store at 4°C in dark
HCl, 1 M
Mix in the following order:
913.8 ml H2O
86.2 ml concentrated HCl
KCl, 1 M
74.6 g KCl
H2O to 1 liter
MgCl2, 1 M
20.3 g MgCl2×6H2O
H2O to 100 ml
MgSO4, 1 M
24.6 g MgSO4×7H2O
H2O to 100 mlAPPENDIX
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MOPS buffer
0.2 M MOPS [3-(N-morpholino)-propanesulfonic acid], pH 7.0
0.5 M sodium acetate
0.01 M EDTA
NaCl, 5 M (292 g NaCl and H2O up to 1 liter)
NaOH, 10 M
Dissolve 400 g NaOH in 450 ml H2O
Add H2O to 1 liter
PBS (phosphate-buffered saline)
10x stock solution, 1 liter:
80 g NaCl
2 g KCl
11.5 g Na2HPO4×7H2O
2 g KH2PO4
Working solution, pH ~7.3:
137 mM NaCl
2.7 mM KCl
4.3 mM Na2HPO4×7H2O
1.4 mM KH2PO4
Sodium acetate, 3 M
Dissolve 408 g sodium acetate×3H2O in 800 ml H2O (or DEPC-H2O)
Add H2O to 1 liter
Adjust pH to 4.8 or 5.2 (as desired) with 3 M acetic acid
SSC (sodium chloride/sodium citrate), 20x
3 M NaCl (175 g/liter)
0.3 M Na3citrate×2H2O (88 g/liter)
Adjust pH to 7.0 with 1 M HCl
TAE (Tris/acetate/EDTA) electrophoresis buffer
50x stock solution:
242 g Tris base
57.1 ml glacial acetic acid
37.2 g Na2EDTA×2H2O
H2O to 1 liter
Working solution, pH ~8.5:
40 mM Tris×acetate
2 mM Na2EDTA×2H2OAPPENDIX
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TE (Tris/EDTA) buffer
10 mM Tris×Cl, pH 7.4, 7.5, or 8.0
1 mM EDTA, pH 8.0
Tris×Cl [tris(hydroxymethyl)aminomethane], 1 M
Dissolve 121 g Tris base in 800 ml H2O
Adjust to desired pH with concentrated HCl
Mix and add H2O to 1 liter
Approximately 70 ml of HCl is needed to achieve a pH 7.4 solution, and
approximately 42 ml for a solution that is pH 8.0.
1 x Binding buffer (poly(A)
+-RNA isolation)
0.5 M NaCl; 10 mM Tris, pH 7.2; 0.1 mM EDTA; 0.2 % SDS
Wash buffer (poly(A)
+-RNA isolation)
0.1 M NaCl; 10 mM Tris, pH 7.2; 0.1 mM EDTA; 0.2 % SDS
Elution buffer (poly(A)
+-RNA isolation)
10 mM Tris, pH 7.2; 0.1 mM EDTA; 0.2 % SDS
10X DNase I Buffer (Atlas array)
400 mM Tris-HCl, pH 7.5, 100 mM NaCl, 60 mM MgCl2
Phenol:chloroform:isoamyl alcohol (poly(A)
+-RNA isolation)
25:24:1; equilibrated with 0.1 M  sodium citrate, pH 4.5, 1 mM EDTA
10X Termination Mix (Atlas array)
0.1 M EDTA, pH 8.0, 1 mg/ml glycogen
10X denaturing solution (Atlas array)
1 M NaOH, 10 mM EDTA
2X neutralizing solution (Atlas array)
1 M NaH2 PO4 ,pH 7.0
Wash Solution 1 (Atlas array)
2X SSC, 1% SDS
Wash Solution 2 (Atlas array)
0.1X SSC, 0.5% SDSAPPENDIX
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APPENDIX IV
Primers for generation of probes for Northern Hybridization
Target genes Primer Sequences
Flip-L Sense 5'- GCCAGCTCTCTTTTGCTACCTTG -3'
Antisense 5'- GCTTGCTCTGCATCCTGTAAGTCTC -3'
Bcl-XL Sense 5'- AGAGAGGCAGGCGATGAGTTTG -3'
Antisense 5'- GGCTCTAGGTGGTCATTCAGATAGG -3'
JunD Sense 5'- TCGACATGGACACGCAAGAACG -3'
Antisense 5'- GTTGACGTGGCTGAGGACTTTC -3'
zyxin Sense 5'- GGAGATTGACTCTCTGTCCTCACTG -3'
Antisense 5'- GGCACCATTTTTTGATTGGCTG -3'
GST Sense 5'- ACCTTGCCCGAAAGCACAAC -3'
Antisense 5'- TTGCCCAGAAACTCAGAGTAGAGC -3'
Chop-10 Sense 5'- TGAGTCCCTGCCTTTCACCTTG -3'
Antisense 5'- ACGCAGGGTCAAGAGTAGTGAAGG -3'
Pim-1 Sense 5'- ATGGAAGTGGTCCTGTTGAAGAAG -3'
Antisense 5'- TGGCTCACCATCAAAGTCCG -3'
Aktivin type I rec’ Sense 5'- CTACCATAACCGCCAGAGGTTG -3'
Antisense 5'- CAAGTCTCGATGAGCAATTCCC -3'
c-myc Sense 5'- TCTGTGGAGAAGAGGCAAACCC -3'
Antisense 5'- GCTTGCTCTGCATCCTGTAAGTCTC -3'
Elf-1 Sense 5'- CAAACCTGACATGAACTACGAGACC-3'
Antisense 5'- CCCTCCTTTAATTCCTGGACTTG-3'
GAPDH Sense 5'- CCAAACGGGTCATCATCTC -3'
Antisense 5'- TGGATGCAGGGATGATGTT -3'
APPENDIX V
Primers for generation of probes for matched tumor/normal array assay
Target genes Primer Sequences
Hybridization
Temperature
ERK3
Sense
Antisense
5'- ACG ATG TGG GCT CTC TTA CGG AAC -3'
5'- CCA GGA AAT CCA GTG CTT CTC G -3'
68°C
PIPKb
Sense
Antisense
5'- ATG TGC CTG ATG CTA AGC GGA C -3'
5'- GGC TGC TAA AAC TTT GTC CTT CAG TC -3'
65°C
PIPKg
Sense
Antisense
5'- GCT GTG AAA CCG CTG GGG -3'
5'- CGC CCT CCT CGT CTG AGG C -3'
65°C
KIAA 0740
Sense
Antisense
5'- CGGATGGAGTAAGGGGTTCATTG -3'
5'- TCGGGAGATACACCTCACTGTTGG -3'
65°C
KIAA 1036
Sense
Antisense
5'- GAAACTGCTGGTTCTGCTGGTG -3'
5'- CCATTCTGGGTCCTCCGCC -3'
63°C
KIAA 1140
Sense
Antisense
5'- GAATGCCGCAGCCATCTATG -3'
5'- CATCTTGCTTGGACTTCAGGGTG -3'
68°C
Plecha2
Sense
Antisense
5'- GCGGCAAGTTTCTGCGG -3'
5'- GGCTGATGGGTGTGTGGACC -3'
68°CAPPENDIX
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APPENDIX VI
Primers for generation of array materials for self-made arrays
 (see APPENDIX VII for the Arrangement)
Seq ID Primer Sequences Ta Template cDNA
(bp)
26-11-1 Sense
Antisense
5'-AGGGCTTTGGGCAGGAG -3'
5'-CAAACAGGAAGTTTATGAGAAA -3' 61°C Genomic
DNA
95
26-11-2 Sense
Antisense
5'-AGGGGGGGGGAGAATGA -3'
5'-GAATGTGAAAGTGTAACTGGAG -3' 54°C cDNA 797
26-11-3 Sense
Antisense
5'-ATATTGTATATAAATCCAATGTTTTC -3'
5'-AGGACAGCATTTCATTGGG -3' 54°C Genomic
DNA
587
26-11-4 Sense
Antisense
5'-GTCAGGATGGGAACTCAAACA -3'
5'-GGGAAGGCTTTGCATCTAA -3' 61°C cDNA 314
26-11-5 Sense
Antisense
5'-AGAAATGTCCAGCAGCCCA -3'
5'-GCAACCTTATAATGGAGAAACAA -3' 54°C cDNA 667
26-12-1 Sense
Antisense
5'-GGAGGTGACTGGGGTGAG -3'
5'-CATCTGATCCTGAGCCACTT -3' 54°C Genomic
DNA
173
26-12-3 Sense
Antisense
5'-GTGTGTCTGTGTGCCACC -3'
5'-CTCCAGTTGAATTCTTAATACTT -3' 54°C cDNA 254
26-21-4 Sense
Antisense
5'-CCCCCTTTCGCTCCTG -3'
5'-GAAGCCAGCCTTAACCAG -3' 54°C Genomic
DNA
115
26-22-4 Sense
Antisense
5'-GTTTTCTCTGCAAACAAACCC -3'
5'-TATGTGCTTTTTAGATACCCAA -3' 54°C Genomic
DNA
240
26-22-7 Sense
Antisense
5'-TCAAGGACATTTGCGAGGG -3'
5'-GTAGATCCAGGCCATCTCTC -3' 61°C cDNA 622
26-31-1 Sense
Antisense
5'-GGAAGTGAATGTATGTTTCGT -3'
5'-AAAACCTATAATCGTGTTCCC -3' 54°C Genomic
DNA
130
26-31-3 Sense
Antisense
5'-CAGTGTCTCGTAAGTGGTC -3'
5'-TCTTAAATTTCATAAACTTTGGTCT -3' 54°C Genomic
DNA
300
26-31-7 Sense
Antisense
5'-AGACAGAGGCAGGCAAAC -3'
5'-TCTCGGCATCACGCTCA -3' 61°C cDNA 177
26-32-1 Sense
Antisense
5'-GAGGTGTGGGGGGGGTG -3'
5'-ACTTCCTTAACCTGGCATTC -3' 61°C cDNA 780
26-32-2 Sense
Antisense
5'-GTCCCACCCCCGTTGAG -3'
5'-TACCTTATACTTCAGTTGTAGA -3' 54°C cDNA 1383
26-32-3 Sense
Antisense
5'-CTTCATAAAGTTAAGAAAGACCC -3'
5'-CAGGCGCATAAGTCAGTT -3' 54°C Genomic
DNA
301
26-32-4 Sense
Antisense
5'-CAAAGGCGCACATTTAAAGA -3'
5'-GATCGTAGAAGCCTGACG -3' 61°C cDNA 362
26-32-5 Sense
Antisense
5'-AGCCAAGCAATAAGAGAGT -3'
5'-TGAGAGAGAGACCCAAACC -3' 61°C Genomic
DNA
1653
26-32-
5A
Sense
Antisense
5'-GCAGAAGCAGAGCTCCA -3'
5'-AACATCTAAGACTCGGATCGT -3' 61°C cDNA 223
26-32-
5B
Sense
Antisense
5'-AGCCGGCGGCTCAGAA -3'
5'-GCATCATCATCTTTCTCTCTT -3' 61°C cDNA 216
26-32-8 Sense
Antisense
5'-AGTTCAATTTCCATCACCCAC -3'
5'-GAGAGCCTTCTGAGTGTTG -3' 54°C cDNA 175
26-41-2 Sense
Antisense
5'-AAATAAACATGCAGCTTTAAGT -3'
5'-GTCTTTATGCTGTTTTCTTTTTG -3' 54°C Genomic
DNA
276
26-41-3 Sense
Antisense
5'-GAAAGGGTGGCAAGTACAC -3'
5'-CTTTTCGTTCCTCCTACCC -3' 54°C cDNA 588
26-41-6 Sense
Antisense
5'-TGGTCTGTGATTTATTCAATGG -3'
5'-ATGGACCTAGAATTTTCCTACAC -3' 54°C cDNA 1565
30-11-3 Sense
Antisense
5'-GAGTGACTGGAAGGTTATGA -3'
5'-AATGTCCGGCTGTACACA -3' 54°C cDNA 326APPENDIX
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Seq ID Primer Sequences Ta Template cDNA (bp)
30-11-5
Sense
Antisense
5'-GGAACAGTAATACTGAAGCG -3'
5'-GCTTGAGAGTTTCTAGAAATG -3'
54°C Genomic
DNA
245
30-11-6
Sense
Antisense
5'-CTGCTCACCGTCGTAGTT -3'
5'-GGCTCCAGCATGGCTATC -3'
61°C cDNA 841
30-12-1
Sense
Antisense
5'-GACGGGTTCAGCAATGGG -3'
5'-CATACAACATCAGTCATCAGG -3'
61°C cDNA 1100
30-12-2
Sense
Antisense
5'-GAACTGCCAGCGAGGAC -3'
5'-GGAAGTGGGACAGGGTTT -3'
54°C cDNA 1504
30-12-3
Sense
Antisense
5'-GCCTTATAAGATTTGAATATTAAC -3'
5'-ATACCACCTATAATGTCTGTGT -3'
54°C Genomic
DNA
290
30-12-4A
Sense
Antisense
5'-GCAAGACCAAGACGAAGAA -3'
5'-TGCTGTCACTCTCTCCTTC -3'
54°C cDNA 878
30-12-4B
Sense
Antisense
5'-CCTGCTGGTACCGCAG -3'
5'-ACATCAACAGGCTGTAGTCC -3'
54°C cDNA 876
30-12-4C
Sense
Antisense
5'-GCCGTGACGGCGGAA -3'
5'-CAGCAGCAGGCTGTAGT -3'
54°C cDNA 917
30-12-5
Sense
Antisense
5'-TCTTCCCTAGCCCTCTCA -3'
5'-AGTCTCTCCAGATGTGGCA -3'
54°C Genomic
DNA
249
30-21-2
Sense
Antisense
5'-CCCAGACTGCTTAGCTTTC -3'
5'-AGAGACAATTACTGACACAAG -3'
54°C Genomic
DNA
180
30-21-3N
Sense
Antisense
5'-CAGCTCTAGAGATCCGAC -3'
5'-AGCCCTCAGCATAACTTCA -3'
61°C cDNA 1266
30-21-3P
Sense
Antisense
5'-ACAGAAGATCATTGAGACACT -3'
5'-TTGGCTGCTGGCTTCTC -3'
54°C cDNA 116
30-21-4
Sense
Antisense
5'-GCACGAGGAAAGGTGCA -3'
5'-AAACACTGCTGGAAAGGAC -3'
54°C Genomic
DNA
945
30-22-1
Sense
Antisense
5'-ACACACACACACACAATGC -3'
5'-CCACAGAAGACATCCAGCAT -3'
54°C Genomic
DNA
148
30-22-4
Sense
Antisense
5'-GTGAGCAGAGACAGGAAA -3'
5'-CTCATGCAGGTACCCTCC -3'
54°C Genomic
DNA
90
30-31-3
Sense
Antisense
5'-TCTCCAGCTCGCCAGT -3'
5'-CACTTCACAGGCTGCACAC -3'
61°C cDNA 32?
30-32-1
Sense
Antisense
5'-ACCTGCCTGCCTCTGTC -3'
5'-GACGGAGGTAACATTTAACAA -3'
54°C cDNA 281
30-32-11
Sense
Antisense
5'-CCAGGCGTGGAATTCAG -3'
5'-CTGAGACTCCATCATAAACT -3'
54°C Genomic
DNA
187
30-32-13
Sense
Antisense
5'-AGTGTCCTGTGTTTGTAGTG -3'
5'-GGGCTGCCTGCAGAACA -3'
54°C cDNA 318
30-32-14
Sense
Antisense
5'-AATCTCATCTCCTGGAAATTCT -3'
5'-CGAAAGAGTGGGTTTCAGG -3'
54°C cDNA 72
30-32-2
Sense
Antisense
5'-CCAGTGCTCTGTGCAGT -3'
5'-CGGTGTGGCTGACTTG -3'
54°C Genomic
DNA
247
30-32-3
Sense
Antisense
5'-TGCCAACCATTGCTCATCA -3'
5'-AGAACTTCCTTCCCTCTCC -3'
54°C cDNA 192
30-32-6
Sense
Antisense
5'-GGCTCAGGAGATGGTCAG -3'
5'-GCTTTCCTCTCTTTTTTTTCC -3'
54°C cDNA 608
30-32-9
Sense
Antisense
5'-AGGGACAGGGAGGAGAAA -3'
5'-TAGATTGGAAATGCTGAGACA -3'
54°C Genomic
DNA
729
30-41-7
Sense
Antisense
5'-TTTATCACATTTCAAGATACTGG -3'
5'-TGGTAGAGCAATTAACCTAATAT -3'
54°C Genomic
DNA
192
30-42-10
Sense
Antisense
5'-GAGCCCGTCAAGCTGTAAT -3'
5'-GGCGTGGGAACACTGGA -3'
54°C Genomic
DNA
96APPENDIX
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Seq ID Primer Sequences Ta Template cDNA (bp)
30-42-4
Sense
Antisense
5'-ATAAAGTCGTCAGAATTAATGA -3'
5'-CAACAGTAAGGAGTCATGCT -3'
54°C cDNA 81
30-42-8
Sense
Antisense
5'-ATTTGAATGTCTTCTGTGAAATG -3'
5'-TGCAACCTTATAATGGAGAAAC -3'
54°C Genomic
DNA
218
30-42-10
Sense
Antisense
5'-TGGTTCATCACCGTAGCAAAGG-3'
5'-GGCGTGGGAACACTGGA-3'
61°C cDNA 96
30-42-
10E
Sense
Antisense
5'-TTTTCTGGAGACTTCTGGATGCC-3'
5'-TCCTCTGTACCTCACTTGGAGTCA-3'
54°C cDNA 138
CAB45
Sense
Antisense
5'-TGGATGGACACCTCAACAA-3'
5'-CTTTATATTCATCCCACGAAACA-3'
54°C cDNA 285
GAPDH
Sense
Antisense
5'-CCAAACGGGTCATCATCTC-3'
5'-TGGATGCAGGGATGATGTT-3'
54°C cDNA 300
HPRT
Sense
Antisense
5'-GCCGAGGATTTGGAAAAAGTG-3'
5'-TGCAACCTTAACCATTTTGGGG-3'
54°C cDNA 399
L29
Sense
Antisense
5'-AAGATGGGTCACCAGCAGCTCTAC-3'
5'-AAAGACTAGCATGATCGGTTCCAC-3'
54°C cDNA 232
NEUA
Sense
Antisense
5'-TAGACTCTCCATGCTGAATGA-3'
5'-GCGTTGGAAAAGTATCTATATTT-3'
54°C cDNA 345
NEUC
Sense
Antisense
5'-TACCAGCACTTAAAGGGAAA-3'
5'-AGTGCCGCCAGCACAG-3'
54°C cDNA 266
NEUD
Sense
Antisense
5'-TGGAGAGTTTGGAGTACATTC-3'
5'-GGAAGCAGTAAGCCAGAA-3'
54°C cDNA 397
NEUF
Sense
Antisense
5'-GCAAGTCCCAAGTCTGATG-3'
5'-GTATACAGGCTCTCCATTACA-3'
54°C cDNA 139
NEUG
Sense
Antisense
5'-GAGTAAGCCTAAGTAAGAAAAGA-3'
5'-TGCTGCTGGTGGGGGT-3'
54°C Genomic
DNA
107
ODC
Sense
Antisense
5'-AGTCGCCAGAGCACATCC-3'
5'-CTGATGCGACATAGTATCTG-3'
61°C cDNA 425
PLA2
Sense
Antisense
5'-GCAGATGGCTCGAGAATA-3'
5'-TGAGGGCCAGACCCAGT-3'
61°C cDNA 290
UN1G
Sense
Antisense
5'-CTAAGAGTCCTCCTGCTCATATCC-3'
5'-TGATGAAGCTGGCTCAGT-3'
61°C cDNA 73
UN3G
Sense
Antisense
5'-AAGAAGAGGCCACGGTGTT-3'
5'-CCCTTCAGTGGGCTCTCC-3'
61°C cDNA 64APPENDIX
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APPENDIX VII
 Gene positions on the self-made arrays
Gene No. Position Gene No. Position Gene No. Position
26-11-2 1_A1 26-41-6 1_B6 30-42-1G 2_A11
26-11-4 1_A2 26-41-6Z 1_B7 30-42-4 2_A12
26-11-5 1_A3 30-11-3 1_B8 30-42-5G 2_A13
26-11-6G 1_A4 30-11-5 1_B9 30-42-8 2_A14
26-11-7 1_A5 30-11-5C 1_B10 30-42-10 2_A15
26-12-1 1_A6 30-11-6 1_B11 30-42-10E 2_A16
26-12-2G 1_A7 30-12-1 1_B12 ALK 2_A17
26-12-3 1_A8 30-12-3 1_B13 CAB45 2_A18
26-12-4G 1_A9 30-12-4A 1_B14 GAPDH 2_A19
26-21-2G 1_A10 30-12-4B 1_B15 HPRT 2_A20
26-21-3 1_A11 30-12-4C 1_B16 HEX 2_A21
26-21-4 1_A12 30-12-5 1_B17 L29 2_A22
26-22-4 1_A13 30-21-2 1_B18 LPG 2_A23
26-22-7 1_A14 30-21-3N 1_B19 NEUA 2_A24
26-31-1 1_A15 30-22-1 1_B20 NEUC 2_B1
26-31-3 1_A16 30-22-4 1_B21 NEUD 2_B2
26-32-1 1_A17 30-31-3 1_B22 NEUF 2_B3
26-32-2 1_A18 30-31-9G 1_B23 NEUG 2_B4
26-32-3 1_A19 30-32-2 1_B24 ODC 2_B5
26-32-4 1_A20 30-32-3 2_A1 PLA2 2_B6
26-32-5 1_A21 30-32-5G 2_A2 UN1G 2_B7
26-32-5A 1_A22 30-32-6 2_A3 UN3G 2_B8
26-32-5B 1_A23 30-32-9 2_A4 P38 2_B9
26-32-8 1_A24 30-32-11 2_A5
26-32-9 1_B1 30-32-13 2_A6
26-41-1G 1_B2 30-32-16G 2_A7
26-41-1T 1_B3 30-32-16R 2_A8
26-41-2 1_B4 30-41-4R 2_A9
26-41-3 1_B5 30-41-7 2_A10APPENDIX
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APPENDIX VIII
Phosphorimage files of Cancer Profiling
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
PMNL II (Jiyeon Yang)
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
PMNL I (Frank Wempe)
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
Ba/F3 (Blood)
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
EOL-1 (Blood)
a g Plekha
KIAA0740
PEST GAPDH KIAA1036
PIP kinase
KIAA0424 YB-1
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
Human Brain/Normal
Human Prostate/Normal
BPH-1 (Prostate Cancer)
J Shikawa (Endometrium)
Hec-1a (Endometrium)APPENDIX
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A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
Human Pancreas/Normal
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
HUP-T4 (Pancreas)
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
HS 766t (Pancreas)
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
DAN-G (Pancreas)
PA-TU-8988T (Pancreas)
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
Human Pancreas/Normal
DAN-G (Pancreas)
HS 766t (Pancreas)
HUP-T4 (Pancreas)
PA-TU-8988T (Pancreas)APPENDIX
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A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
SU 8686 (Pancreas)
YAPC (Pancreas)
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
Human /Normal (Lung)
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
ScLc214 (Lung)
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
LcLc97M1(Lung)
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
NCI-H-226 (Lung)
NCI-H-460 (Lung)
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
VM-CuB1
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
BEN (Lung)
H322M (Lung)
(Lung)APPENDIX
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A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
Human Tissue/Tumor (Lung)
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
H322M (Lung)
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
H82 (Lung)
HOP-62 (Lung)
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
SISO (Cervix)
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
SK-Mel 1 (Melanoma)
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
SK-Mel 3 (Melanoma)
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
OVCAR5 (Overy)
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
SW-626 (Overy)
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
SK-OV-3 (Overy)APPENDIX
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A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
Human Tissue/Normal (Colon)
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
CX-1 (Colon)
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
CX-14 (Colon)
CaCo-2 (Colon)
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
COLO-205 (Colon)
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
KM-12 (Colon)
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
SW-620 (Colon)
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
SW-480 (Colon)
LOVO (Colon)
HCC-2998 (Colon)APPENDIX
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A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
Human Tissue/Normal (Overy)
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
IGROV1 (Overy)
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
OVCAR-3 (Overy)
OVCAR-4 (Overy)
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
OVCAR-8 (Overy)
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
BT-20 (Breast)
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
BT-474 (Breast)
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
MDA-MB-157 (Breast)
MX-1 (Breast)
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
SK-BR-3 (Breast)APPENDIX
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A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
SCC-4 (Head and Neck)
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
SCC-9 (Head and Neck)
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
SCC-15 (Head and Neck)
SCC-25 (Head and Neck)
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
SCC-27 (Head and Neck)
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
Hel (Eukaryotic cell lines)
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
Laz509 (Eukaryotic cell lines)
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
Raji (Eukaryotic cell lines)
HL60 (Eukaryotic cell lines)
A
B
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
DOH (Eukaryotic cell lines)APPENDIX
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APPENDIX IX
DIE NATUR. Aphoristisch
Fragment  [verfaßt von Georg Christoph Tobler]
[32. Stück des Journal von Tiefurt, privatim; Ende 1782 oder Anfang 1783.
Pfälzisches Museum 1783. I, 5]
Natur! Wir sind von ihr umgeben und umschlungen - unvermögend aus ihr
herauszutreten, und unvermögend tiefer in sie hineinzukommen. Ungebeten und
ungewarnt nimmt sie uns in den Kreislauf ihres Tanzes auf und treibt sich mit uns
fort, bis wir ermüdet sind und ihrem Arme entfallen.
Sie schafft ewig neue Gestalten; was da ist war noch nie, was war kommt
nicht wieder- alles ist neu, und doch immer das Alte.
Wir leben mitten in ihr, und sind ihr fremde. Sie spricht unaufhörlich mit uns,
und verrät uns ihr Geheimnis nicht.
Wir wirken beständig auf sie, und haben doch keine Gewalt über sie.
Sie scheint alles auf Individualität angelegt zu haben, und macht sich nichts
aus den Individuen. Sie baut immer und zerstört immer, und ihre Werkstätte ist
unzugänglich. Sie lebt in lauter Kindern, und die Mutter, wo ist sie?- Sie ist die
einzige Künstlerin: aus dem simpelsten Stoff zu den größten Kontrasten; ohne
Schein der Anstrengung zu der größten Vollendung-zur genausten Bestimmtheit,
immer mit etwas Weichem überzogen. Jedes ihrer Werke hat ein eigenes Wesen, jede
ihrer Erscheinungen den isoliertesten Begriff, und doch macht alles Eins aus.
Sie spielt ein Schauspiel: ob sie es selbst sieht wissen wir nicht, und doch
spielt sie’s für uns die wir in der Ecke stehen.
Es ist ein ewiges Leben, Werden und Bewegen in ihr, und doch rückt sie nicht
weiter. Sie verwandelt sich ewig, und ist kein Moment Stillestehen in ihr. Fürs
Bleiben hat sie keinen Begriff, und ihren Fluch hat sie ans Stillestehen gehängt. Sie
ist fest. Ihr Tritt ist gemessen, ihre Ausnahmen selten, ihre Gesetze unwandelbar.
Gedacht hat sie und sinnt beständig; aber nicht als ein Mensch, sondern als Natur. Sie
hat sich einen eigenen allumfassenden Sinn vorbehalten, den ihr niemand abmerken
kann.
Die Menschen sind alle in ihr und sie in allen. Mit allen treibt sie ein
freundliches Spiel, und freut sich je mehr man ihr abgewinnt. Sie treibt’s mit vielen
so im verborgenen, daß sie’s zu Ende spielt ehe sie’s merken.
Auch das Unnatürlichste ist Natur, auch die plumpste Philisterei hat etwas von
ihrem Genie. Wer sie nicht allenthalben sieht, sieht sie nirgendwo recht.
Sie liebt sich selber und haftet ewig mit Augen und Herzen ohne Zahl an sich
selbst. Sie hat sich auseinandergesetzt um sich selbst zu genießen. Immer läßt sie
neue Genießer erwachsen, unersättlich sich mitzuteilen.
Sie freut sich an der Illusion. Wer diese in sich und andern zerstört, den straft
sie als der strengste Tyrann. Wer ihr zutraulich folgt, den drückt sie wie ein Kind an
ihr Herz.
Ihre Kinder sind ohne Zahl. Keinem ist sie überall karg, aber sie hat Lieblinge
an die sie viel verschwendet und denen sie viel aufopfert. Ans Große hat sie ihrenAPPENDIX
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Schutz geknüpft. Sie spritzt ihre Geschöpfe aus dem Nichts hevor, und sagt ihnen
nicht woher sie kommen und wohin sie gehen. Sie sollen nur laufen; die Bahn kennt
sie. Sie hat wenige Triebfedern, aber nie abgenutzte, immer wirksam, immer
mannigfaltig.  Ihr Schauspiel ist immer neu, weil sie immer neue Zuschauer schafft.
Leben ist ihre schönste Erfindung, und der Tod ist ihr Kunstgriff viel Leben zu haben.
Sie hüllt den Menschen in Dumpfheit ein, und spornt ihn ewig zum Lichte. Sie macht
ihn abhängig zur Erde, träg und schwer, und schüttelt ihn immer wieder auf.
Sie gibt Bedürfnisse, weil sie Bewegung liebt. Wunder, daß sie alle diese
Bewegung mit so wenigem erreicht. Jedes Bedürfnis ist Wohltat; schnell befriedigt,
schnell wieder erwachsend. Gibt sie eins mehr, so ist’s ein neuer Quell der Lust; aber
sie kommt bald ins Gleichgewicht. Sie setzt alle Augenblicke zum längsten Lauf an,
und ist alle Augenblicke am Ziele.
Sie ist die Eitelkeit selbst, aber nicht für uns denen sie sich zur größen
Wichtigkeit gemacht hat. Sie läßt jedes Kind an sich künsteln, jeden Toren über sich
richten, Tausende stumpf über sich hingehen und nichts sehen, und hat  an allen ihre
Freude und findet bei allen ihre Rechnung.
Man gehorcht ihren Gesetzen, auch wenn man ihnen wiederstrebt; man wirkt
mit ihr, auch wenn man gegen sie wirken will.
Sie macht alles was sie gibt zur Wohltat, denn sie macht es erst unentbehrlich.
Sie säumet, daß man sie verlange; sie eilet, daß man sie nicht satt werde.
Sie hat keine Sprache noch Rede, aber sie schafft Zungen und Herzen durch
die sie fühlt und spricht.
Ihre Krone ist die Liebe. Nur durch sie kommt man ihr nahe. Sie macht Klüfte
zwischen allen Wesen, und alles will sich verschlingen. Sie hat alles isoliert,, um alles
zusammenzuziehen. Durch ein paar Züge aus dem Becher der Liebe hält sie für ein
Leben voll Mühe schadlos.
Sie ist alles. Sie belohnt sich selbst und bestraft sich selbst, erfreut und quält
sich selbst. Sie ist rauh und gelinde, lieblich und schrecklich, kraftlos und allgewaltig.
Alles ist immer  da in ihr. Vergangenheit und Zukunft kennt sie nicht.Gegenwart ist
ihr Ewigkeit. Sie ist gütig. Ich preise sie mit allen ihren Werken. Sie ist weise und
still. Man reißt ihr keine´Erklärung vom Leibe, trutzt ihr kein Geschenk ab, das sie
nicht freiwillig gibt. Sie ist listig, aber zu gutem Ziele, und am besten ist’s ihre List
nicht zu merken.
Sie ist ganz, und doch immer unvollendet. So wie sie’s treibt, kann sie’s
immer treiben.  Jedem erscheint sie in einer eignen Gestalt. Sie verbirgt sich in
tausend Namen und Termen, und ist immer dieselbe. Sie hat mich hereingestellt, sie
wird mich auch herausführen. Ich vertraue mich ihr. Sie mag mit mir schalten. Sie
wird ihr Werk nicht hassen. Ich sprach nicht von ihr. Nein, was wahr ist und was
falsch ist alles hat sie gesprochen. Alles ist ihre Schuld, alles ist ihr Verdienst.
Johann Wolfgang GoetheZ
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ZUSAMMENFASSUNG
Apoptose ist ein zelluläres Suizidprogramm, das in jeder Zelle eines mehrzelligen
Lebewesens stattfinden kann. Apoptose ist im Gegensatz zur Nekrose ein
physiologischer Prozess, dessen Ziel die Eliminierung von Zellen ist, die vom
Gesamtorganismus entweder nicht mehr benötigt werden oder diesem schaden
können. Hämatopoetische Zellen sind abhängig von einer Vielzahl verschiedener
Zytokine, die deren Überleben und Differenzierung gewährleisten. Entzieht man
hämatopoetischen Zellen ihre entsprechenden Wachstumsfaktoren, gehen die Zellen
in kurzer Zeit in Apoptose.
FDCP1-Zellen sind murine Leukozyten, die myeloische Vorläuferzellen der
Monozyten-Granulozyten-Linie darstellen. FDCP-1 Zellen können in Zellkultur mit
GM-CSF oder dem pleiopotenten Wachstumsfaktor IL-3 gehalten werden (in
unserem Falle IL-3). Nach Entzug von IL-3 folgt eine prä-apoptotische Phase von
etwa 8 Stunden, in denen die Apoptose durch Wiederzugabe von IL-3 vollständig
rückgängig gemacht werden kann. Bei Wiederzugabe von IL-3 erst nach etwa 12
Stunden sterben fast alle Zellen, was bedeutet, dass in diesen Zellen zwischen Stunde
8 und 12 die unwiederbringliche Entscheidung zur Einleitung der Apoptose gefällt
wird.
Wie viele andere biologische Prozesse ist die Regulation der Apoptose hierarchisch
strukturiert. Die Aktivierung einer exekutiven Ebene (Caspasen, DNasen) führt zur
Zerstörung wichtiger Zellfunktionen und zum unwiederbringlichen Zelltod. Über
dieser exekutiven Ebene steht eine regulative Ebene (Bcl2-homologe Proteine,
regulative Caspasen und weitere Faktoren). Die Proteine der exekutiven Ebene sind
meist konstitutiv in den Zellen vorhanden und werden bei einem Überschreiten eines
Schwellenwertes auf einer regulativen Ebene nach dem "Schneeballprinzip" aktiviert.
Auf regulativer Ebene findet neben posttranslationaler Regulation (Bcl2-homologe
Proteine und regulative Caspasen) eine transkriptionelle Aktivierung statt. Diese
transkriptionell aktivierten Faktoren (z.B. p53 Kinase oder NF-kB regulierte Gene)
können direkt oder indirekt Apoptose positiv oder negativ regulieren.
Der zeitlich streng geordnete Ablauf der Apoptose in FDCP1-Zellen sowie die
Tatsache, dass bis zu einem bestimmten Zeitpunkt die Zellen durch Wiederzugabe
von IL-3 zu retten sind, spricht dafür, dass viele regulative Gene während derZUSAMMENFASSUNG
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Apoptose nur transient aktiviert werden.
Bereits vor Beginn der praktischen Arbeit dieser Dissertation wurde in unserem
Laboratorium ein Genfallensystem entwickelt, um transkriptionell induzierte
regulative Gene während der Apoptose zu identifizieren. Mit Hilfe eines molekularen
Schalters, der auch durch kurzfristige Expression der Cre-Rekombinase (hier das
Reportergen) von der Expression des "gefloxten" Genes A (TKneo) auf die
Expression des Genes B (IL-3) umschaltet, sollten Gene identifiziert worden, die
während der Apoptose nach IL-3 Entzug in FDCP1-Zellen transkriptionell induziert
werden. Das Prinzip der Genfalle besteht darin, ein promotorloses Reportergen in
natürliche Gene einzuführen. Das Reportergen soll bei der Integration ins Zielgenom
unter die Kontrolle des natürlichen Promotors gelangen und wie das getroffene
natürliche Gen exprimiert werden. Entscheidend für die Nutzbarkeit dieses Systems
ist die möglichst unbeeinflusste zufällige Integration ins Genom. Retrovirale
Vektoren eignen sich besonders gut als Genfalle, da sie neben der Zufälligkeit des
Integrationsortes eine genau definierte Struktur als Provirus im Zielgenom aufweisen.
Die Position des Reportergens im Provirus wird so planbar und kann wie in unserem
Projekt so gewählt werden, dass der Beginn des Reportergens möglichst weit am 5'-
Ende des Provirus liegt.
Für 102 „Genetrap specific tags“ (GTSTs) konnten Provirus-flankierende DNA-
Sequenzen generiert werden. 86 waren lang genug um den Integrationsort im
Mausgenom zu bestimmen. von diesen 86 Klonen konnten 73 Virusintegrationen
spezifischen Genen zugeordnet werden. Bei den übrigen kann es sich um bisher nicht
identifizierter kodierende oder nichtkodierende Gene handeln.
Bei der Überprüfung der Virusintegrationen stellte sich heraus, dass bei etwa 50% der
Klone die Virusintegration in inverser (antisene) Orientierung zu dem getroffenen
Gen vorlag. Es muss in diesen Fällen davon ausgegangen werden, dass die
Aktivierung des Cre-Rekombinase Reportergenes durch eine Integration in eine
antisense RNA stattgefunden hat. Nach Schätzungen haben vermutlich etwa 8% der
Gene antisense RNAs. Die ungewöhnliche Häufung der antisense Integrationen
konnte auch in weiteren Projekten mit Cre-Rekombinase als Reportersystem
festgestellt werden (andere gebräuchliche Reportergene in Genfallen zeigen diese
Eigenschaft nicht). Da bereits eine sehr geringe Konzentration der Cre-Rekombinase
reicht aus, um eine Rekombination hervorzurufen, ist zu vermuten, dass auch sehrZUSAMMENFASSUNG
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schwach exprimierte mRNAs mit dem Cre-Reportersystem identifiziert werden
können. Zudem könnte das Fehlen einer kodierenden Region in den meisten antisense
RNAs dazu führen, dass die Integration zu besonders günstigen Voraussetzungen für
den Translationsstart des Cre-Reportergenes führt. Bei der Analyse der Expression
der Gene mit antisense Integrationen konnte festgestellt werden, das diese in fast
allen Fällen nach IL-3 Entzug herunterreguliert werden, was die Vermutung nahe
legt, dass den antisense Transkripten eine regulatorische Rolle zukommt.
Von den 50 identifizierten Genen mit wohldefinierter Funktion konnten 28 Genen
Überlebens- oder Apoptose-Funktionen zugewiesen werden. Der große Anteil von
Genen mit Überlebensfunktionen ist bemerkenswert, da Apoptose die Konsequenz
des IL-3-Entzugs ist und eigentlich erwartet wurde, dass hauptsächlich pro-
aopoptotische Gene hochreguliert würden. Da, wie bereits beschrieben, einige der
integrierten Gene auch herunterreguliert werden (Integrationen in antisense
Orientierung), war unklar ob die jeweilige Regulation pro- oder anti-apoptotische
Folgen hat.
Bei der Betrachtung der Regulation dieser Genen, fällt auf, dass pro- wie anti-
apoptotische Gene herunter- wie heraufreguliert werden. Es ergibt sich eine durchaus
widersprüchliche, ambivalente Antwort auf den Apoptosestimulus. Wie bereits zuvor
gezeigt werden konnte, erzeugt ein zeitlich limitierter IL-3-Entzug in FDCP1-Zellen
eine reduzierte nachfolgende Apoptose nach einem weiteren IL-3-Entzug. Die
Induktion von Überlebens-Genen so wie Herunterregulation von Apoptose-Genen
scheint also in einer zeitlich befristeten ersten Phase nach IL-3-Entzug von großer
Bedeutung zu sein.
Mit der Absicht, diese Hypothese mit weiteren Genexpressionsmustern zu erweitern,
wurde eine Hybridisierung mit Atlas Arrays von Clontech durchgeführt. Bei den
Hybridisierungen wurde ein Vergleich der Transkriptmengen der auf dem Filter
vorhandenen 588 Gene vor IL-3-Entzug mit den Mengen 4 und 8 Stunden nachher
durchgeführt. Für etwa 50% der gebundenen Gene konnte ein Hybridisierungssignal
detektiert werden. Nur 12 Gene zeigten signifikante Regulation nach IL-3 Entzug. Bis
auf einen Fall konnten die Ergebnisse des Atlas Arrays in Northern Blot
Experimenten verifiziert und um weitere Messzeitpunkte erweitert werden. Von den
12 identifizierten Genen konnten 9 Apoptose oder Überlebensfunktionen zugeordnet
werden. Die starke Herunterregulation von c-Myc und Pim-1 spiegelte zudem bereitsZUSAMMENFASSUNG
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aus der Literatur bekannte Daten wieder.
Zusammenfassend stellen die durch den Atlas-Array erhaltenen Daten eine
Bestätigung der Hypothese einer ambivalenten Antwort der Zelle auf den
Apoptosestimulus dar.
Da diese Arbeit Teil einer Kooperation mit der Schering AG (Berlin) war, hatten wir
die Möglichkeit, die Genexpression nach IL-3-Entzug in FDCP1-Zellen auch mittels
Hybridisierungen mit Affymetrix Chip zu untersuchen. Die Hybridisierungen wurden
bei Schering in Berlin durchgeführt. Für die Analyse wurden mRNA Proben von 0, 2,
4, 6 und 8 Stunden miteinander verglichen. Ausgehend von der Fülle der Rohdaten
wurden Gene ausgewählt, die im Zeitraum von 0 bis 8 Stunden mindestens zu einem
Zeitpunkt 3-fach hoch- oder herunterrguliert waren. Auch in diesem Fall konnte ein
Anteil von 70% der Gene der Apoptose- oder Überlebensfunktionen zugeordnet
werden.
Erstaunlicherweise konnten trotz der sehr unterschiedlichen Methoden zur
Identifizierung regulierter Gene etwa ein gleicher Anteil von Genen identifiziert
werden, denen man Apoptose- oder Überlebensfunktionen zuordnen kann. Dieser
hohe Anteil spricht für eine sehr spezifische Antwort der FDCP1-Zellen bei
Wachstumsfaktorentzug. Die Regulation der Apoptose nach IL-3-Entzug lässt sich
nach diesen Daten nicht auf die Regulation weniger Faktoren zurückzuführen,
sondern stellt eine sehr komplexe Antwort dar, die je nach Situation der jeweiligen
Zelle zu einem schnelleren oder auch verzögerten Verlauf der Apoptose führt.
Arrays beruhen auf der Vorwahl der gebundenen Gene. Der Atlas Array liegt nach
heutigen Maßstäben mit seiner sehr limitierten Zahl von 588 Genen (etwa 1-2% aller
Gene) weit hinter dem Affymetrix Chip mit etwa 5000 Genen (etwa 20-30% aller
Gene). Mit 3-4 solcher Affymetrix Chips können alle Gene eines
Säugertranskriptoms abgedeckt werden. Es steht außer Frage, dass diese Methode an
Effektivität schwer zu überbieten ist. Ein Nachteil wird jedoch immer die Vorauswahl
der Gene bleiben. Hohe Anforderungen stellt bei der Analyse von Affymetrix Chip-
Hybridisierung der große Umfang der ermittelten Ergebnisse dar.
Genfallensysteme beruhen auf völlig anderen Bedingungen. Sie sind nicht von einer
Vorauswahl von Genen als experimenteller Randbedingung abhängig, so dass der
Anteil bekannter Gene etwa dem momentanen Wissenstand zu den Funktionen aller
Gene entspricht. Da das Cre-Rekombinase- Reportersystem besonders sensitiv zu seinZUSAMMENFASSUNG
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scheint, könnte ein höherer Anteil an unbekannten bzw. niedrig exprimierten Genen
nachgewiesen werden. Vergleicht man die Genfallenergebnisse mit den
Affymetrixdaten, konnten nur etwa 23,5% der durch Genfallen identifizierten Gene
auf dem Affymetrix Array wieder gefunden werden. Dieser geringe Anteil spricht für
das Genfallensystem als System zur Identifizierung noch unbekannter Gene.
Die von uns verwendete Methode zur Herstellung der Genfallen-Integrationsbank
beginnt mit der Negativselektion zur Eliminierung konstitutiv aktiver Loci. Da viele
Gene, wenngleich hochreguliert, auch im nichtinduzierten Zustand eine basale
Expression zeigen, werden Zellklone mit Genfallenintegrationen in diesen Loci aus
dem Klonpool eliminiert. Dadurch sinkt die Zahl der möglichen identifizierbaren
Gene. Solche relativ hoch exprimierten Gene sind nur dann zu isolieren, wenn durch
eine sehr ungünstige Provirusintegration die Translation des Cre-Reportergenes stark
reduziert ist.
Während der Tumorigenese kommt es in vielen Fällen zu Mutationen,
Überexpressionen oder Inaktivierungen von Apoptose- oder Überlebensgenen.
Verstärkte Proliferation ergibt sich nicht nur aus einer Aktivierung des Zellzyklus,
sondern kann auch durch eine verminderte Apoptose verursacht werden..
Es war nun naheliegend zu untersuchen, ob aus unserer GTST-Integrationsbank
weitere, vielleicht weniger bekannte Gene eine Tumor-relevante Funktion haben.
Basierend auf unseren Erfahrungen mit der Arrayhybridisierung wurden 70 GTST-
spezifische DNA-Proben generiert und auf eine Nitrozellulosemembran aufgebracht
(sog. „custom array“). Diese Arrays wurden dann mit den cDNAs aus Tumorzellen
bzw. aus normalen Geweben hybridisiert. Der Vergleich der Hybridisierungssignale
ermöglicht die Eingrenzung von GTSTs mit differenzieller Expression in
Tumorzellen gegenüber den jeweiligen normalen Geweben. Eine Gruppe von 7
Genen, deren Genprodukte möglicherweise Zielstrukturen für die Entwicklung von
Therapeutika sein könnten, wurden ausgewählt und mit Hilfe von Matched Tumor
Arrays auf ihre differenzielle Expression in Patientenproben untersucht. Dabei wurde
festgestellt, dass in den Tumorproben nur ERK3 und mehrere Gene für bisher
unbekannte Proteine differenziell exprimiert wurden.
Von diesen scheint ERK3 als mögliches Zielprotein für eine Tumortherapie von
besonderer Bedeutung zu sein: 1) Die mit den Matched Tumor Arrays gewonnenen
Ergebnisse zeigen, dass ERK3 am stärksten in Brustkrebs (7-fach), Magenkrebs (2,5-ZUSAMMENFASSUNG
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fach) und Gebärmutterkrebs (2,3-fach) hochreguliert wird. Diese differenzielle
Expression von ERK3 mit hoher Organspezifität erlaubt möglicherweise eine sehr
spezifische Hemmung. 2) Es wurde bereits gezeigt, dass die Expression von ERK3
durch spezifische Inhibitoren der p38 Kinase und Proteasomen stark unterdrückt
wird. Bei den Inhibitoren handelt es sich um Ableitungen von Peptiden oder kleine
chemische Moleküle, was für die Entwicklung von Medikamenten von großem
Vorteil ist. 3) ERK3 besitzt eine völlig unterschiedliche Phosphorylierungsstelle als
die anderen ERKs. Daher sollte es möglich sein, bei der Hemmung der Aktivierung
von ERK3 eine hohe Selektivität gegenüber anderen ERKs zu erreichen. 4) Es wurde
nachgewiesen, dass ERK3 ein relativ kurzlebiges Protein ist (t1/2 = ca. 30 min.), was
ein Targeting auch auf der transkriptionalen Ebene, z.B. durch RNA Interferenz,
ermöglicht
Trotz all dieser Vorteile setzt die Beurteilung von ERK3 als ein gutes Zielprotein
letztendlich voraus, das die Unterdrückung der Expression oder Aktivität von ERK3
tatsächlich zur verringerten Proliferation oder verstärkten Apoptose in Tumorzellen
führen wird. Da über die nachfolgenden Ereignisse der ERK3-Aktivierung bislang
wenig bekannt ist, sind weitere Untersuchungen nötig, um die anti-apoptotische oder
pro-proliferative Wirkung von ERK3 aufzuklären bzw. zu bestätigen.LEBENSLAUF
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